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Abstract 
Introduction. The ectopic canine (EC) is a common clinical complication of 
dental development appearing in 1-2% of the Western population The 
aetiology is controversial with opinion divided as to a genetic or environmental 
mechanism. This study addresses the hypothesis that genetic factors play an 
important role in the aetiology of ectopic maxillary canines. Elucidation of the 
extent of genetic factors will determine the feasibility of further molecular 
studies to identify putative genes responsible for ectopic eruption and aid in 
their identification. Molecular control of tooth eruption would reduce or 
eliminate the need for surgical procedures associated with buried and impacted 
teeth and facilitate treatment of those dentofacial anomalies where failure of 
tooth eruption is a feature.  
Methods. The study is divided into five parts: 1. A segregation analysis was 
carried out on 63 pedigrees where a proband was identified as affected with 
EC, in order to determine whether a genetic component does exist and to 
provide parameters for further investigation by linkage analysis. 2. Following a 
positive result from the segregation analysis, linkage analysis was carried out 
on DNA obtained from an informative, three generation family with seven 
affected members. 3. Whole exome sequencing was carried out on two 
distantly related affected members of this family, common, novel and rare 
variants being identified. 4. The exons and intron-exon junctions of the 
candidate genes were sequenced using Sanger sequencing in the family and in 
18 unrelated cases of EC. 5. In situ hybridisation was carried out using the 
genes ANO5 and PPP1R14C. 
14 
 Results. The segregation analysis identified a major genetic component with 
autosomal dominant transmission and the likelihood of a single major locus 
being involved. The linkage analysis identified several regions of interest and 
this data was used to filter the results of the exome sequencing. The presence 
of variations in both PPP1R14C and ANO5 were necessary to precipitate the 
phenotype. Sanger sequencing of unaffected family members and of unrelated 
cases showed no similar variants. In situ hybridisation showed both PPP1R14C 
and ANO5 to be expressed in tooth and supporting tissues, leading to a 
supposition of digenic inheritance.  
Conclusion. The genes PPP1R14C and ANO5 are implicated in the aetiology 
of EC in a digenic inheritance pattern in this family. Further sequencing of 
affected families and functional studies are required as well as investigation of 
the methylation status of discordant monozygotic twins. 
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Chapter 1 Introduction and Literature Review 
1.1 Introduction 
The ectopic canine (OMIM 189490) is a clinical complication of dental 
development. (Figure 1). It appears in 1-2% of the Western population (Ericson 
and Kurol, 1986, Grover and Lorton, 1985, Shah et al., 1978, Thilander and 
Jakobsson, 1968) and in 4-7 % of the Maltese population (Camilleri, 1995, 
Camilleri et al., 1995). The condition has been reported to be more common in 
females than in males in roughly a 2:1 ratio. Ectopic maxillary canines have 
been found in a skull dating from 7250 B.C (Iseri and Uzel, 1993). Nelson 
reported a high prevalence of ectopic maxillary canines in an isolated 
prehistoric population (Nelson, 1992). Colyer described the condition in a 
medieval English population, with 5 specimens out of 166 (3%) exhibiting 
palatally displaced canines (Colyer, 1922). 
1.1.1 Aetiology of ectopic canines 
The aetiology of ectopic canines is probably heterogenic and most likely 
multifactorial. A number of causes have been put forward over the years, such 
as the long path of eruption, narrow or large arches, crowding, lack of guidance 
by the lateral incisor root, cystic enlargement of the follicle and familial 
tendency (Coulter and Richardson, 1997, Bass, 1967, Zilberman et al., 1990, 
Jacoby, 1983, Thilander and Jakobsson, 1968). A genetic basis has been 
suggested (Svinhufvud et al., 1988, Bjerklin et al., 1992, Peck et al., 1994). The 
racial variation, female preponderance, familial occurrence, and association 
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with other dental anomalies has been attributed to a polygenic aetiology 
(Kotsomitis and Freer, 1997).  
A controversy exists over the aetiology of ectopic canines. Peck and Peck 
support a genetic theory (Peck et al., 1994) while Becker et al. propose that this 
anomaly arises from environmental factors, namely lack of mechanical 
guidance by the lateral incisor root (Becker et al., 1981). 
1.1.2 Evidence for a genetic aetiology 
The preponderance of evidence supports the view of Peck and Peck 
(1994).Other dental anomalies are seen to occur with ectopic canines. There is 
a clear association between this phenomenon, tooth agenesis and tooth 
malformations, particularly involving the lateral incisors (Moss, 1972, Becker 
et al., 1984, Svinhufvud et al., 1988, Oliver et al., 1989, Brin et al., 1993, 
Pirinen et al., 1996).  Svinhufvud et al. (1988) demonstrated an association of 
canine malposition to hypodontia 1  (Svinhufvud et al., 1988). Pirinen et al. 
(1996) showed that the aetiology of ectopic canines is genetic and is related to 
hypodontia (Pirinen et al., 1996). Camilleri et al. carried out a complex 
segregation analysis on a series of families with ectopic canines and found that 
the data indicated a major genetic component with a single causative locus. 
The best fitting model was that of a single dominant gene with autosomal 
dominant inheritance (Camilleri et al., 2008). The reported range of bilateral 
occurrence of ectopic canines varies between 17 and 45% (Ericson and Kurol, 
1 The term hypodontia is taken to mean agenesis of up to six teeth. 
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1988,  McKay, 1978, Nordenram and Stromberg, 1966, Power and Short, 
1993). 
Figure 1. Radiograph showing ectopic maxillary and mandibular canines 
and retained deciduous teeth with no permanent successors. 
The prevalence rates of bilateralism for other dental anomalies under genetic 
control, such as missing maxillary lateral incisors(Davis, 1987)and maxillary 
canine-first premolar transposition(Peck et al., 1993) are similar, being 20-46% 
and 23-43 % respectively. The gender ratio shows a bias towards females 
(Becker et al., 1981, Ericson and Kurol, 1988, McKay, 1978, Nordenram and 
Stromberg, 1966, Power and Short, 1993, Zilberman et al., 1990). The ratios 
range from M1:F1.3 to M1:F3.2. These ratios compare favourably with other 
dental anomalies of genetic origin, the gender ratio of hypodontia being quoted 
as M1:F1.3 to M1:F1.6 (Davis, 1987) and that for maxillary canine-first 
premolar transposition M1:F3.8 (Peck et al., 1993). 
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1.1.3 Environmental influence 
There is however, evidence of an environmental component. Timely extraction 
of the deciduous canines will ameliorate the condition (Ericson and Kurol, 
1988, Power and Short, 1993). There is support for environmental factors such 
as lack of guidance by the lateral incisor root although the developmental 
absence of lateral incisors often allows the canine teeth to erupt into the line of 
the arch (Becker et al., 1981, Chaushu et al., 2002, Chaushu et al., 2003b). 
Excess space in the dental arch may play a part (Paschos et al., 2005). Both 
genetic and environmental factors may be involved (Ely et al., 2006). Camilleri 
et al. presented a series of monozygotic twins with ectopic canines. The 
concordance of these twins was low and equivalent to that of a similar series of 
dizygous twins. Furthermore, 85% of the three-generation families in this study 
showed instances where an obligate carrier exhibited a normal phenotype, 
although the condition was transmitted. This is consistent with an 
environmental or an epigenetic component (Camilleri et al., 2008). 
 
1.1.4 Local prevalence 
This condition is a clinical problem on the Island of Malta having an impact on 
orthodontic services. Patients with ectopic maxillary canines constitute a major 
load of specialist practice treatments (eighteen per cent of a private workload, 
of which 14% required fixed appliance treatment in combination with oral 
surgery [data not shown]). The problem is similarly evident at the School 
Dental Clinic in Mater Dei Hospital. A random survey of 270 DPTs taken of 
individuals between the ages of eight and eighteen years of age found 19% to 
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have EC. The prevalence of hypodontia in this sample was 29% (unpublished 
data). In a sample of 168 patients with ectopic canines from a private practice, 
the incidence of hypodontia is just over 20%. These figures are well above 
those quoted for orthodontic populations (Rose, 1966, Sacerdoti and Baccetti, 
2004). The incidence of lateral incisor hypodontia in the general population is 
also higher than average (Camilleri and Mulligan, 2007) and is significantly 
different to the prevalence of lateral incisor hypodontia in a European 
population (Bot and Salmon, 1977). 
 
1.1.5 Founder effect 
The prevalence of the associated conditions of ectopic canines and hypodontia 
appears to be higher in Malta than elsewhere. If a genetic aetiology is present, 
one explanation of this phenomenon may be the ‘founder effect’. The Maltese 
population has grown dramatically over the past 500 years, from 17,000 in 
1535 to over 400,000 in the twenty first century. (Blouet, 2004) Any particular 
genes carried by the founders may well be over represented in the present 
population (Figure 2). In small populations the relative importance of genetic 
drift is higher; deleterious alleles can become more frequent and 'fixed' in a 
population due to chance. This makes the Maltese population a good subject 
for investigation of EC as the chances of genetic heterogeneity are lower and 





Figure 2. Population Growth of the Maltese Islands. The Islands were 
constantly ravaged by North African corsairs after the first millennium 
and up to the early 1500’s the population never grew above the 10,000 
mark. The arrival of the Knights of Malta brought an influx of about 
10,000 knights, soldiers and dependents. The stability offered by a military 
base allowed the population to grow rapidly and now exceeds 400,000, 
with a relatively minor foreign input. Data taken from Blouet (2004). 
 
1.1.6 Diagnosis of Ectopic Canines 
The permanent canines are usually palpable by age 9 or 10. Inability to palpate 
the canines at this age is an indication for radiographic localisation of the 
permanent canines. However this method is not entirely satisfactory as 
palpation of the canines requires a degree of clinical experience. Many general 
dental practitioners (GDP) may not possess the skills to evaluate the clinical 
presentation. Furthermore, as these teeth are among the last to erupt at 12-13 
years, the tendency is to await the eruption and in doing so, miss the 
opportunity for timely referral to a specialist. At present, the accepted 
interceptive treatment is limited to extraction of the deciduous canines in 
selected cases. This encourages the permanent canines to erupt into their 
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correct place. By this time though, the permanent canines are already erupting 
along an ectopic path. There is no scientific evidence to support this method. 
No randomised controlled studies (RCT) of adequate quality have been 
published to date (Parkin et al., 2009). The success rate varies, with 62-78% of 
cases being reported as normalised (Ericson and Kurol, 1988, Power and Short, 
1993). Only mild cases stand a good chance of correction. The earlier this 
procedure is carried out, the better the prognosis. However, as the condition is 
painless and not obvious to the layman, a large proportion of cases are 
identified either by chance or by loss of a deciduous tooth in the adult years, 
leading the individual to seek treatment very late on in the development of the 
dentition. Early identification is essential if these patients are to be treated 
successfully and fixed appliance treatment is necessary to correct established 
cases.  
 
1.1.7 Sequelae of untreated ectopic eruption 
Failure to diagnose and treat EC may lead to palatal or buccal placement of the 
tooth, leading to difficult orthodontics or the loss of the canine. This would 
require complex prosthetic replacement. Other complications include loss of 
space for the tooth by drift of adjacent teeth, further complicating any 
orthodontics or prosthetic replacement. Dentigerous cyst formation may result 
in 1.44% of impacted teeth (Mourshed, 1964) and the ectopic canine may cause 
root resorption of the adjacent central and lateral incisor teeth, this occurring in 




1.1.8 Associated dental anomalies 
Garn et al demonstrated the existence of a genetic interrelationship among 
tooth agenesis, systematic tooth size reduction and generalized retardation of 
tooth development, three of the abnormalities that appear associated with 
ectopic canines (Garn et al., 1963, Garn et al., 1964, Garn and Lewis, 1970). 
Both Bjerklin and Baccetti found an increased prevalence of other 
developmental anomalies associated with ectopic canines, notably tooth 
agenesis, tooth size reduction, ankylosed deciduous molars, other ectopically 
positioned teeth and supernumerary teeth (Bjerklin et al., 1992, Baccetti, 1993, 
Baccetti, 1998). Shalish et al. demonstrated an association between ectopic 
canines, ankylosed deciduous molars and ectopically erupting mandibular 
premolars (Shalish et al., 2009, Shalish et al., 2010) 
It is unlikely that EC is an isolated phenomenon, evidence points to it being a 
genetic anomaly frequently occurring in association with other genetically 
interrelated dental anomalies. 
 
1.2 Mechanisms of tooth eruption 
1.2.1 Eruption of the maxillary canine 
The maxillary permanent canine starts to calcify at 1½ years of age, between 
the roots of the first primary molar. As the jaws grow, the canine moves 
apically, away from the first primary molar. The first premolar then develops in 
the same site as the canine (Broadbent, 1941). As the jaws grow rapidly in 
depth and width, the teeth move to maintain their correct relation to each other. 
As the maxilla grows, the first premolar moves distally relative to the canine, 
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providing space for the canine to erupt. This involves precise co-ordination of 
movement of the tooth germs in the growing maxilla. This movement is most 
likely effected by osteoblast-osteoclast interaction, controlled by the dental 
follicle, as part of the eruption process. A deficiency in the cell signalling 
process of one tooth or more adjacent teeth, at an early stage, could well cause 
the tooth buds to move in the wrong direction (or fail to move), leading to 
ectopic eruption or impaction of the tooth.  
 
1.2.2 Intraosseous movement of the tooth 
The intraosseous stage of tooth eruption involves bone resorbtion to form an 
eruption pathway and interradicular bone formation, root growth and fundic 
bone apposition which move the erupting tooth into the eruption pathway. The 
primary determinant of both the direction and rate of tooth eruption is the rate 
of formation of the eruption pathway and it's co-ordination with bone 
formation in selected areas of the crypt and alveolar crest (Schroeder et al., 
1992, Wise et al., 2007). These events are regulated by the dental follicle, 
which develops regions to initiate and control bone formation, regions to 
initiate and control bone resorbtion and regions which remain neutral. Where 
these regions develop in a particular follicle determines the direction of tooth 
eruption and when they develop. It also determines the time of eruption and 
how they are synchronised and will determine whether there will be 
complications (Marks and Schroeder, 1996). 
 
24 
1.2.3 Control of tooth eruption by dental follicle 
The dental follicle initiates and controls tooth eruption by inducing bone 
resorbtion occlusal to the tooth and bone deposition at the base of the crypt 
(Marks and Cahill, 1987, Wise et al., 2007). The coronal half of the follicle 
produces bone resorbing factors such as CSF-1 and RANKL while the basal 
half produces BMP2, a bone formation factor (Wise et al., 2005, Wise and 
Yao, 2006). The tooth germ is carried to the surface by bone deposition at the 
base of the crypt and bone resorbtion ahead. Communication takes place 
between tooth germs and bone-forming/resorbing cells, synchronising the two 
processes, perhaps to ensure correct spatial positioning of teeth in the 
jaws (Ohazama et al., 2004, Gao et al., 2003). CSF-1 reduces expression of  
OPG in cultured dental follicle cells (Wise et al., 2000) as well as reducing the 
amount of OPG secreted (Wise et al., 2004). 
1.2.4  Osteoblast regulation 
Bone tissue consists of hydroxyapatite crystals and various kinds of 
extracellular matrix proteins including type I collagen, osteocalcin, osteonectin, 
osteopontin, bone sialoprotein, and proteoglycans (Mundlos et al., 1997, 
Young et al., 1992, Robey et al., 1993). Most of these bone matrix proteins, 
together with hydroxyapatite crystals, are secreted and deposited by polarised 
mature osteoblasts, which are aligned on the bone surface.  
Runx2 null mice (Komori et al., 1997) have no bone tissue, osteoblasts or 
osteoclasts. Runx2 dominant negative mice display an osteopenic phenotype 
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(Ducy et al., 1999). This indicates that RUNX2 is essential for osteoblast 
commitment from undifferentiated mesenchymal cells.  
RUNX2 has been shown to be essential for normal bone formation, with 
perturbation of bone formation if levels are insufficient. However RUNX2 
inhibits osteoblast differentiation at a late stage (Liu et al., 2001). 
Adult transgenic mice overexpressing Runx2 showed osteopenia with a 
decrease in bone mineral density due to enhanced osteoclastogenesis (Geoffroy 
et al., 2002). This is consistent with evidence that Runx2 is autoregulated in 
part by negative feedback on its own promoter to stringently control expression 
and function during bone formation. (Drissi et al., 2000). Osteoblasts 
from synostosed sutures exhibited an increase in RUNX2 expression and 
activity, possibly explaining the enhanced proliferation and bone-forming 
ability of these cells (Shevde et al., 2001). 
RUNX2 expression is affected by a diversity of signalling pathways. 
Binding of the extracellular matrix (ECM) to cell surface integrins; 
mechanical loading; FGF2; PTH; and BMPs all influence RUNX2 dependent 
transcription. These act via the mitogen-activated protein kinase (MAPK) and 
protein kinase A and C (PKA, PKC) pathways, activating RUNX2 by 
phosphorylation. This gene plays a central role in coordinating multiple 
signalling pathways affecting osteoblast differentiation (Franceschi et al., 
2003, Franceschi and Xiao, 2003).  
1.2.5  Osteoclast regulation 
Osteoclastogenesis in the alveolar bone, essential for the accommodation of 
normal tooth development and eruption, is mediated by RANK-RANKL 
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signalling (Suzuki et al., 2004). The spatiotemporal pattern and relative 
abundance of CSF-1, RANKL and its antagonist OPG, during tooth eruption 
are key determinants of site-specific osteoclast activity in bone surrounding the 
tooth (Heinrich et al., 2005). 
Runx2 affects osteoblast-osteoclast interaction. CSF-1 is secreted from 
osteoblasts and provides a survival signal to osteoclast precursors and 
osteoclasts (Tsurukai et al. 2000).  
RANKL is expressed in committed preosteoblastic cells and acts by 
increasing transcription via the RUNX2 binding sites on the Rankl promoter, 
however the ability of osteoprogenitor cells to support osteoclast formation 
decreases with their maturation stage (Manolagas 2000). Osteoclastogenesis is 
strongly induced by undifferentiated stromal marrow cells, which produce high 
RANKL levels. As maturation proceeds, RANKL levels drop and OPG levels 
rise (Gori et al., 2000).  
The action of RUNX2 on the Rankl promoter region is affected by Histone 
Deacetalase (HDAC), which condenses chromatin, making it less accessible to 
transcription machinery. At the same time, RUNX2 does have a slightly 
positive effect on the basic promoter activity of the Rankl gene (Mori et al. 
2006). 
Evidence suggests that RUNX2 is a key regulator of RANKL expression at 
least in chondrocytes. RUNX2 may indirectly affect the pattern of RANKL 
expression by inducing selective and sequential expression of other 
signalling and transcription factors which act on the Rankl promoter 
(Kishimoto et al., 2006). 
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The RANKL antagonist OPG is strongly expressed in Runx2-/- calvarial cell 
lines (Enomoto et al., 2003, Gao et al., 1998). However RUNX2 binding 
elements are also present in the promoter region of the Opg gene. RUNX2 
increases the activity of the Opg promoter, suggesting that RUNX2 also 
regulates osteoclastogenesis by inducing the expression of OPG 
(Thirunavukkarasu et al., 2000).  
Forced production of soluble RANKL was found to be insufficient for the 
complete rescue of osteoclast differentiation in Runx2-/- mice, suggesting the 
presence of another requirement for osteoclast differentiation. Also, treatment 
of RUNX2-deficient calvarial cells with 1,25(OH)2D3 affected both RANKL 
and OPG expression and induced osteoclastogenesis (Notoya et al., 2004). 
Thus, while RANKL is necessary for osteoclast formation, it is not sufficient. 
Furthermore the requirement for RUNX2 may be bypassed, at least in vitro, 
with expression of RANKL and OPG  and initiation of osteoclastogenesis 
being influenced via alternative pathways. 
Overexpression of RUNX2 will also affect osteoblast-osteoclast 
interaction. Apert’s and Crouzon syndromes are due to a mutation on FGFR2, 
which causes increased affinity for FGF2 .This results in overproduction and 
overactivity of RUNX2 (Kim et al., 2006, Wilkie and Morriss-Kay, 2001). 
These related syndromes are also characterized by ectopic and unerupted teeth 
and delayed dental development (Kaloust et al., 1997, Wilkie and Morriss-Kay, 
2001). 
Overexpression of RUNX2 increases osteoblast number but inhibits their 
terminal maturation, resulting in accumulation of less mature osteoblasts 
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and consequent osteopenia. The increase in immature osteoblast numbers will 
lead to a dearth of osteoclast-inducing osteoprogenitor cells. (Liu et al., 2001). 
 
1.2.6 Osteoblast osteoclast interaction 
The experiments of Cahill and of Marks (Marks and Cahill, 1984, Cahill and 
Marks, 1980) have conclusively demonstrated that tooth eruption is dependent 
on osteoclastic activity to form an eruption pathway for the tooth to move 
inside the bone. Teeth apparently have a ‘window of opportunity’ to erupt. 
Should this slot be missed, eruption may fail or the tooth may erupt ectopically 
(Marks et al., 1983). Experiments in rodents where osteoclastic activity is 
temporarily disrupted produce a picture which is remarkably similar to the 
clinical condition in humans, namely delayed and ectopic eruption of teeth 
together with ankylosis and odontome formation (Cielinski et al., 1994, 
Kodama et al., 1991, Huang and Wise, 2000, Zou et al., 2003, Yoda et al., 
2004). Furthermore, in the clinical situation, tooth eruption in humans is often 
accelerated by localised chronic inflammation. All too often a premolar will 
erupt, sometimes years ahead of schedule (and other premolar teeth), beneath a 
chronically infected deciduous molar tooth (O'Meara, 1966).Should a sinus be 
present, the permanent tooth will often follow the track and erupt buccally 
(Camm and Schuler, 1990). Osteoclasts are activated by the products of 
inflammation, with proteins such as TNF-α IL1A, CSF1 and MCP1 being 
common to both inflammation and tooth eruption. TNF-α and IL1A increase 
the production of RANKL (Bezerra et al., 2005). Inducing inflammation close 
to the follicle of the ectopic tooth may alter the direction of tooth eruption. 
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Extraction of the deciduous tooth will often correct the path of eruption of the 
ectopic permanent tooth (Ericson and Kurol, 1988, Power and Short, 1993). 
The closer the crown of the affected tooth is to the root of the deciduous tooth, 
the more likely the procedure is to succeed. It is possible that the correction of 
ectopic eruption is due to reactivation of osteoclasts by cytokines produced by 
surgically induced inflammation and the subsequent local increase in bone 
turnover as the socket heals.  
Premature extraction of a deciduous tooth has a similar effect on the eruption 
of its successor, even if erupting normally. Eruption is speeded up initially, 
only to return to normal some time after, once the extraction socket has healed. 
Indeed, the healed socket will then retard eruption (Loevy, 1989). Exposure of 
the crown of an ectopic tooth will stimulate eruption of the tooth. The success 
of this procedure is dependent on the age of the individual (Altonen and 
Myllarniemi, 1976). Exposure in adult patients often results in a small amount 
of eruption, possibly due to the transient inflammation produced or the 
conversion of the follicle to periodontal ligament. That eruption does not 
proceed further may be due to the lack of active growth of the alveolar process.  
Examination of serial radiographs of patients with unilateral ectopic maxillary 
canines shows that the ectopic eruption pattern may sometimes be evident at or 
shortly after crown formation. The affected tooth does not upright itself at age 
9 (Fernandez et al., 1998, McSherry and Richardson, 1999) but the crown tends 
to move further mesially than vertically, in contrast with other maxillary 
canines. The crown will therefore recede from the occlusal plane as alveolar 
height increases and migrate towards the midline. The apex will migrate 
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distally, indicating that root formation is proceeding faster than tooth 
movement (Marks and Schroeder, 1996). This indicates a failure of formation 
of the eruption pathway of the tooth. The frequent deformation of the apices of 
these teeth supports this hypothesis. Ankylosis of deciduous teeth is associated 
with ectopic movement of canines and the prevalence of other ectopic teeth is 
also increased (Bjerklin et al., 1992, Baccetti, 1998, Baccetti, 2000, Chaushu et 
al., 2003b). Ankylosis takes place when the cementum of a tooth fuses with the 
bone of the socket. This could either be due to ectopic ossification of the 
ligament or due to failure of osteoclasts or dentinoclasts to remove the bony 
bridge. Cementum formation may also be affected. Histological examination of 
sections of impacted canines show acellular cementum to be deficient and 
cellular cementum to be virtually absent (Giuliana et al., 1995). 
 
1.2.7 Genetic disorders and tooth eruption 
The weight of evidence points to the causative gene being one which affects 
bone turnover. Given the complex nature of bone turnover, the possibility of 
genetic heterogeneity must be considered. A list was compiled of known 
genetic disorders where ectopic eruption, failure or delay of eruption was a 
feature (Wise et al., 2002) (Table 1). The common feature running through all 
these disorders is their disruptive effect on bone remodelling, be it through loss 
of bone specific transcription factors, bone structural elements, cellular 
function, or a more fundamental effect on overall growth and development. 
This is in keeping with the theory of Cahill and Marks that tooth eruption is 
regulated by coordinated bone apposition and resorbtion. This makes it  
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Table 1. List of genetic conditions where delay or failure of eruption is a feature. The full list may be 
found as Table 22, in Appendix 2. 
Condition OMIM Phenotype Gene Mode of Inheritance 
Gene 
function/Pathogenesis 




FGFR2 Autosomal dominant 












RUNX2 Autosomal dominant 
Osteoblast-specific 
transcription factor, 
regulator of osteoblast 
differentiation 





PTHR1 Autosomal dominant 
Activation of phospholipase 
and inhibition of 
adenylcyclase through 
stimulation of inhibitory G 
proteins 
Hutchinson-Gilford 






LMNA Autosomal dominant 
Control of nuclear 
architecture and function 
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unlikely that there is a single gene wholly responsible for the eruption of teeth, 
as bone turnover is the product of several major genes and many more minor 
ones. In those syndromes where ectopic teeth are a prime feature, such as 
Apert’s syndrome and Cleidocranial Dysplasia, the genes affected, FGFR2 and 
RUNX2, are those directly regulating bone turnover. Moreover, FGFR2 is 
upstream of RUNX2 (Choi et al., 2005). Wolf-Hirschorn syndrome, whose 
dental manifestations are delayed eruption of permanent teeth, retained 
deciduous teeth and ectopic teeth, is caused by partial deletion of terminal 
portion of short arm of chromosome 4. Mild forms have been correlated with 
4p16.3 deletions. It is worth noting that the homeobox gene MSX1 on located 
on 4p16.1, FGF3 (expressed in the enamel knot, and a downstream gene of 
RUNX2) (Aberg et al., 2004) on 4p16.3, EVC on 4p16. FGF’s are regulators of 
bone formation, MSX1 is a major homeobox gene, upstream of RUNX2 and 
EVC plays an essential role in skeletal development.  
Not all bone remodeling anomalies cause delayed or ectopic eruption. Paget’s 
Disease of bone, a genetically heterogeneous condition caused by mutations 
which increase production or reduce inhibition of Receptor Activator of 
Nuclear Factor Kappa B Ligand (RANKL), an osteoclast differentiation factor, 
does not seem to adversely affect the eruption pathway, the observed clinical 
effect being premature loss of deciduous teeth in the juvenile variant. 
Presumably the increase in osteoclastic activity leads to an acceleration, but not 
disturbance, of the eruption of the permanent dentition. The inference here is 
that ectopic eruption of teeth is a disease caused by a localised disruption of the 
eruption pathway, possibly either by failure of the follicle to induce sufficient 
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osteoclasts to accumulate over the tooth germ or to induce bone deposition 
apically, or both. Inflammatory products may rescue this failure of eruption. 
Several gene products may be involved. The condition is not transmitted in a 
purely Mendelian fashion and the magnitude of the genetic and environmental 
components is unclear. Thus the condition of ectopic canines may be described 
as a complex disease. 
1.3 Identification of the disease gene 
1.3.1 Familial aggregation 
In order to establish the genetic component of a disease, a pedigree analysis 
will determine whether familial aggregation of affected members is evident. 
Pedigrees are identified on a case-control basis and the proportion of affected 
members divided by the population prevalence. This gives a figure known as 
the Relative Risk. The higher this figure, the more indicative it is of a genetic 
component. However familial aggregation may occur for other reasons than 
genetic and further investigation is required prior to undertaking molecular 
studies. 
1.3.2 Segregation Analysis 
Segregation analysis is the next step, with a large number of pedigrees 
systematically collected and ascertainment bias catered for. Segregation 
analysis uses Maximum Likelihood models to fit the pedigree data to various 
genetic scenarios. Dominant, recessive, polygenic and sporadic (no genetic 
component) models may all be tested and the most likely model determined. 
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Penetrance, population allele frequency and heritability, or the proportion of 
cases of a disease which can be attributed to a genetic effect, may also be 
calculated.  
1.3.3 Identification of the genetic component 
A positive result from the segregation analysis is a basis to proceed to 
molecular studies. There is no specific protocol to determine disease genes, as 
long as the end result is a short list of plausible genes which can then be 
examined for mutations. There are four basic methods of establishing this list; 
i.e. functional cloning, the candidate gene approach, positional cloning and 
next-generation sequencing (Figure 3). Functional cloning and the candidate 
gene approach require prior knowledge of either the biochemical basis of the 
defect or of the function of the gene. These methods are nowadays considered 
obsolete. 
1.3.4 Positional Cloning 
Here the position of the gene is determined purely by reference to its physical 
position on the gene map. The first step in positional cloning is to carry out 
genome wide linkage analysis or association studies using markers spaced  
evenly throughout the genome. This may narrow the search down to a specific 
region which may then be examined for possible candidates. By genotyping 
genetic markers and studying their segregation through pedigrees, it is possible 
to infer their relative positions throughout the genome. The discovery of 
Restriction Fragment Length Polymorphism (RFLP) markers and consequently 
the more polymorphic, mini and microsatellite DNA markers have permitted
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Figure 3. The pathways to a candidate gene. 
the identification of several disease genes. The development of high density 
Single Nucleotide Polymorphism (SNP) arrays allows the use of SNPs to act as 
highly efficient markers for the analysis of Mendelian diseases (Sellick et al., 
2004). Advances in molecular technology have permitted the positional cloning 
of regions tracked by this technique and have allowed the identification of the 
mutations responsible. This method works very well for diseases with 
Mendelian or near-Mendelian inheritance.  
1.3.5 Genetic maps 
The number of crossovers between two loci is an indication of the distance 
between them. This is the basis of genetic maps. As recombination frequency is 
not constant throughout the genome, genetic distances do not correspond 
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exactly to physical distances but the basic map unit, the Centimorgan, is 
roughly equal to 1 megabase (Mb) (Dib et al., 1996).  
1.3.6 Two point vs multipoint analysis 
Two point analysis compares the probability of the data assuming the disease 
locus is unlinked, to the probability of the data assuming the disease locus is at 
a specific location, i.e. each locus is analysed separately. Multipoint analysis 
uses a map of genetic markers to reconstruct inheritance along a chromosome 
and calculates LOD scores by comparing each possible location to an unlinked 
locus. The incorporation of a genetic map allows the chromosomal order of 
linked loci to be established and the maximum inheritance information can be 
deduced from the available marker data. Multipoint linkage analysis is 
therefore more efficient than two-point analysis. This is particularly relevant to 
genotyping with single nucleotide polymorphisms, (SNP) as these are biallelic 
and consequently less informative than other markers. Multipoint analysis is 
susceptible to linkage disequilibrium (LD) and this must be taken into account 
when using dense SNP arrays. 
1.3.7 LOD scores 
The significance threshold for two point linkage analysis has traditionally been 
set at a LOD score of 3.0. More stringent criteria are necessary for multipoint 
analyses in order to reduce the chance of false positive reports and ranges have 
been suggested for multipoint LOD scores (Table 2) (Lander and Kruglyak, 
1995). 
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Table 2. LOD scores for multipoint linkage analysis as suggested by 




Statistical evidence that would be expected to occur no more 
than one time at random in a genome scan. This would include 
LOD scores from 2.2 to 3.5. 
Significant 
linkage 
Statistical evidence that would be expected to occur no more 
than 0.05 times at random in a genome scan. This would 




Statistical evidence that would be expected to occur no more 
than 0.001 times at random in a genome scan. This would 
include LOD scores over 5.4 
Confirmed 
linkage 
Significant linkage that has been confirmed in a further sample, 
preferably by an independent group of researchers. 
Areas of 
interest LOD scores below 2.2 
Exclusion
of linkage LOD scores below -2
1.3.8 Parametric linkage analysis 
Traditional linkage analysis is known as parametric analysis. Parametric 
methods are more powerful than allele sharing methods, as they examine 
alleles inherited from a known common ancestor, i.e. are identical by descent 
(IBD). In other words the marker allele and disease locus are genetically 
linked. Parametric analysis requires extended pedigrees with multiple affected 
members for optimal performance. LOD scores may be summed across 
different families in order to achieve significance. It permits refined 
recombination mapping in order to localise disease genes and can deal with 
locus heterogeneity. Parametric methods are most powerful when used to 
detect single rare alleles with strong effects. Parametric linkage analysis may 
be used to investigate several patterns of inheritance, however is dependent on 
a genetic model and requires the model to be well defined. As complex 
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diseases encompass several often unknown parameters, an incorrect model may 
affect the estimation of the recombination fraction (Clerget-Darpoux et al., 
1986). A number of strategies have been developed to overcome the problem 
of uncertain inheritance. These involve multiple testing with the necessity to 
adjust the significance level of the LOD score (Risch, 1991, MacLean et al., 
1993, Greenberg et al., 1998). However the exact performance of these 
strategies in the case of multilocus models is unclear.  
Parametric ‘affected only’ analysis examines the likelihood of inheritance IBD 
between affected members only. This eliminates the need to specify the 
penetrance; however the mode of inheritance and allele frequency is still 
required. 
1.3.9 Locus heterogeneity 
Locus or genetic heterogeneity is a confounding factor in parametric analysis, 
as this will affect the LOD score if summed over a number of different 
families, therefore genetic homogeneity is preferable (Cui et al., 2010). Careful 
study of the phenotype and selection of families may reduce the problem and 
several linkage analysis programs incorporate a model which can deal with a 
limited amount of heterogeneity. 
One other way of avoiding this problem is to use a small, relatively isolated 
population which has recently rapidly expanded from a bottleneck. The small 
number of founders and the relatively short timeframe results in an increased 
frequency of founder effects and less mutational heterogeneity. 
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1.3.10 Linkage disequilibrium 
The algorithm used in most multipoint analysis packages assumes independent 
segregation between markers, i.e. random crossing over. This is not the case as 
alleles which are physically close together are unlikely to be separated by 
crossover events. Furthermore, crossing over at one point inhibits similar 
events in the vicinity and crossing over is not evenly distributed, chromosomes 
exhibiting both ‘hot’ and ‘cold’ breakage spots. These factors contribute to 
linkage disequilibrium (LD), which may be defined as the non-random 
association of alleles at adjacent loci. On a population level, LD is eroded by 
recombination, therefore older populations, such as Africans; exhibit less LD 
than other populations (Reich et al., 2001). LD has been shown to be present in 
isolated, and therefore younger, populations; however the amount of LD 
exhibited is variable. It is more likely to occur in the case of rare alleles, e.g. 
founder mutations (Kruglyak, 1999).  
Multipoint linkage analysis programs assume linkage equilibrium between 
genetic markers. (Abecasis et al. 2002). It has been demonstrated that the 
algorithm can give misleading results in the presence of linkage disequilibrium, 
especially if founders are not genotyped (Schaid et al. 2002). LD is a 
recognised problem in multipoint analysis and must be addressed, either by 
using programs which deal with LD or by preselecting markers not in LD. 
Linkage disequilibrium however, is the basis of allele sharing methods 
described below. 
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1.3.11 Allele sharing methods 
Allele sharing methods, incorrectly known as nonparametric or model-free 
analyses, make no prior assumptions about the disease. These methods 
examine alleles that are shared between affected individuals and do not take 
into account unaffected individuals. Here alleles which are identical by state 
(IBS) are analysed to see if their assortment deviates from that which would be 
expected to occur were the trait and marker to be in linkage equilibrium. 
Alleles which are IBS may have the same DNA sequence, but they are not 
necessarily derived from a known common ancestor. In the case of rare disease 
alleles in related individuals however, IBS may be taken to imply IBD. Allele 
sharing analyses are more useful in the case of complex disease where multiple 
loci each exert small effects along with environmental factors and the mode of 
inheritance is unclear. These analyses may be linkage or association based.  
1.3.12 Allele sharing linkage analysis 
Nonparametric linkage analysis requires family data where more than one 
member is affected, such as affected sibling pairs; the data being assessed to 
see whether the inheritance of alleles IBD differs from that which would be 
expected by chance. Extended pedigrees are not a requirement and may raise 
problems in assessment of data from multiple related individuals (Ott et al., 
2011). 
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1.3.13 Homozygosity mapping 
This is a technique that may be used in the investigation of rare recessive 
disorders. It relies on the detection on stretches of homozygosity common to 
the affected individuals. There is therefore no need to reconstruct the whole 
pedigree, or identify consanguineous matings. 
1.3.14 Association analysis 
Association analyses may be population-based case-control or family-based 
analysis. Here the frequencies of genetic markers are compared between 
unrelated affected cases and unaffected controls; i.e. to look for LD between a 
disease gene and a flanking genetic marker. The case-control method is useful 
for complex diseases where it would be unlikely to find pedigrees with 
sufficient affected members. 
Association methods make use of recombination events in a population sample. 
As the shared ancestry of a mutation in a population extends much further back 
than that of any one pedigree, the increased number of recombination events 
allow for finer localisation of disease markers. The use of a control sample will 
further increase resolution, as the ancestry of the unmutated allele extends 
much further back and comparison of the groups may further localise the 
disease allele. SNPs are the markers of choice and microarray chips have been 
developed which carry close to a million SNP markers, with a resolution of 1-
200 kilobases (Kb). 
The small genetic effects exerted by the target loci means that large sample 
sizes are required in order to achieve sufficient power to detect association. 
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The use of large numbers of individuals makes these analyses susceptible to the 
effects of population stratification, where Type 1 errors (false positives) are the 
result of different allele frequencies as a consequence of ethnic mixing of the 
population sample and not due to the disease. Family-based association 
analysis is immune to this; however collecting sufficient numbers to achieve 
significance may be impractical (Risch and Merikangas, 1996).  
1.3.14.1 Case-Control Methods 
The case-control method is the method of choice for analysis of complex 
diseases where it would be unlikely to find pedigrees with sufficient affected 
members (Risch and Merikangas, 1996). Furthermore, in the case of late-onset 
disorders, compilation of pedigrees is not always possible. However, the small 
genetic effects exerted by the target loci means that large sample sizes are 
required in order to achieve sufficient power to detect association, leading to 
Type 1 errors. Finally, independent replication of results, the gold standard of 
genetic studies, is problematic (Ioannidis et al., 2001). Hurdles in the path of 
successful replication are the need for an even larger sample size and if carried 
out in other populations, the difference in both variant frequencies and LD 
patterns may make the signal undetectable (Clerget-Darpoux and Elston, 
2007). 
1.3.14.2 Family-based Methods 
Family-based association analysis is immune to population stratification as 
members of a pedigree share a common genetic background. Small pedigrees 
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such as parent-offspring trios or affected sibling pairs are preferable. Extended 
pedigrees are not a requirement and may raise problems in assessment of data 
from multiple related individuals (Ott et al., 2011). Family-based designs also 
allow for parent of origin effects such as imprinting (Weinberg, 1999). 
However collecting sufficient numbers to achieve significance may be 
impractical (Risch and Merikangas, 1996). 
Both types of association analyses have their merits, and there are no set 
criteria for optimal selection of a strategy. Both designs give overall similar 
estimates of association when compared (Evangelou et al., 2006) and in 
practice the choice rests mainly on the sampling conditions as well as the mode 
of inheritance (Cui et al., 2010). 
The analysis of data depends on the study design. Chi squared tests, logistic 
regression or odds ratios may be used in simple cases, however statistical 
packages are freely available. A P-number is generated which gives the 
probability of the marker and disease locus being in LD. 
Complex disease is much commoner than Mendelian disease. Allele sharing 
methods are independent of the need to specify a genetic model. Furthermore, 
other covariates such as environmental input may be factored in. Association 
analysis reports have largely superseded linkage analysis in the literature over 
the past decade, their flexibility in these respects contributing to their 
popularity. 
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1.3.15 Combined linkage and association analysis 
The two techniques may be used to reinforce each other. Nonparametric 
linkage analysis may be carried out as a replication study to confirm suggestion 
of association. The transmission disequilibrium test is a family-based test is 
unique in that it performs a matched analysis of untransmitted versus 
transmitted alleles thus performing both a test of association and of linkage 
(Dudbridge, 2007). 
1.3.16 Fine mapping 
The number of markers required for a genome wide linkage scan is in the order 
of 400-1000. Linkage analysis peaks are generally in the order of several Mb in 
width. Further analysis may be carried out either by genotyping more 
individuals or with the use of a secondary map with more markers, less widely 
interspersed within the area of interest. Nonetheless, as fine mapping here is 
dependent on recombination events, the finest resolution is rarely less than 1 
Mb (Boehnke, 1994). This may encompass an enormous number of genes, 
which will require filtering by other means. Candidate genes may be selected 
for sequencing, as in the discovery of the PTHR1P gene’s role in Primary 
Failure of Eruption (Decker et al., 2008), however this may be tedious and 
expensive. The dense markers used in association analysis will increase the 
resolution and narrow the interval to be investigated. The precision obtained 
will depend on the age of the mutation, marker density and sample size. 
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1.3.17 Copy Number Variations and Loss Of Heterozygosity 
A copy number variation (CNV) is a segment of DNA that is 1 kb or larger and 
is present at a variable copy number in comparison with a reference genome.. 
CNVs with a population frequency of > 1% are called copy number 
polymorphisms or CNPs (Feuk et al., 2006). CNVs may be inherited in a 
Mendelian fashion, similar to SNPs and may often be in strong LD with each 
other (McCarroll et al., 2008). In theory, dense SNP arrays may detect CNVs 
by analysing the number of copies of that SNP and arranging them in 
chromosomal order, however it seems that the data clusters poorly and causes 
assays to produce Mendelian inconsistencies and violate Hardy-Weinberg 
equilibrium (McCarroll, 2008). SNP arrays may also be used for virtual 
karyotyping and will provide information in cases of copy number neutral loss 
of heterozygosity (LOH) (Mei et al., 2000). Current technology involves the 
use of dedicated copy number probes hybridised with SNP arrays, though these 
platforms may still have difficulty in detecting small copy gains or losses. 
CNVs affect less than 0.5% of the genome but are responsible for a large part 
of human variation; though evaluating the data from CNV analyses is not 
straightforward and the data is susceptible to a number of artefacts such as sex 
ratios and tissue type. A high false discovery rate is common. Furthermore, it 
seems that common CNVs available on current platforms are unlikely to play a 
major role in the genetic basis of common diseases (Craddock et al., 2010, 
Wang et al., 2012). As the disease model is that of Mendelian inheritance, it is 
possible that CNVs may play a part in the aetiology of EC and linkage analysis 
results may be used to filter the data. 
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1.3.18 Genetic markers 
A genetic marker should be locus specific, polymorphic and easily genoptyped. 
There are two types of genetic marker used in linkage analysis nowadays. 
Short tandem repeats (STRs) are a variant of microsatellite DNA consisting of 
short, repeated sequences of DNA, 2-5 bases long. The number of repeats 
varies considerably between individuals and therefore the markers are 
polymorphic, giving high information content (Evans and Cardon, 2004). SNPs 
are single-base variations in the DNA sequence. The vast majority of SNPs are 
biallelic and so are not as informative on an individual basis. There are 
advantages and disadvantages to using either SNPs or STRs as markers.  
On a one to one basis, SNPs are less informative than microsatellites because 
of their biallelic nature. This may be a disadvantage for association and linkage 
analysis. Polymorphism information content which is important in linkage 
analysis is one half to one third lower for SNPs than for STRs.  
Closely linked SNP markers with strong linkage disequilibrium (LD) will 
generate false positives. Many linkage analysis programs based on the Lander-
Green algorithm assume linkage equilibrium between genetic markers. 
(Abecasis et al. 2002). It has been demonstrated that this algorithm can give 
misleading results in the presence of linkage disequilibrium, especially if 
founders are not genotyped (Schaid et al. 2002). 
Multipoint linkage analysis is extremely sensitive to genotyping error and error 
rates as small as 1% can significantly decrease the power to detect loci 
(Abecasis et al. 2001). An increase in marker density also increases the number 
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of genotyping errors present in the data and the net effect may actually be a 
decrease in the power to detect linkage. Besides, the biallelic nature of SNPs 
reduces the ability of software packages to detect genotyping errors. 
However SNPs have several advantages over STRs. SNPs are much cheaper to 
genotype, in terms of cost and labour and they are associated with a lower 
genotype error (John et al., 2004). A dense map of SNPs provides greater 
linkage resolution. Thus savings can be made where fine mapping is required. 
SNPs are much commoner than STRs and therefore are much more closely 
placed. This increase in density makes them more informative than 
conventional microsatellites. LOD peaks which are not detectable by 
microsatellite scans may be ascertained by using dense SNPs (John et al., 
2004). SNPs are simpler to assay and also have a low mutation rate, therefore 
are more stable over generations. 
SNPs therefore do have drawbacks however but are cheaper and more efficient 
as markers than microsatellites and consequently are in wider use. The 
Affymetrix Genome-Wide Human SNP Array 6.0 chip (Affymetrix, USA) 
contains over 906,600 SNPs spaced evenly throughout the genome (Table 3). 
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Non Polymorphic Copy Number Probes 946,000 
SNP Average Inter-Marker Spacing (bp) 3230 
Copy Number Probe Average Inter Marker Spacing (bp) 3160 
Combined average coverage (bp) 1600 
Average Minor Allele Frequency (Caucasian) 19.6% 
Average Heterozygosity (Caucasian) 26.7% 
1.3.19 Next Generation Sequencing 
Linkage analysis has been successful in identifying many disease genes. 
However even under ideal circumstances the disease locus can rarely be 
mapped to an area of less than 1 Centimorgan (cM). An area this size may 
contain hundreds of genes and conventional Sanger sequencing entails 
considerable time and expense. The emergence of next-generation massively 
parallel sequencing and high throughput sequence capture methods has made 
possible the capture of the whole human genome. However whole-genome 
sequencing is limited in throughput and too expensive to investigate significant 
numbers of individuals. It also produces vast amounts of data that present 
problems in storage and computational power in analysis. The targeted 
sequencing of all known exons is far more cost effective. Protein coding 
regions constitute only 1% of the total human genome but are responsible for 
85% of mutations (Choi et al., 2009). Mutations having major genetic effects 
generally disrupt protein coding regions or exon splice sites, mutations in 
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regulatory regions tend to have lesser effects (Ng et al., 2009) . Thus exome 
sequencing is a highly efficient method of capturing a large percentage of 
genomic variation and has reversed the recent decline in interest in monogenic, 
Mendelian disorders (Antonarakis and Beckmann, 2006). Nonetheless, a large 
amount of data is generated which must be filtered to narrow the search down 
to a manageable number of candidate genes. The polymorphisms are filtered 
first against a control set, obtained either from public databases, assuming that 
there are no disease alleles present, or from a control cohort of individuals 
known to be unaffected. This leaves the 'novel' polymorphisms as potential 
candidates.  
Further filtering may be applied by comparing of affected individuals, either on 
a whole exome basis if unrelated or by comparison of areas IBD in related 
persons. The remainder of the polymorphisms may be prioritised by prediction 
of the functional consequences using programs such as SIFT (Kumar et al., 
2009) or PolyPhen2 (Adzhubei et al., 2010). 
1.4 Disease segregation 
One possible method of identifying the cause of EC is to use a trait which 
segregates out with the disease/trait as a marker for EC. There is a strong 
clinical association between ectopic canines, tooth agenesis and other dental 
anomalies, leading to the assumption that the causative loci may be in linkage 
disequilibrium. This approach has been successful in other genetically isolated 
populations such as Finland (Jorde, 1995). Case-control association analysis 
using the responsible polymorphism may lead to the gene(s) responsible for 
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ectopic eruption and the use of preselected markers would reduce genotyping 
costs. The strong presence of founder effects in the Maltese population makes 
this approach more feasible. There are a number of developmental anomalies 
associated with EC (Table 4).  
Table 4. The developmental dental anomalies associated with EC. 





incisors and lower 
second premolars 
Unknown Svinhufvud et al., 
1988; Pirinen et al., 
1996 




Vastardis et al., 
1996; Neubuser et 









Unknown Garn et al., 1961; 
Rune and Sarnas, 











Unknown Grahnen, 1956; Garn 
and Lewis, 1970; 
Becker et al., 1981; 
Baccetti, 1998; 
Langberg and Peck, 
2000; Paschos et al., 








Unknown Bjerklin et al., 1992; 




enamel on central 
incisors and 
molars 
Unknown Baccetti, 1998; 
Bartolo et al., 2010 
1.4.1 Heritable dental anomalies and EC 
Ideally, the variations recognised as being linked with these heritable dental 
anomalies would be used to locate and identify the gene responsible for EC as 
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these would be in linkage disequilibrium and indeed genes responsible for 
tooth agenesis have been identified in humans. However the experimental 
evidence is difficult to apply to the clinical situation. The genes known to be 
associated with non-syndromic tooth agenesis are MSX1, PAX9 and AXIN2 
(Vastardis et al., 1996, Neubuser et al., 1997, Lammi et al., 2004).  















AXIN2 * ** *** ** (Lammi et al., 2004) 
AXIN2 * ** *** ** (Bergendal et al., 2011) 
PAX9 n/a No ** *** (Stockton et al., 2000) 
PAX9 n/a * ** *** (Frazier-Bowers et al., 2002) 
PAX9 n/a No * *** (Nieminen et al., 2001) 
PAX9 No * ** *** (Jumlongras et al., 2004) 
PAX9 n/a * ** *** (Goldenberg et al., 2000) 
PAX9 n/a * ** *** (Arte, 2001) 
MSX1 n/a ** ** * (van den Boogaard et al., 2000) 
MSX1 n/a ** ** * (Lidral and Reising, 2002) 
MSX1 n/a No ** * (Vastardis et al., 1996) 
MSX1 No No ** * (Jumlongras et al., 2001) 
Whole blocks of teeth, chiefly incisors and premolars in AXIN2 cases, 
premolars and molars in the case of MSX1, and molars in the case of PAX9, are 
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found to be missing (oligodontia 2) in the reported families (Table 5). The 
clinical picture associated with ectopic canines is much milder and has been 
termed Incisor-Premolar Hypodontia (IPH). 
The genes MSX1, MSX2, EGF, EGFR, FGF-3 and FGF-4 have been excluded 
as candidate genes in humans. (Nieminen et al., 1995, Arte et al., 1996, 
Mostowska et al., 2003). Major craniofacial and other anomalies are also 
produced (Jabs et al., 1993, Qiu et al., 1995, Stockton et al., 2000, van den 
Boogaard et al., 2000). There are no effects reported on the eruption of teeth in 
affected families. The vast majority of research carried out on tooth agenesis 
has been on rodents. This causes problems as the dentitions are dissimilar. The 
incisors, unlike human teeth, are continuously erupting and there is only one 
dentition in rodents, corresponding to the primary dentition. In humans only 
the secondary dentition exhibits IPH, the primary being minimally affected. To 
date, experiments have concentrated on demonstrating the effect on 
odontogenesis only; no molecular studies have been published showing any 
association of these genes with tooth eruption. An attempt has been made to 
establish a link between ectopic canines and the genes Pax9 and Msx1 (Peck et 
al., 2002), however the evidence for this is scanty (Camilleri, 2005). The 
experimental oligodontia produced in Msx1 and Pax9 knockout animals also 
affects whole blocks of teeth, molars or incisors. 
The heterogenic nature of tooth agenesis has made it difficult to identify the 
culpable genes (Arte, 2001). Much research has been dedicated to identifying 
the cause of IPH, this being the subject of a COST (European Cooperation in 
2 The term oligodontia is taken to mean agenesis of more than 6 teeth. 
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Science and Technology) action in the late 1990s. However this has been 
fruitless to date, so the possibility of using IPH to identify the cause of EC 
remains remote. Likewise, no mutations have been identified as being 
responsible for other heritable dental anomalies associated with EC. 
1.5 Study Design 
1.5.1 Segregation Analysis 
Previous studies have indicated that the condition is transmitted in an 
autosomal dominant fashion (Svinhufvud et al., 1988). The most powerful 
methods for investigating Mendelian disorders are either exome sequencing or 
parametric linkage analysis. Problems may have been encountered with exome 
sequencing as family members share large parts of their genome, resulting in a 
large number of candidate genes if a single family was used. Also, locus 
heterogeneity may have confounded the results were unrelated individuals to 
be used. Several three-generation extended pedigrees had been ascertained. 
One family had a large number of affected members (8/21 members). This 
family would have been suitable for either parametric linkage analysis or 
whole exome sequencing, however parametric linkage analysis was deemed to 
be preferable as the intial investigation. 
1.5.2 Multipoint mapping 
Multipoint linkage analysis is more efficient than two-point analysis. The 
chromosomal order of linked loci can be established and the maximum 
inheritance information can be deduced from the available marker data. This is 
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particularly relevant to genotyping with SNPs as these are biallelic and 
consequently less informative. Multipoint analysis is susceptible to LD and this 
must be taken into account when using dense SNP arrays. The program 
MERLIN is an analytical method based on binary gene flow trees (Abecasis et 
al., 2002). MERLIN can perform both parametric and nonparametric 
multipoint linkage analysis, using dense marker maps and present this 
information in the form of haplotypes and whole genome scans. MERLIN can 
handle more than 100,000 markers on a chromosome when the family is of 
moderate size. MERLIN can also take LD between markers into account 
(Abecasis and Wigginton, 2005), though the program encounters problems 
when analysing small numbers of individuals (Rüschendorf, personal 
communication). Although the maximum number of members the program can 
handle is limited (max bits < 17) it can handle larger pedigrees than other 
linkage analysis programs. A major advantage of MERLIN over other 
programs is error detection, particularly non-Mendelian inconsistencies. As 
SNP genotyping errors are often not detected as Mendelian inconsistencies, 
this is a significant benefit. 
1.5.3 Choice of marker 
The SNP 6.0 chip has close to a million markers and dedicated copy and a 
similar number of dedicated Copy Number probes. The number of SNP 
markers is in excess of requirements, however would be useful were fine 
mapping to become an option. The present sample size is too small for 
association analysis to reach significance, however were the sample size to be 
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increased in the future; the data may well be useful. Copy Number Variation 
analysis would be carried out, with the advice of Dr. Bert Eussen, Dept. of 
Clinical Genetics, Erasmus MC, The Netherlands. 
Accordingly it was decided to carry out parametric linkage analysis on an 
informative extended family, using the Affymetrix SNP 6.0 chip 
for genotyping. The program MERLIN would be used for analysis, with 
advice from Dr Franz Ruschendorf, Max Delbruck Centre, Berlin. 
1.5.4 Whole Exome Sequencing 
This would be carried out on two distantly related affected members of the 
pedigree. Heterozygous, nonsynonymous variants or frameshift indels within 
suggestive LOD regions would be prioritised as candidate genes. These 
variants would then be examined by Sanger sequencing in all members of the 
pedigree to confirm their segregation with the phenotype and also in a number 
of unrelated individuals. 
1.5.5 In situ hybridisation 
In situ hybridisation would be carried out on candidate genes in order 
to determine if they are expressed in developing tooth tissue. The procedure 
would be carried out in the Department of Craniofacial Development and 
Orthodontics, King's College  London. 
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Chapter 2  Aims of the Study 
2.1 Aims and objectives 
The study has two aims. In view of the controversy over the aetiology of the 
trait, the first aim is to establish that EC does indeed have a genetic aetiology. 
The objectives here are to determine the familial relative risk, in order to 
establish that familial clustering is consistent with a genetic component and to 
determine the most feasible genetic model for the trait. 
The second aim is to attempt to identify the gene or genes responsible for EC. 
The objectives are to carry out a positional cloning experiment in order to 
identify transmission of a haplotype responsible for the trait. Sequencing of the 
areas of interest will highlight potential variants and in-situ hybridisation will 
determine whether the tissue of expression of these variants is appropriate. 
Unrelated cases will be examined in order to determine whether the same 
variants are responsible. The genes MSX1 and PAX9, as well as the SNPs 
identified as being associated with tooth eruption, would be examined for 
linkage and common variants. 
2.2 Null Hypothesis 
The null hypothesis is that there is no genetic aetiology for EC. 
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2.3 Potential Benefits 
Identification of a functional mutation may lead to development of a clinical 
assessment for the condition, whereby affected individuals may be recognised 
early and the appropriate interceptive measures taken.  
The eruption of teeth is dependent on the successful formation of an eruption 
pathway in the bone, through osteoclastic action (Cahill and Marks, 1980). 
Identification of the gene product may allow local control of osteoclastic 
activity, influencing the path of eruption of teeth. This is of particular relevance 
to the treatment of cleft lip and palate patients, where eruption of teeth into 
facial bone grafts is a major factor in stabilising the graft, ensuring its long-
term success (Bergland et al., 1986).  
Control of tooth eruption would reduce or eliminate the need for surgical 
procedures associated with buried and impacted teeth. 
Incisor-premolar hypodontia is closely linked to EC. Identification of the 
genetic cause of EC may facilitate identification of the genetic cause of 
hypodontia. 
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Chapter 3 Materials and Methods 
3.1 Segregation analysis 
Familial clustering is observed in many EC cases, but this is not in itself 
evidence of a genetic aetiology, as family members share a similar 
environment. The weight of evidence is consistent with a genetic aetiology, 
however a controversy does exist (Becker et al., 1981) and although the mode 
of transmission is thought to be autosomal dominant (Peck et al., 1994, 
Svinhufvud et al., 1988) other modes of transmission may exist (Feichtinger et 
al., 1977). Determination of the genetic component is necessary prior to 
embarking on a study of this type and this may be carried out by twin studies or 
by complex segregation analysis. A segregation analysis will provide a genetic 
model for carrying out linkage or association studies by quantifying the genetic 
component, determining the mode of transmission, establishing whether the 
trait is due to a single major gene or the product of several minor genes and 
determining the allele frequency and penetrance of the gene.  
A familial relative risk computation and a segregation analysis would first be 
carried out in order to determine whether the familial clustering is consistent 
with a genetic aetiology and also to determine the most feasible genetic model.  
Ethical approval was obtained from the University of Malta Medical School 
Ethics Committee (Ref. 063/2004; copy in Appendix I). Thirty-seven 
consecutive probands with ectopic maxillary canines were identified during 
routine clinical examination at a private clinic (SC) and at the School Dental 
Clinic, Floriana.  
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The maxillary canines were classified as being ectopic if the tooth was present 
but eruption had not taken place by the age of 16; if eruption had taken place 
either palatal to the line of the arch or high in the buccal sulcus, above 
keratinsed gingiva or was transposed or pseudotransposed; and crowding 
should not be the major factor in the position of eruption of the tooth. In the 
case of a congenitally missing lateral incisor, one or both of the canines had 
erupted mesial to its normal position, in place of the missing lateral. 
The inclusion criteria were Maltese ethnicity, taken as both sides of the family 
having been resident for a minimum of three generations and a positive history 
of ectopic (buccally or palatally displaced) canines or failure of eruption of the 
canine tooth by the age of 16. Individuals affected by an orofacial cleft or a 
genetic syndrome likely to influence eruption of teeth were excluded. A further 
set of twenty-six consecutive families was selected on the strength of two 
probands, in order to identify families with a stronger genetic predisposition. 
Families with an affected twin were investigated even if the other twin was 
unaffected. Ectopic or missing teeth were identified by clinical examination, 
from existing records or from the family history. Radiographic investigation 
was undertaken only where clinically necessary. The pedigrees may be found 
in Appendix 2. 
3.1.1 Data analysis 
The proportion of affected relatives in different groups was compared using a 
chi square test or Fisher’s exact test, where appropriate. The pedigree data was 
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analysed to assess the familial risk of EC and other related phenotypes, using 
the familial relative risk computed. 
The segregation analysis program Pedigree Analysis Program PAP, (Hasstedt, 
2005) was used to model the inheritance of EC throughout the 63 pedigrees. 
Pedigree members were defined as affected or unaffected with EC (with no 
further clinical information used). Genetic models assumed a single locus 
model with penetrances and mutation frequency maximized for each model. 
Nested models were compared using the likelihood ratio test, where the 
difference in -2log (likelihood) has a chi-square distribution, with the degrees 
of freedom equal to the difference in the number of additional parameters fitted 
in the most general model. Sporadic (no genetic effect), recessive and 
dominant models were compared to a codominant model. A polygenic model 
was also tested and compared to the dominant model. An ascertainment 
correction for the probands in each family was applied (Khoury et al., 1993). 
Five sets of monozygotic and six sets of dizygotic twins were included in the 
sample. A further two sets of monozygotic twins and one set of triplets were 
subsequently referred by a colleague aware of the research focus in twins. 
These were not included in the pedigree or segregation analyses however were 
used in assessing the pairwise concordance. 
3.2 Linkage analysis 
There have been few linkage studies on tooth eruption disorders. Cherubism is 
a familial autosomal dominant disorder that may be related to tooth 
development and eruption. A study by Tiziani established a linkage to 
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Chromosome 4p.16 with a LOD score of 4.21(Tiziani et al., 1999). Mangion 
performed a genome wide linkage search and localized the gene to 
chromosome 4p16.3, with a LOD score of 5.64. (Mangion et al., 1999). Using 
linkage and haplotype analysis, Ueki localised the area to a 1.5Mb region and 
detected point mutations in the SH3BP2 gene (Ueki et al., 2001). Parametric 
linkage analysis carried out by Decker on a 3-generation family found splice 
site mutations in the PTHR1 gene in affected individuals. These mutations are 
thought to cause premature degradation of the precursor or nullify the function 
of the receptor, causing haploinsufficiency (Decker et al., 2008). Other studies 
have since confirmed PTHR1 as the causal gene for Primary Failure of 
Eruption (Yamaguchi et al., 2011). In genome wide association studies, Pillas 
et al found five loci with suggestive association to the timing of primary tooth 
eruption (Pillas et al., 2010). Geller et al found four loci associated at genome 
wide significance with the timing of permanent tooth eruption in subjects 
between the ages of 6 and 14. One SNP was also associated with the timing of 
deciduous tooth eruption (Geller et al., 2011). 
An informative, three-generation, 21 member family with eight members 
exhibiting EC had been identified (Figure 4). The phenotypes were detailed 
(Figure 5).  
The phenotype of individual 41 was different from the rest of the affected 
kindred in that his canine had erupted high and buccal, though crowding was 
not evident. In addition, he did not exhibit hypodontia and his lateral incisors 
were of normal size. Provision was made for his being a phenocopy.
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Figure 4. The family tree used in the study. The pedigree numbers are outside the symbol, the age of the subject is inside. Males are 
square symbols, females round. Individual #41 was categorised as a phenocopy and so is not marked as affected. 
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Figure 5. The phenotypes of the affected members of the family. EC was present in all members. IPH was present in all affected 
members except #23 and #41. The canine in #41 was buccal and this individual was categorised as a phenocopy.
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Genomic DNA was obtained from saliva using Oragene kits (DNA Genotek, 
CA) and extracted according to the recommended protocol.  
Equipment: Water bath set at 50°C 
Reagents: Oragene·DNA Purifier (OG-L2P, Ethanol (70% and 90%) at room 
temperature, TE buffer (10 mMTris-HCI, 1mM EDTA, pH 8.0) 
microcentrifuge capable of running at 13,000 rpm (15,000 x g)  
The entire Oragene·DNA/saliva sample was mixed by inversion and gentle 
shaking for a few seconds. It was incubated in the water bath at 50°C for over 1 
hour. 500µL of the sample was transferred to a 1.5 mL microcentrifuge tube 
and 20 µL (1/25thvolume) of Oragene·DNA Purifier OG-L2P added to the 
microcentrifuge tube and mixed by vortexing for a few seconds. It was then 
incubated on ice for 10 minutes and centrifuged at room temperature for 5 
minutes at 13,000 rpm (15,000 x g). The clear supernatant was transferred with 
a pipette tip into a fresh microcentrifuge tube and the pellet containing 
impurities discarded. To 500 µL of supernatant, 500 µL(i.e., an equal volume) 
of room- temperature, 90% ethanol was added and mixed gently by inversion 
10 times. The tube was left to stand for 10 minutes at room temperature then 
placed the tube in the microcentrifuge in a known orientation and centrifuged 
at room temperature for 2 minutes at 13,000 rpm (15,000 X g). The supernatant 
was carefully removed and 250 µL of 70% ethanol was added and left to stand 
at room temperature for 1 minute. The ethanol was then carefully removed 
without disturbing the pellet. The 70% ethanol wash was repeated, then all 
ethanol was removed and the pellet dried in air overnight. The pellet was then 
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dissolved in 100 µL TE buffer by incubating at room temperature for at least 8 
hours, aliquoted and stored at -20°C for a maximum of three months. 
 The DNA was further purified using the phenol-chloroform method.  
Saturation of phenol with water 
Reagents: Phenol ,Water Bath, 8-hydroxyquinoline, Chlorofom, Isoamyl 
alcohol. 
Equipment: Large separating funnel, measuring flasks, Pasteur pipette, pH 
meter (Metroohm654 pH meter, Switzerland), Fume cupboard, 
Method: The crystalline phenol was placed in a water bath at 65°C until melted 
and twice the volume of distilled water was added to the phenol in a large 
separating funnel, in the fume cupboard. The phenol and water were mixed to a 
fine emulsion and then allowed to separate and the lower organic layer was 
collected. This step was repeated until the pH of the upper aqueous phase was 
found to be between pH3.0 and 4.5. 8-hydroxyquinoline was added as an 
antioxidant. 
An equal volume of 200mM Tris-HCl was added to water-saturated phenol in 
the separating funnel in the fume cupboard. The two phases were mixed well, 
allowed to separate at room temperature and the lower organic phase was 
removed. This step was repeated another two times. The equilibrated phenol 
was aliquoted and stored in light-tight containers under a layer of 100mM Tris-
HCl (pH 8.0) at -20°C indefinitely. 
Chloroform was added to isoamyl alcohol in the proportion of 24:1, then equal 
parts of phenol and chloroform:isoamyl alcohol were mixed. The mixture was 
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stored in light-tight containers under a layer of 100mM Tris-HCl (pH 8.0) at 
4°C for up to one month. 
The molecular weight of the DNA was assessed by visualisation on 0..5% 
agarose gel.  
Preparation of 50X TAE running Buffer  
Equipment: 1L Beaker, magnetic stirrer. 
Reagents: Tris-base: 242 g, Acetate (100% acetic acid): 57.1 ml, EDTA: 100 
ml 0.5M sodium EDTA. 
Method: The ingredients were mixed and distilled water added up to one litre. 
The stock mixture was stored at 4C. It was diluted for use by addition of 20 mL 
solution to 980mL distilled water. 
Preparation of gel 
Reagents: Agarose Gel, TAE running buffer, distilled water, Ethidium 
bromide, sealing tape. 
Equipment: Pyrex beaker, gel box and comb, microwave oven. 
Method:The TAE buffer was diluted to 1X and the appropriate mass of agarose 
measured out into a beaker with the appropriate volume of buffer. In this case, 
100mL was sufficient for most purposes. The beaker was microwaved until the 
agrose was fully melted. While the agarose was cooling, the open edges of the 
gel box were sealed with tape. The agarose solution was poured into the taped 
gelbox. and left to cool for about 30 minutes, until the gel was solid.  
The molecular weight of the samples was determined by electrophoresis. 
Materials: Mixing dish, electrophoresis bath, UV hood connected to scanner. 
Reagents: Loading buffer, 100 base-pair ladder. 
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Method: The comb was removed from the gel and placed in the electrophoresis 
bath. 4µL template DNA/PCR product was placed in the wells of the agarose 
gel. One well was reserved for the 100 base-pair ladder. The voltage was set to 
120v and left for 15 minutes. The gel was removed from the bath, placed under 
the UV hood and scanned. The images were saved to disk or discarded as 
appropriate. 
Purity was determined by spectrophotometry (Biophotometer, Eppendorf AG, 
Germany).  
Equipment: Tubes with a minimum capacity of 50µL, Spectrophotometer 
(Biophotometer, Eppendorf AG). 
Reagents: Distilled water or TE buffer 
Method 
The spectrograph was set to read for double stranded DNA. 5µL of DNA 
solution was diluted in 45µL (10x dilution) TE buffer. The spectrophotometer 
was calibrated to zero using TE buffer, noting the orientation of the cuvette. 
The cuvette was rinsed thoroughly using distilled water and dried. 50µL of the 
diluted DNA was placed in the cuvette, with the same orientation as the blank 
and the concentration and the 260/280 reading noted. Recalibration was carried 
out every 10 readings. 
3.2.1 Genotyping 
This was carried out at the Erasmus-MC laboratories in the University of 
Rotterdam (Netherlands Consortium for Systems Biology, P.O. Box 2040, 
3000 CA Rotterdam, The Netherlands) using Affymetrix Genome-Wide 
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Human SNP Array 6.0 chips. These chips contain 1.8 million genetic markers, 
including over 906,600 SNPs spaced at 1-5 kilobase (Kb) intervals throughout 
the genome and more than 946,000 probes for the detection of CNVs (Table 3). 
3.2.2 Quality Control 
Genotypes were called using the Birdseed Algorithm for Genome-Wide 
Human SNP Array 6.0. The quality control criteria for the genotyping data 
were set at a sample call rate of over 90%. Quality control call rate ranged 
between 90 and 98% and MAPD values were within bounds. 
3.2.3 Compilation of pedigrees 
The full pedigree, named V1, was used for quality control. The LOD score of 
the pedigree was estimated by assigning a score of 0.3 for each informative 
meiosis and subtracting 0.6 where the phase of the parents was unknown. 
Using this method, the maximum LOD score extractable from V1 was 
calculated to be 3.9. Assuming autosomal dominant inheritance and full 
penetrance, individuals #37, #49 and #410 would not contribute towards the 
final LOD score and would add to the computational burden.V1 was modified 
by removal of these individuals and renamed V2. The large family was split 
into two in version V3 in order to include all individuals. Individuals #37, 
#410, #49, #43 and #413 were removed from V1 in order to increase the speed 
of the run and used for quality control (V4). 
Although the criteria for ectopic eruption were satisfied, the phenotype of 
individual 41 differed from the rest of the affecteds in the family. In order to 
69 
avoid the possibility of phenocopies, the dissimilarity warranted his exclusion. 
#41 was coded unknown (V6) and unaffected (V7). The maximum LOD score 
from pedigree V7 was 3.9.  
As the segregation analysis and quality control checks indicated reduced 
penetrance, a parametric ‘affected only’ analysis was also carried out. All 
unaffected members were coded as unknown, this pedigree being named V8. 
The maximum LOD score for V8 is 1.5. These pedigrees may be found in 
Appendix 2. Pedigrees V8 and V7 were used in the final analysis. 
3.2.4 Data analysis 
The program Alohomora (Ruschendorf and Nurnberg, 2005)  was used to 
convert Affymetrix genotype data into linkage and haplotype information, 
create Merlin input files and to carry out quality control. The Caucasian allele 
frequency file “GW6_freqA_Caucasian_na23” and Genetic map 
“deCodeGW6_map_decode_na30_2009-11-13” were used (Affymetrix, USA). 
The linkage analysis program MERLIN (Abecasis et al., 2002), was used to 
carry out parametric multipoint linkage analysis on the pedigrees. The program 
was run at the Max Delbruck Centre, Berlin. 
MERLIN gives the option to use a sliding window to analyse the data, reducing 
computational requirements, however as this may result in false positive peaks 
at the peripheries of the window (Rüschendorf, personal communication), this 
option was not used in the pedigree analyses and each chromosome was 
calculated as a whole.  
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As the degree of penetrance was unknown, MERLIN was used to run a 
conservative, parametric ‘affected only’ analysis with the pruned marker set on 
pedigree V8 using a dominant model and a minor allele frequency (MAF) of 
0.001. Further analyses were also run on pedigree V7 with the genetic model: 
dominant with reduced penetrance, MAF 0.001, penetrances AA=0.00, AB= 
0.90, BB= 0.90, where A is the unaffected allele and B is the minor, disease 
allele. 
3.2.5 Genotyping Quality Control 
In order to verify the relationship between individuals, the data were subjected 
to standard quality assurance checks. Gender checking and relationship 
checking was carried out using the Graphical Representation of Relationship 
(GRR) program (Abecasis et al., 2001) and checking for Mendelian errors 
(PedCheck) (O’Connell and Weeks, 1998) were performed through Alohomora 
on pedigree V1. “Unlikely genotypes” are equivalent to double recombinations 
in a short chromosomal segment and may be due to genotyping errors or a 
wrong SNP position in the genetic map. These were deleted using Alohomora. 
3.2.6 Linkage Disequilibrium 
In order to exclude the effects of LD, two calculations were run using pedigree 
V4. An autosomal dominant model with full penetrance was assumed, with 
inter-marker distances of 10 Kb and of 50 Kb. A discrepancy between the 
results raised the suspicion that LD may be in operation. Merlin does take LD 
between markers into account, however large numbers of subjects are 
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necessary, program operation being problematical with one single family 
(Rüschendorf, personal communication). Further testing involved the use of a 
control set of 1460 samples, also genotyped with the Affymetrix SNP 6.0 chip. 
Here, markers were tested for Linkage Disequilibrium using the program 
PLINK (Purcell et al., 2007) and the option “ --indep-pairwise 1500 150 0.2”, 
where 1500 is the size of the moving window, 150 is the size of the window 
shift and 0.2 is the maximum value of r2 allowed. A pruned set of 86542 SNPs 
genome-wide was created, where the value of r2 did not exceed 0.2.  
3.2.7 Haplotyping 
This was carried out on the areas of interest using Haplopainter (Thiele and 
Nurnberg, 2005).  
3.2.8 Exclusion of linkage 
Using data derived from Pedigree V8, the LOD scores of markers spanning the 
genes, SH3BP2, PTHR1, MSX1 and PAX9 were examined in order to exclude 
the possibility of linkage. SNPs flanking those identified by Geller et. al. as 
being associated with the timing of permanent tooth eruption were similarly 
treated.  
3.2.9 Copy Number Variations 
The affected members of pedigree V8 were selected and allocated to two 
groups according to family branch. The unaffected members formed the 
control group. The data were then analysed using Nexus Copy Number 
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(Biodiscovery, USA) by comparing the average numbers of events in each 
affected group first separately and then in combination, against the control 
group. 
3.3 Whole Exome Sequencing 
3.3.1 Exome capture and library preparation 
This was carried out at the Department of Genetics, King’s College London. 
DNA from individuals 32 and 410 used as these samples were readily 
available. Sample preparation for exome sequencing was undertaken using the 
Agilent SureSelect All Exon Target Enrichment System for Illumina Paired-
End Sequencing. Briefly, 3μg of genomic DNA were diluted in 120μl TE and 
sheared into 150-200 bp DNA fragments, using a Covaris S220 ultra-sonicator 
(Covaris, USA) according to the manufacturer’s instructions. DNA fragments 
were purified using the Agencourt AMPure XP beads (Beckman Coulter 
International SA) on a Dynal magnetic separator (Invitrogen Corporation) and 
their size was assessed on an Agilent 2100 Bioanalyzer (Agilent Technologies 
UK), using DNA 1000 chips. Next, DNA end-repair, 3’-dA overhang and 
adapter ligation were carried out using the NEBNext® DNA Sample Prep 
Reagent Set 1 (New England Biolabs, USA), according to the manufacturer’s 
instructions. The necessary purification steps were carried out using Agencourt 
AMPure XP beads and the size of the DNA fragments was again assessed on 
an Agilent 2100 Bioanalyzer.  
The adapter-ligated libraries thus generated were amplified by PCR using the 
Herculase II Fusion DNA Polymerase Kit (Agilent Technologies UK) and 
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purified using the Agencourt AMPure XP beads. The libraries were quantified 
on a Qubit Fluorometer (Invitrogen Corporation, USA) and analysed with the 
Agilent 2100 Bioanalyzer. Five-hundred and fifty nanograms of each library 
was concentrated in a 3.4μl final volume and after 24h of hybridization with 
the target RNA baits, libraries were captured with Dynal MyOne Streptavidin 
T1 magnetic beads. The hybridised libraries were purified on a Dynal magnetic 
separator and amplified using the Herculase II Fusion DNA Polymerase Kit. 
The amplified and captured libraries were purified with Agencourt AMPure XP 
beads, assessed with an Agilent 2100 Bioanalyzer, using the 2100 High 
Sensitivity chip and quantified with a Qubit Fluorometer using the HS dsDNA 
assay kit. Based on the average length of DNA fragments, libraries were 
diluted to a 1nM final concentration, in a volume of 32μl, according to the 
following formula:  
μg DNA  x  106pg  x  1 = pmol DNA 
  660pg          1μg       N     
where N is the length of the fragment and 660pg/pmol is the average molecular 
weight of a nucleotide pair. 
3.3.2 Massive parallel sequencing 
Clonal cluster generation was performed in a cBot Cluster Generation System 
(Illumina Inc, USA), using the Standard Cluster Generation Kit v4 according to 
the manufacturer’s guidelines. Initially, single–molecule DNA templates were 
immobilised in the flow cell and copied by 3’ extension. After removal of the 
original DNA templates, the immobilised copies were subjected to isothermal 
bridge amplification. Following linearisation, blocking and primer 
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hybridisation of the DNA clusters, 76bp paired end reads were generated in a 
Genome Analyser IIx (IlluminaInc, USA), using the TruSeq SBS Kit v5–GA 
Κit. 
3.3.3 Stepwise filtering approach for exome sequencing 
Exome sequencing was carried out using the SureSelect All Exon Target 
Enrichment System (Agilent Technologies UK) and sequencing on a Genome 
Analyser IIx (IlluminaInc USA) with 76bp paired end reads. Sequence reads 
were aligned to the human reference sequence hg18 using the 
Novalignsoftware (Novocraft Technologies SdnBhD). PCR and optical 
duplicates were removed with MarkDuplicates 
(http://picard.sourceforge.net/index.shtml) and poor quality alignments were 
removed using the SAMtools software (Li et al., 2009).Capture efficiency and 
completeness were assessed with the BEDtools package (Quinlan and Hall, 
2010).Variants with a minimum 4X coverage were called using SAMtools and 
each call set was evaluated based on the number of variant sites and the 
transition to transversion mutation ratio. Variant annotation was carried out 
using the Annovar software (Wang et al., 2010). Variants that were not present 
in either dbSNP (build 129 and 132) or the 1000 genomes dataset (December 
2010 data release) or in 250 additional control exomes available in-house were 
considered as novel. The data was analysed using Microsoft Excel, filtering for 
heterozygous, nonsynonymous variants or frameshift indels with a frequency 
of < 0.001 in the 1000 Genomes or dbSNP databases. Variants were also 
checked against the pooled allele frequencies of 50 Maltese subjects. Variants 
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present at a frequency < 0.1were also included in subsequent analysis. Variants 
not present in both sets of exomes were then discarded. Variants that were not 
consistent with the inheritance pattern of each trait and with prior linkage data 
were filtered out. As the disease has been predicted to be dominant, 
homozygous variants were discarded. Nonsynonymous SNVs or frameshift 
insertions/deletions (indels) in exons or splice sites were prioritised. 
Pathogenicity of putative disease causing variants was assessed using the SIFT 
algorithm (Kumar et al., 2009) and PolyPhen2 (Adzhubei et al., 2010). Gene 
expression pattern and function, where known, were also taken into account in 
selecting candidates for further investigation. 
DNA was also collected from 18 other unrelated EC cases recruited 
consecutively, for validation of the results. 
3.3.4 Sanger Sequencing 
The four variants were sequenced in the whole family, Sequencing of exon 1 
and intron-exon boundaries of PPP1R14C as well as exon 17 of ANO5 was 
carried out on 18 other unrelated sporadic cases. Details of the primers and 
thermocycler programs used for PCR are given in Tables 6 and 7. Reddymix 
1x mastermix (Thermo Scientific, USA), was used following the 
manufacturer’s instructions. PCR products were visualised on 1.2% agarose 
gel.
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Table 6. Primers for Investigation of Candidate Genes. 
Primer 






PPP1R14C PPP1F GTCCTCGGCGGCTTCTTT 57°C 579 
PPP1R GGGCACAGAGGAGCTAGAGA 
ANO5 ANO5F AACCCTTCCAACCAAAACCT 52°C 190 
ANO5R AAAAATCTGTTTCCCGGTCA 
EPM2A EPM2AF TCCTACCGTTCTGTTTTTCACTC 55°C 434 
EPM2AR CTGCAGTTTCGAACACAGTAAA 
VSTM2L VSTM2LF CAGCTGAAGCCAGACCACTC 56°C 482 
VSTM2LR AGGAAGAAGGGAGGGAGACA 
Table 7. Conditions for PCR. The same program was used for all four 
primer pairs. 
Cycle 
95○C 5 min 
95○C 20 seconds 30 cycles
**○C 35 seconds 
72○C 50 seconds 
72○C 7 minutes 
5○C hold 
3.4 In situ hybridisation 
In situ hybridisation was carried out in the Department of Craniofacial 
Development and Orthodontics, Dental Institute, King’s College on human 
embryos. In situ hybridisation (ISH) was carried out at the epithelial thickening 
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stage and the bud, cap and bell stage for both PPP1R14C and ANO5.  
The probe, chamber solution and hybridisation buffer were prepared. 
Synthesis of 32S Probe 
Mix: 
5X reaction buffer    5.0µl: 
1M DTT         0.5μl 
10mM GTP       1.2μl 
10mM ATP        1.2μl 
10mM CTP        1.2μl 
50μM UTP        1.0μl 
DNA           6.4μl 
RNasein (40U/μl)    0.5μl 
35S UTP         7.0μl 
Polymerase enzyme    1.0μl 
and incubate 40 mins at 37°C. Add 1μl Polymerase enzyme more and incubate 
60 mins at 37°C. Add: 
DNase 2.5μl /tube 
RNase Inhibitor  0.5μl 
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tRNA (10mg/ml)  1.0μl 
1M DTT      0.5μl 
RNase-Free DNase 0.5μl 
Incubate 10 min at 37°C . Then add 
DEPC H2O 160μl 
1M DTT   4.0μl 
5M NaCl  4.0μl 
3M NaOAc 20μl (Sodium Acetate) pH 5.2 
EtOH    400μl 
Precipitate O/N at -20C, 588µl/tube, or 1h at -80°C, centrifuge at 13,000rpm 
for 10mins and add 10mM DTT/EtOH Wash 500μl/tube, centrifuge at 
13,000rpm for 10mins and add 50mM DTT/H2O 50μl/tube. Add Hydrolysis 
Solution 50µl/tube at 60℃. Add 10mM DTT/EtOH Wash 500μl/tube, 
centrifuge at 13,000rpm for 10mins and add 50mM DTT/H2O 50μl/tube. Add 
Hydrolysis Solution 50µl/tube at 60℃ 
Add Neutralising Buffer 50μl/ tube (on ice), add PPE 504μl/tube. Place in -
80°C freezer for 1 hour, centrifuge at 13,000rpm for10mins and add 10mM 
DTT/ EtOH wash 500µl/tube. Centrifuge at 13,000rpm 5mins and dry for 5 
mins. Add 50mM DTT/ H2O 50μl / tube and store in -80°C freezer. 
Solution for Chamber 100 ml/1 Chamber 
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10 mls 20X SSC 
50 mls Formamide 
40 mls H2O 
Hybridisation Buffer 
885μl = Buffer for 1ml (final probe) 
Formamide 500µl 
50% Dextran Sulfate 200µl 
5M NaCl 60µl 
20mg/ml tRNA 25µl 
1M DTT 50µl 
1M Tri-Hcl pH8.0 20µl 
0.5M EDTA 10µl 
50X Denhalt’s 20µl 
(2 X 104/cpm) X number of slides X 100μl = probe for Hybridisation buffer 
S35 probe + Hybridisation Buffer + DEPC H2O = 100μl for 1 slide 
E.g. if cpm=800,000 and 4 slides for in situ, (2 X 104/800000) X 400 = 10 
S35 probe 10μl + Hybridisation Buffer 354μl + DEPC H2O 36μl = total 400μl 
80 
The tissue was frozen, sectioned, dehydrated and fixed with paraformaldehyde. 
It was then permeabilised with Proteinase K, to allow penetration of the probe 
in order that it may hybridise with the target. The 32S probe was mixed with 
hybridisation buffer. The hybridisation solution was then applied and heated to 
denature the probe. Excess probe was digested with RNase and washed off. 
Dithiothreitol and Ammonium Acetate were added. The hybridisation was 
visualised by dipping in radiosensitive emulsion and prolonged darkroom 
exposure (2 weeks). The slides were then developed and fixed. 
Day1 
Place slides in 15 mins Histoclear X2, then place in 2 mins 100% EtOH. 
Rehydrate by placing in   
2 mins 95% EtOH (17.5 mls H2O + 332.5 mls EtOH) 
2 mins 90% EtOH (35 mls H2O + 315 mls EtOH) 
2 mins 80% EtOH (70 mls H2O + 280 mls EtOH) 
2 mins 60% EtOH (140 mls H2O + 210 mls EtOH) 
2 mins 30% EtOH (280 mls H2O + 70 mls EtOH) 
2 mins DEPC H2O (repeat)      
20 mins HCL in DEPC H2O 
Permeabilise by digestion with Proteinase K by placing for 
5 mins 2 X SSC (35 mls 20X SSC + 315 mls H2O) 
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10 mins ProK (35 mls 1M Tris pH8) 
2 mins 2mg/ml Glycine in DEPC PBS (700μgs Glycine+350 mls PBS) 
1 min PBS (Repeat step) 
Fix for 20 mins in 4%PFA in PBS (14 g PFA + 200 mls PBS) 
 Rinse for 2 mins PBS 
Acetylate by placing for 10 mins 0.1M Triethanolamine (TEA) in H2O 
(4.65mls TEA +345.35 mls H2O+ HCL 800μl +875μl acetic anhydride (AA)) 
Stir thoroughly 
Wash for 5 mins with PBS followed by 2 mins in DEPC H2O 
Place for 2 mins 30% EtOH         
2 mins 60% EtOH        
2 mins 80% EtOH        
2 mins 90% EtOH       
2 mins 95% EtOH       
2 mins 100% EtOH          
Day2 
Prepare 2L Wash solution mix 200 ml 20X SSC with 1L Formamide, 800 ml 
H2O and g DTT 
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Rinse slides for 15 mins in Wash Solution at 55 °C, followed by a further 20 
mins rinse at 55 °C and a final rinse at 65 °C. Then rinse twice for 15 mins 
rinse in RNase Buffer at 37 °C 
Rinse for 30 mins in RNase A (40μg/ml = 10 mg/250 ml) at 37 °C followed by 
a further 15 mins rinse in RNase Buffer 37 °C and two rinses of 20 mins rinse 
in Wash Solution at65 °C. Rinse for 20 mins in 0.1 X SSC/DTT at 65 °C and a 
further 5 mins rinse in 0.1 X SSC/DTT RT. 
Rinse for 2 mins in Ammonium Acetate/ 70% EtOH, 2mins in 95% EtOH, 
2mins in 100% EtOH and leave for 1 hour to dry 
Day3 Dipping 
Waterbath 45 °C, 2％ Glycerol, 1:1 emulsion 
After dipping, leave slides 2 hours in dark box, then slides should be left in 
4°C. 
2 weeks later. Developing 
Developer: 
Developer: 31.6 g/200 ml dH2O. Warm water up to 40°C. After dissolving 
powder, cool to 17°C. 
Fix: Fix 50ml, dH2O 150 ml 
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Place slides in developer 5mins and wash with tap water. Fix for 5mins and 
wash with running tap water for 1hour. Dip slides in distilled water and place 
in Hematoxylin (1/4) for 2-4 mins. Wash with tap water for 10mins 
Control slides detect false positives resulting from background, either by 
targeting another area of the transcript or by using unlabeled or antisense 
probes. In this situation, due to the scarcity and expense of the tissue sections, 
control slides were not specifically used, however both ISH procedures were 
carried out on adjacent slides, with the different slides acting as each other’s 
control. 
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Chapter 4 Results 
4.1 Segregation analysis 
Sixty-three families were identified in total. The number of individuals of 
known dental status was 524. One hundred and thirty-nine individuals had EC. 
The percentage of dental anomalies in the sample for first degree relatives was 
noted and differences against published population prevalences investigated. 
In the first degree relatives of EC probands there was a significantly higher 
prevalence of EC (15%, p < 0.001) and lateral incisor agenesis (7.88%, p = 
0.01) as compared to figures for the Maltese population.  
There were eight cases of maxillary canine transposition in the whole sample. 
Three were probands, five were first degree relatives; one was a second degree 
relative. Seven were in the upper jaw, giving a prevalence of 1.4%. This is 
significantly higher (p<0.001) than the prevalence estimated in a Caucasian 
population. Two cases of mandibular canine-lateral incisor transposition were 
also recorded.  
The percentage of first, second and third degree relatives with ectopic 
maxillary canines was used to calculate the relative risk (λR) to the first, second 
and third degree relatives. This is calculated as (λR= κR/κ) where κ is the 
population prevalence and κR is the percentage of relatives affected according 
to the type of relative i.e. of the first, second or third degree. Ascertainment 
bias was corrected for by exclusion of the probands from the calculation. The 
result is shown in Table 8. The relative risk was then used to plot the dropoff 
for each decreasing degree of unilineal relationship (Figure 6). There was no 
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difference in EC risk between families ascertained from one or two probands 
for first, second or third degree relatives (p = 0.49, p = 0.52, p = 0.65). Nor was 
there a difference in the numbers of sib-sib and parent-offspring affected pairs 
for each type of family ascertainment (p = 0.89) 
Table 8. The proportions of ectopic canine-affected subjects used in 
calculating the relative risks. 
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There was an appreciable gender bias, with the affected Female to Male Ratio 
for 1st, 2nd and 3rd degree relatives being 1.78.  The gender ratio for the 
probands was 1.64 and elimination of the probands from the calculation gave a 
ratio of 1.89. However there was no appreciable risk difference between 
relatives of male or female probands, p = 0.77  
The proportion of male first degree relatives affected vs. proportion of female 
first degree relatives was not significant, (p= 0.12) 
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Figure 6. Relative risk dropoff as a function of degree of relation. In 
diseases where the parameter λR -1 decreases by a factor of 2 for each 
decreasing degree of unilineal relationship, this is suggestive of a single 
locus. (λR = Relative Risk).  
Although there was no evidence of sex-linked transmission, 85% of the three-
generation families show instances where an obligate carrier showed a normal 
phenotype, although the condition was transmitted to their children. Repeat- 
sequence diseases exhibit anticipation, i.e. increasing severity or earlier 
incidence of the disease through generations. There was no apparent pattern of 
anticipation no augmentation or attenuation of phenotype through the 
generations was noted. 
The segregation analysis program PAP was used to fit different genetic models 
to the pedigrees. A likelihood ratio test was applied to determine any 
significant difference in the fit of the various models (Table 9). All the genetic 
models fitted provided a significantly better fit than the sporadic model, 
confirming that EC has a genetic basis. The parameter estimates from the co-
dominant model were very similar to the dominant model. The dominant model 
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had the least parameters and therefore provided the more parsimonious model, 
with the -2log (likelihood) for the recessive model being substantially higher. A 
mixed dominant model did not provide an improved fit, implying that there is 
no evidence for a polygenic component in addition to the Mendelian locus. 
These results showed that a single dominant gene best accounts for the 
inheritance of EC in these pedigrees, with a mutation frequency of 11%, and 
penetrances of 36% in mutation carriers. From the dominant model fitted in the 
segregation analysis, the risk to the sibling of an EC case was approximately 
0.18. This compared well with the average estimate of 0.15 obtained from the 
pedigree analysis. The population prevalence predicted by the dominant model 
was determined using the formula: q2*p1 + 2q(1-q)*p2 + (1-q)2*p3, where q is 
the allele frequency, and p1, p2, p3 the penetrances for the three genotypes. 
The calculated prevalence was 7%, which also compared well with the 
estimated population prevalence of 5.5%. This supports the dominant model as 
being the most likely. 
Seven pairs of monozygotic twins formed part of the sample (Table 10). Of 
these, five were completely discordant, in that one twin was unaffected. Of the 
other two pairs, one pair was a mirror-image and the other set had one twin 
affected unilaterally, the other bilaterally. The pairwise concordance in this 
sample was 28.6%. Curiously, one set of twins exhibited both ectopic and 
supernumerary teeth, being discordant for the numbers of both ectopic and 
supernumerary teeth. Seven pairs of dizygotic twins are also on record, with 
two showing concordance for EC, a pairwise concordance rate of 28.6%. 
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Table 9. The -2 log likelihoods of the various models tested. The wild-type 
allele frequency and the penetrance of the genotypes AA, AB and BB were 
computed for the various models. Chi square tests were used to compare 
models with a difference of no more than one degree of freedom. 









AA AB BB h2 
Mixed 
Dominant 0.89 0 0.32 0.47 379.76 4 - 0.09 
Polygenic - 0.12 0.4 384.49 2 
0.07 
Sporadic - 0.18 - 387.86 1 
0.01 
Dominant 0.89 0 0.36 - 380.34 3 
1.00 Co-
dominant 0.89 0 0.36 0.36 - 380.34 4 0.09 
Recessive 0.38 0 0.32 - 383.22 3  - 
Table 10. The pairwise concordance rates of the monozygotic and 
dizygotic twins/triplets in the sample. 
Monozygotic Twins Multiple births 
Sex Concordance (No. of impacted canines) Sex 
Concordance (No. of impacted 
canines) 
1 F 1 1 F/F 1 2 
2 F 1 0 F/F 1 1 
3 M 1 0 F/F 0 1 
4 M 1 0 F/F 3 0 
5 M 2 0 F/F 2 0 
6 F 1 0 M/M/M 0 1 0 
7 F 2 1 F/F/F 0 0 1 
Concordance = 2/7;     28.6% Concordance = 2/7;      28.6% 
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4.1.1 Discussion 
4.1.1.1 Dental Anomalies 
There was a significantly higher prevalence of EC in first degree relatives of 
EC probands (15%, p < 0.001) as compared to figures for the Maltese 
population (Camilleri, 1995)(Camilleri et al., 1995 unpublished observations). 
Familial clustering is a common feature of the trait; however this could be due 
to environmental as well as genetic factors. 
The prevalence of canine transposition in the sample was far higher than the 
0.27% prevalence estimated in a Caucasian population (Yilmaz et al., 2005). 
The highly significant difference is indicative of transposition being an extreme 
variant of EC and is consistent with the highly variable expression exhibited. 
The prevalence of lateral incisor agenesis in the Maltese population is 3% 
(Camilleri and Mulligan, 2007). The high figure found in association with EC 
suggests that both traits are related, in keeping with previous evidence (Becker 
et al., 1981, Svinhufvud et al., 1988, Peck et al., 1994, Pirinen et al., 1996, 
Baccetti, 1998). A limitation is that the prevalence of premolar agenesis was 
not calculated as this is difficult to estimate in family members unaffected by 
EC without undertaking radiographic investigation. As the manifestations of 
hypodontia are extremely variable, the prevalence may have been 
underestimated here.  
4.1.1.2 Pedigree Analysis 
The pattern of transmission was that of an autosomal dominant trait. 
Expression was highly variable both within and between families. Incomplete 
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penetrance was evident with obligate carriers unaffected by EC. This may be 
explained by the highly variable expressivity seen, with failure of penetrance in 
some cases. 
Considering the high population prevalence, the figure for λR suggests a major 
genetic component. When the dropoff in λR-1 (decreasing degrees of relation) 
was plotted as a function of the relative risk, the gradual decrease for every 
decreasing degree of relationship was strongly suggestive of a single locus, 
though it did not rule out genetic heterogeneity (Risch, 1990) (Figure 6). 
However, there was no difference in prevalence between families ascertained 
from one or two probands for first, second or third degree relatives. Nor was 
there a difference in the sib-sib/parent-offspring relationships in the two types 
of family. This is indicative of a single gene as multiple genes would be 
expected to give a higher prevalence in families ascertained from two 
probands. 
There was a considerable gender bias towards females. This was not in itself 
surprising as there is a greater tendency for females to seek orthodontic 
treatment than males (Chestnutt et al., 2006). Elimination of the probands from 
the calculation produced an increase in the Female to Male ratio of the sample. 
There is no plausible explanation to date for this bias. However there was no 
significant difference between the risks to relatives of male or female probands. 
This reinforced the evidence for a major genetic component. Were the trait to 
be multifactorial, the risk would be higher for the relatives of the less 
susceptible gender (Pericak-Vance and Haines, 1998).  
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4.1.1.3 Segregation Analysis 
The inheritance of EC in the families was modelled assuming a single major 
gene and with polygenic inheritance. The results of the segregation analysis 
implied that the sporadic model was rejected compared to all the genetic 
models. The dominant model fitted equally as well as the co-dominant model, 
suggesting that a dominant mode of inheritance adequately described the 
inheritance of EC in these pedigrees. The polygenic model was rejected, and 
there was no evidence for a polygenic component in addition to a dominantly 
inherited major gene. 
4.1.1.4 Twin study 
The inclusion of the first five sets of monozygotic and the first six sets of 
dizygotic twins was serendipitous. These families were selected on the basis of 
affected probands only. The low concordance shown by the monozygotic twins 
(Table 10) was indicative of epigenetic or other factors influencing the eruption 
of teeth and was at variance with the epidemiological evidence of a major 
genetic component to the condition. Furthermore, the incidence of 
monozygotic twinning for the Maltese Islands is 4.5 per 1000 (Savona-Ventura 
and Grech, 1988). The prevalence of monozygotic twins selected 
consecutively, (i.e. the first five sets) in this sample was nearly double that 
number and the difference was statistically significant, (p = 0.01) 
Monozygotic twins share identical DNA sequences, however they are often 
discordant for certain phenotypes including complex diseases. Twin 
discordance has been reviewed by Silva (Silva et al., 2011) (Table 11).  
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Table 11. Causes for monozygotic twin discordance (Silva et al 2011). 
Zygotic Chromosomal mosaicism (pre and post-twinning) 
Unequal allocation of stem cells between twins 
Unequal placental territoriality 
Epigenetic Differential DNA methylation 
Skewed X inactivation 
Genomic imprinting 
Mitochondrial Unequal distribution of mitochondrial DNA 
Different level of heteroplasmic mutations 
Genomic DNA Post zygotic gene mutation 
Transposition of mobile elements 
Differential triplet repeat expansion 
Copy number variations 
In the case of EC, the segregation analysis showed the disorder most likely to 
be genetic, autosomal dominant and unlikely to be due to a de novo mutation. 
The possible means to explain discordance in these twins may be heritable 
epigenetic mechanisms such as differential DNA methylation. Copy number 
variations (CNV) may also be a possible explanation (Notini et al., 2008). De 
novo, asymmetric CNV formation may be associated with the twinning event 
(Bruder et al., 2008). There was no pattern of anticipation, i.e. increasing 
severity or earlier incidence of the disease through generations and therefore no 
evidence from the pedigree analysis to support repeat expansion as a cause for 
EC. 
Methylation of Cytosine-Guanidine (CG) dinucleotides found in stretches of 
multiple repeats (CpG islands) affects regulatory regions. Certain imprinting-
associated diseases such as Beckwith-Wiedemann Syndrome are associated 
with multiple births and discordance in monozygotic twins (Elliott and Maher, 
1994). Methylation aberrations may be transmitted through generations 
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(Rakyan et al., 2001, Sandovici et al., 2003). Incomplete erasure of methylation 
patterns in the germline may give phenotypes exhibiting variable expression 
and incomplete penetrance (Kearns et al., 2000). Incomplete penetrance is 
usually attributed to differences in action of quantitative trait loci however 
there is no evidence of polygenicity in this case. Promoter methylation is a 
possible explanation for the highly variable expression and incomplete 
penetrance seen in EC subjects.  
4.1.2 Conclusions 
The evidence gathered from analysis of the pedigrees supported the hypothesis 
of a genetic aetiology for EC, with a single locus being involved. The most 
likely mode of transmission was autosomal dominant. On a population level, 
there was a mutation frequency of 11%, with penetrance of 36% in mutation 
carriers. There was no indication of a major environmental component in this 
sample. Further investigation into the molecular aetiology of EC is therefore 
justified and parametric linkage analysis on an informative family is feasible.  
4.2 Genome wide linkage analysis 
4.2.1 Results 
All quality assurance checks were completed successfully on pedigree V1. 
Pedigree V2 may have included a phenocopy and was only used to confirm the 
quality control results on V4. No analysis was carried out on Pedigree V3 as 
the separation of the two families would result in greater loss of information 
than would be gained by the inclusion of individuals 37, 49 and 410. The 
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analysis of V6 would not give any additional information over that provided by 
V7; this pedigree was also discarded. 
4.2.1.1 LD quality control 
The calculation run on V4 10 Kb gave a narrow peak of 60 Kb with a LOD of 
3.3 on chromosome 1p21. Increasing the marker spacing to 50 Kb gave a 
smaller peak in a different region. The width of the peak and the shift in 
position3 led to the suspicion that this peak may be an artefact caused by LD 
(Table 12). This was confirmed by a similar calculation using V2 and the LD 
pruned marker set, which gave no positive peaks at all. 
Table 12. The change in size and position of the peak with a spaced 
marker set. 
Pedigree Start Position End Position  Size (b) LOD 
V4 10 Kb 95,352,399 95,981,826 629,427 3.3 
V4 50 Kb 85,332,120 85,553,405 221,285 2.5 
4.2.1.2 Analysis of V8 
Maximal LOD scores of 1.5 were seen on Chromosomes 4, 5, 6, 11, 13 and 20. 
(Table 13, Figure 7A). 
3All chromosomal positions refer to Genome Reference Consortium build 37. 
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Table 13. Positive LOD scores Pedigree V8. 
Pedigree Chr Start Position End Position Size (b) LOD 
V8 4 141,629,176 146,281,857 4,652,681 1.5 
V8 5 178,621,576 180,692,321 2,070,745 1.5 
V8 6 143,837,815 153,851,594 10,013,779 1.5 
V8 10 15,264,688 15,292,006 27,318 0.9 
V8 11 20,154,539 36,454,231 16,299,692 1.5 
V8 13 107,344,212 115,106,996 7,762,784 1.5 
V8 20 35,972,287 59,411,348 23,439,061 1.5 
4.2.1.3 Analysis of V7 
With the reduced penetrance dominant model, (AA 0.00; AB 0.90; BB 0.90) a 
LOD score of 2.6 on Chromosome 11p13-15 was seen, as well as a LOD of 2.5 
on Chromosome 20q.13. (Table 14, Figure 7B). The V7 analysis supported that 
of V8 in that the peaks on Chromosomes 6 and 11 remained broad. The areas 
of greatest interest were therefore the peaks on Chromosomes 6 and 11. There 
was a narrow peak on Chromosome 20 which reached a LOD of 2.5 and 
therefore bore investigating too. 
Table 14. Positive LOD scores Pedigree V7 
Pedigree Chr StartPosition EndPosition Size (b) LOD 
V7 4 141,692,883 146,281,857 4,588,974 0.6 
V7 5 178,621,576 180,692,321 2,070,745 1.6 
V7 6 143,837,815 153,851,594 10,013,779 1.6 
V7 11 20,020,564 36,454,231 16,433,667 2.6 
V7 20 55,026,741 57,832,175 2,805,434 1.6 
V7 20 57,832,175 57,941,413 109,238 2.5 
V7 20 57,941,413 59,411,348 1,469,935 1.6 
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4.2.1.4 Haplotyping 
Haplotyping of the areas with the highest LOD scores in pedigrees V7 and V8 
was carried out using all markers in order to identify the regions of interest. A 
common haplotype was seen in V7 on Chromosome 6 for all affected members 
plus #36 and 411, Chromosome 11 for all affected members plus individual 
#43 (Fig 9), plus another on Chromosome 20 for all affected individuals and 
#38 #41 #411 and #413 (Figure 10). 
4.2.1.5 Exclusion of linkage 
Using data from pedigree V8, the LOD scores on markers spanning the genes 
SH3BP2, PTHR1, MSX1 and PAX9 were found to be less than -2. This is the 
accepted score for exclusion of linkage (Morton, 1955) (Table 15).  
Table 15. Linkage exclusion of eruption related genes. 
Pedigree Gene 1st Marker LOD 2nd Marker LOD 
V8 SH3BP2 rs433030 -2.5 rs1263416 -2.5 
V8 PTHR1 rs1531136 -2.5 rs2132173 -2.5 
V8 MSX1 rs4348044 -2.5 rs3775261 -2.5 




Figure 7. (A) V8 LOD plot. The maximum LOD from this pedigree was 1.5 
and maximum scores were seen on chromosomes 4, 5, 6, 11, 13 and 20. (B) 
V7 LOD plot. The maximum LOD from this family was 3.9 and scores of 
2.6 and 2.5 were seen on chromosomes 11 and 20 respectively. 
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Figure 8. The haplotype on Chromosome 6. The disease haplotype is in 
red, inherited from the maternal founder. Markers have been selected for 
illustration, not all are shown. 
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Figure 9. The haplotype on Chromosome 11. The disease haplotype is in 
red, inherited from the maternal founder. Markers have been selected for 
illustration, not all are shown. 
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Figure 10. The haplotype on Chromosome 20. The disease haplotype is in 
red, inherited from the paternal founder. Markers have been selected for 
illustration, not all are shown. 
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SNPs flanking those indicated by Geller et.al. were also tested for exclusion. 
(Table 16). 
Table 16. Linkage exclusion of SNPs flanking those identified by Geller et 
al. 
Pedigree Chr SNP 1st Marker LOD 2nd Marker LOD 
V8 1 rs2281845 rs12561765 -6.1 rs1059625 -6.1 
V8 2 rs4491709 rs2888447 -6.1 rs7561690 -6.1 
V8 10 rs7924176 rs1874152 -6.2 rs10509350 -6.2 
V8 12 rs12424086 rs1042725 -9.6 rs10878353 -9.6 
4.2.1.6 Copy Number Variations 
No significant copy number events were evident in the areas defined by the 
linkage analysis. 
4.2.2 Discussion 
4.2.2.1 LD and quality control 
The results of the quality control V4 analyses indicate that LD may be in 
operation even with an inter marker spacing of 50 Kb. The narrow initial peak 
obtained in V4 10k and the subsequent shift and further narrowing of this peak 
is indicative of this phenomenon. The use of a pruned marker set confirmed 
this result. In the V2 analysis, using the LD pruned marker set and an 
autosomal dominant model with reduced penetrance, the LOD score of 3.3 
obtained in V4 10k dropped to -1.40. The criterion for exclusion of linkage is a 
LOD of -2, so the LOD score indicated an area of minimal importance. 
Comparing the two methods used to reduce the effects of LD, selection of 
marker SNPs on the basis of genetic distance is a more reliable method than 
selection by physical distance. 
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LD is a recognised problem in pedigrees where parental genotypes are missing. 
This is not the case here. The reason why such strong LD effects should be 
operating in an informative pedigree is puzzling. The Maltese population is 
young, a population bottleneck occurring just over 500 years ago. This equates 
with approximately 20 generations. LD blocks may be large, due to insufficient 
time elapsed to allow decay. LD has been shown to be present in isolated 
populations, however the amount of LD exhibited is variable and should only 
be in operation in the case of rare alleles (Kruglyak, 1999). The genotyping of 
more Maltese families may throw light on this problem. 
4.2.2.2 Genetic model 
Although segregation analysis indicated a single major gene this is not 
necessarily so. The trait is a complex one with reduced penetrance, variable 
expression and an environmental or epigenetic input. These factors may 
confound linkage analysis by incorrect identification of silent carriers as 
unaffected individuals. The mechanism of incomplete penetrance is complex 
and poorly understood and may be a feature of monogenic diseases, occurring 
despite relative genetic and environmental homogeneity (Pereira et al., 1994). 
Parametric LOD score analysis is the most powerful method for establishing 
linkage; however the genetic model, i.e. the mode of inheritance, allele 
frequency and penetrance must be specified. Indeed it has been shown that 
specifying the wrong dominance mechanism of a linked locus decreases the 
expected LOD score however the wrong penetrance assumptions alone had 
relatively small effects on the magnitude of the Z value (Clerget-Darpoux et al. 
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1986). Multipoint analysis is more robust than two-point analysis to 
misspecification of allele frequencies and statistical fluctuations at individual 
markers. (Kruglyak et al., 1996). Furthermore, if a disease is caused by two 
epistatic loci or two independent loci, single-locus linkage analysis is nearly as 
powerful as two-locus linkage analysis in detecting linkage of one of the 
disease loci to a marker locus. However, this result assumes that the mode of 
transmission (dominant or recessive) of the linked locus is correctly specified 
(Goldin and Weeks, 1993). Complex traits may be analysed with parametric 
linkage analysis as long as the marker linked to the gene is inherited in a 
Mendelian fashion (Greenberg et al., 1998). Thus, linkage analysis has been 
shown to be robust to a number of incorrect specifications; however the mode 
of inheritance must be correct. The segregation analysis had identified a 
dominant mode as being the most likely, this supporting previously published 
results (Svinhufvud et al., 1988). 
The analysis of V8 gave maximal LOD scores of 1.5 on chromosomes 5,6,11 
and 13. Parametric affected-only analysis is the most conservative model but 
the chance of false positives is increased and the peaks are wider. The increase 
in LOD scores in the ‘affected only’ analysis is most likely due to the 
elimination of silent carriers.  
Inclusion of unaffected members in the analysis will increase the accuracy of 
disease haplotype estimation in affected individuals. In a family such as this, 
silent carriers must be taken into account, allowing for reduced penetrance in 
the genetic model. On the other hand, over-relaxation of the penetrance vector 
may generate false positive results and indicate a ‘disease’ haplotype where 
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there is none. Indeed, the peaks on chromosomes 10 and 13 apparent in V8 
disappear in V7, while suggestive LOD scores of 2.6 and 2.5 on chromosomes 
11 and 20 are apparent in V7 but not in V8. Furthermore, these peaks are 
marginally narrower in V7 than in V8. The two analyses agree in that the peaks 
on Chromosomes 6 and 11 are both broad and very similar in both analyses. 
These therefore are the areas of greatest interest. The narrow LOD 2.5 peak on 
Chromosome 20 does not resemble a conventional LOD peak, however as 
precautions have been taken to remove LD, this area also bears investigation. 
4.2.2.3 Phenotype 
The phenotype of individual #41 is different from the rest of the affected 
members in the pedigree in that the maxillary canine had erupted high and 
buccal. Buccal canine eruption is generally associated with inadequate arch 
space (Chaushu et al., 2003a). However buccal ectopic canine eruption may 
occur as a distinct phenomenon, in spite of adequate space within the dental 
arch and is associated with an increased prevalence of lateral incisor anomalies 
(Chaushu et al., 2009). The high prevalence of associated dental anomalies in 
both conditions points to a common aetiology and indeed buccal EC is 
frequently found to occur in the same individual together with PDC. Crowding 
was not a factor in the position of this tooth, this being accommodated into the 
arch with the aid of an upper fixed appliance without any form of space 
creation, despite all teeth being of normal size. All criteria for inclusion were 
thus satisfied. Notwithstanding, it was considered unusual that a family 
exhibiting consistent phenotypic expression in seven other members should 
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display such a variation. The problem could have been dealt with by allowing 
for phenocopies in the genetic model, thus relaxing the parameters; however 
this may have masked potentially interesting areas by decreasing the LOD 
score. The alternative of eliminating #41 as an affected member seemed a 
better solution and indeed the analysis of pedigree V7 gave a LOD of 2.6 on a 
16.5 megabase (Mb) region spanning Chromosome 11p13 to 11p15, a LOD of 
2.5 on 20q13 and a LOD of 1.6 on Chromosome 6. 
4.2.2.4 Results of haplotyping 
Haplotyping showed all affected members plus #36 and 411 to carry a common 
haplotype on chromosome 6 (Figure 8), all affected members plus one 
unaffected individual, #43, to carry a common haplotype on chromosomes 11 
(Figure 9) and all members plus #38 #41 #411 and #413 to carry a common 
haplotype only on chromosome 20 (Figure 10). The area of haplotype common 
to all affected members extended from marker rs11025381 to rs4471390 on 
chromosome 11. The haplotyping confirmed the presence of silent carriers, 
hindering interpretation of the result. 
4.2.2.5 Identification of a candidate gene 
In pedigree V7, the area covered by the positive LOD score on Chromosome 
11 is 16 Mb long and contains 59 known genes; the area on Chromosome 20 is 
4.4 Mb and contains 46 genes. Sequencing these genes would be time 
consuming and costly. Reduced penetrance and LD between the SNPs will not 
allow any further refinement of the fields by incorporation of more markers. It 
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may be possible to genotype these areas with alternative markers such as 
microsatellites, which are more informative than SNPs, though these are more 
widely spaced and more costly to process. Fine mapping is also an option but 
would require the genotyping of more individuals. With the advent of next 
generation sequencing, it would be more cost effective to employ exome 
sequencing in order to identify the disease gene. 
4.2.2.6 Exclusion of linkage 
The LOD scores of the SNPs flanking the genes MSX1, PAX9, PTHR1 and 
SH3BP2 were evaluated. No area was found to give a LOD of over -2 in 
pedigree V8. This is interpreted as exclusion of linkage (Morton, 1955). This 
result does not support the hypothesis of Peck et al, who postulated that the 
Msx1 and Pax9 genes may be responsible for PDC and transposed canines, 
both variants of EC (Peck et al., 2002). Furthermore, EC does not seem to 
share any genetic aetiology with Idiopathic Failure of Eruption or Paget’s 
disease of bone. Similarly, the SNPs associated with dental maturation (Geller 
et al., 2011) are excluded from linkage in this family.  
4.2.2.7 Copy number variations 
No significant events were detected by the Copy Number probes. This is not 
surprising as, although CNVs contribute to human variation and play a part in 
the discordance of twins, there is no supporting clinical evidence. A major 
limitation of this analysis is that as it was carried out on a case-control basis; 
the numbers of both cases and controls would be far too small to be interpreted 
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reliably. Nevertheless, there is no evidence to suggest that CNVs may play a 
part in the aetiology of EC. 
4.2.3 Conclusions 
A number of areas of interest have been identified by a conservative ‘affected 
only’ analysis. These results are supported by linkage analysis of the extended 
family and areas on Chromosomes 4,6,11 and 20 bear further analysis. Genes 
associated with oligodontia have been excluded from linkage in this family as 
have SNPs associated with normal eruption. Nor is there evidence for any role 
of CNVs in the aetiology of the trait 
4.3 Exome Sequencing 
Linkage analysis has been successful in identifying many disease genes. 
However even under ideal circumstances the disease locus can rarely be 
mapped to an area of less than 1 Centimorgan (cM). One cM is a unit of 
genetic distance, not physical separation, however approximates in size to one 
Mb. An area of this magnitude may contain hundreds of genes and 
conventional Sanger sequencing would entail considerable time and expense. 
The emergence of next-generation massively parallel sequencing and high 
throughput sequence capture methods has made the targeted capture of all 
known exons highly cost effective. Protein coding regions constitute only 1% 
of the total human genome but are responsible for 85% of mutations (Choi et 
al., 2009). Mutations having major genetic effects generally disrupt protein 
coding regions or exon splice sites, mutations in regulatory regions tending to 
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have lesser effects (Ng et al., 2009). Exome sequencing enables identification 
of mutations in families that are insufficiently informative and not useful for 
linkage or other positional cloning methods. As only a small number of 
individuals need to be sequenced, it is also much quicker and cheaper 
(Singleton, 2011). Thus exome sequencing is a highly efficient method of 
capturing a large percentage of genomic variation and has reversed the recent 
decline in interest in monogenic, Mendelian disorders (Antonarakis and 
Beckmann, 2006). 
4.3.1 Exome capture 
Massively parallel sequencing has made possible the processing of enormous 
quantities of DNA templates within a much shorter timeframe and lower cost 
than Sanger chain termination technology. It has made possible the sequencing 
of whole genomes within a single centre, however the resources required for 
sequencing, storing and analysing the data from large numbers of genomes is 
beyond the reach of most centres. Target enrichment methods may be used to 
maximize the cost-efficiency of the process by selecting the portion of the 
genome most likely to yield information about a disease, that is, the exome. 
Many different methods of target enrichment have been described (Mamanova 
et al., 2010) but the system that has been commercially applied to exome 
sequencing is the hybridisation method. Two variations exist, microarray-based 
and liquid based. In microarray-based capture, sonicated DNA is flowed over 
the probes, where complimentary sequences bind. The unbound DNA is 
washed away and the bound DNA amplified and sequenced. Solution-based 
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methods use biotinylated probes which bind to their complementary sequences 
on the DNA. Streptavidin coated beads are used to separate the hybridised 
probes and the DNA is eluted off. Both RNA and DNA probes are in 
commercial use. Liquid-based capture techniques are preferable in that they are 
less labour intensive, specialized hybridisation equipment is not required and 
the quantity of DNA required is considerably less.  
4.3.2 Limitations of Exome Sequencing 
As with all other techniques whole exome sequencing has its drawbacks 
(Bamshad et al., 2011). Our knowledge of all truly protein-coding exons in the 
genome is still incomplete, so current capture probes can only target exons that 
have been identified so far. There is a degree of variability between capture 
arrays, though commercial kits now target, at a minimum, all of the 
RefSeqcollection and an increasingly large number of hypothetical proteins. 
Considerable uncertainty remains regarding which sequences of the human 
genome are truly protein-coding and regulatory regions and untranslated 
regions are not sequenced. 
The efficiency of capture probes varies considerably and some sequences fail 
to be targeted by capture probe design altogether. Not all templates are 
sequenced with equal efficiency and not all sequences can be aligned to the 
reference genome so as to allow base calling. On average, 82% of the genes on 
the array have at least 90% of bases called. Not all variants may be captured 
It is difficult to detect small insertion/deletion variants (indels) with the short 
sequence reads generated by NGS technologies (Ng et al., 2010a). Exome 
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sequencing is unable to detect structural variants or chromosomal 
rearrangements (Ku et al., 2011) and fails to identify repeat mutations such as 
triplet repeats in spinocerebellar ataxia and copy number variants (Singleton, 
2011). AT and GC rich regions are not easily sequenced (Bloch-Zupan et al., 
2011). 
As the number of sequenced genomes increases, so does the possibility of 
incorporation of pathogenic alleles at appreciable frequency. This particularly 
applies to recessive disorders (Bamshad et al., 2011). Finally, genetic 
heterogeneity may confound results (Ng et al., 2010a). 
4.3.3 Filtering 
A large amount of data is generated which must be filtered to narrow the search 
down to a manageable number of candidate genes.  
The polymorphisms are filtered first against a control set, obtained either from 
public databases, assuming that there are no disease alleles present, or from a 
control cohort of individuals known to be unaffected. It may be assumed that 
common variants in the population are not likely to be the cause of rare 
Mendelian diseases and may be filtered out. This leaves the 'novel' 
polymorphisms and rare variants as potential candidates. Nonsynonymous 
variants, splice acceptor and donor site mutations and coding indels may be 
prioritised, on the assumption that synonymous variants are far less likely to be 
harmful. 
Further filtering may be applied by comparing of affected individuals, either on 
a whole exome basis if unrelated or by comparison of areas IBD in family-
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based studies. As affected family members may be assumed to carry the same 
rare variant, family studies require smaller sample sizes than studies of 
unrelated individuals (Wilson and Ziegler, 2011). 
In families where multiple individuals are affected with a common trait, the 
most distally related individuals are sequenced, presuming that the more 
distantly related the individuals, the fewer genetic variants they share. 
However, even distantly related individuals may share many variants and will 
require more filtering. Homozygosity mapping may be used in the study of 
recessive disorders, on the assumption that the mutation must be present in 
both alleles. 
An alternative, family-based approach, which is used to identify de novo 
variants, involves sequencing parent–offspring trios in which only the offspring 
is affected. This strategy has been used to identify candidate genes for several 
complex traits (Vissers et al., 2010) 
Where unrelated individuals are studied, selection of phenotypes at the extreme 
ends of the distribution curve will make it more likely that they share the same 
rare variant. Careful selection and ranking of phenotypes will avoid the 
problem of genetic heterogeneity (Ng et al., 2010a). Case-control designs may 
also be used and as the cost of sequencing continues to fall and public 
databases increase in size, may become more popular. 
Sequence variations are reported in public databases such as dbSNP or the 
1000 genomes database. The relevance of the variation to the disease may be 
gauged by expression data or functional stratification and prediction of the 
functional consequences may be carried out using programs such as SIFT 
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(Kumar et al., 2009) or PolyPhen2 (Adzhubei et al., 2010). Both these 
programs are based on the degree of conservation of amino acid residues in the 
sequence alignments. PolyPhen2 also takes into account CpG context and 
predicts the alteration in structural features that may affect protein function. 
This function is naturally dependent on knowledge of the structural features of 
that protein. It should be noted that computational algorithms have high rates 
of false positive and false-negative predictions (Wei et al., 2010, Mathe et al., 
2006). Although it is difficult to give an exact numerical value, it is likely that 
the false-negative and false-positive rates are at least 20% for whole exome 
sequencing (WES) data (Robinson et al., 2011). 
4.3.4 Results 
The percentage of the exome covered 10x was 96.55, that covered 20x was 
93.96. The mean coverage was 215x. The numbers and types of variants 
identified in both individuals are given in Table 17. Three heterozygous novel 
variants were found to be common to the two affecteds (Table 18) as well as 
twenty-five other variants with a frequency of 0.01% or less (Table 23, in 
Appendix 2). None of these genes were located within the linkage areas in the 
analysis of Pedigree V8. The LOD score for the variants in Chromosomes 6 
and 22 in Pedigree V8 was -2.5, indicating exclusion of linkage to the trait in 
the affected members of this family. Four variants common to both members 
were found in the areas identified by linkage analysis (Table 19). One variant 
was found on the PAX9 gene. This variant is a G-C transition present on the 
dbSNP database as rs4904210, with a population frequency of 0.3428. 
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The four genes in the linkage areas were prioritised, in order of frequency and 
relevance to function. None of the variants were predicted to be functionally 
relevant (Table 20). 
4.3.4.1 Sanger Sequencing results. 
The variants on ANO5, PPP1R14C and EPM2A were found to be present in all 
affected members. The SNV on VSTM2L, did not segregate with the affected 
members. Combinations of these variants were also present in first degree 
relatives of affected members, but there was no unaffected member with both 
variants of ANO5 or PPP1R14C (Figure 11). During the course of the 
investigation, member #47 developed a macrodont upper right central incisor, 
however none of the variants were found in this individual. 
The variants on PPP1R14C, ANO5, EPM2A or VSTM2L were not present in 
any of the unrelated individuals. However one novel SNV and one SNP were 
found in seven and eleven individuals respectively in exon 1 of PPP1R14C 
(Table 21). These are both missense variations predicted to be harmless. No 
variants were detected in the intron or the intron-exon boundaries of exon 17 of 
ANO5 in any of the eighteen unrelated individuals. 
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Table 17. Summary statistics for exome sequencing, giving the variants in 
each individual as well as those common to both. 
Individual 32 412 Shared 
Variant Known Novel Known Novel Known Novel 
All variants 24707 113 24298 316 15690 3 
Heterozygous 15270 111 15165 311 7745 3 
Homozygous 9437 2 9133 5 7945 0 
Non frameshift 
 
226 13 246 11 147 0 
Heterozygous 129 12 161 10 72 0 
Homozygous 97 1 85 1 75 0 
Frameshift Indels 172 0 175 4 133 0 
Heterozygous 57 0 54 3 27 0 
Homozygous 115 0 121 1 106 0 
SNVs 21478 21232 269 13599 3 
Heterozygous 13335 81 13246 266 6742 3 
Homozygous 8143 1 7986 3 6854 0 
Synonymous 
 
11098 31 10955 97 7060 1 
Heterozygous 6893 30 6849 95 3526 1 
Homozygous 4205 1 4106 2 3533 0 
Non synonymous 
 
10274 49 9966 164 6537 2 
Heterozygous 6383 49 6255 164 3216 2 
Homozygous 3891 0 3711 0 3321 0 
Splice Site(10bp) 2791 18 2790 36 1792 2 
Heterozygous 1723 18 1734 35 892 2 
Homozygous 1068 0 1056 1 900 0 
Unknown 40 0 30 0 20 0 
Heterozygous 26 0 24 0 10 0 
Homozygous 14 0 6 0 10 0 
115 
Table 18. Nonsynonymous novel variants common to the two affected members. The LOD scores of both V7 and V8 analyses 













Chr22 33,402,797 C T HET splicing SYN3 splicing 
-2.495 -6.417 
Chr22 38,379,730 C A HET exonic 
SOX10: nonsynonymous SNV  
NM_006941:exon2:c.G62T:p.R21L, 
-2.495 -6.418 
Chr6 13,711,706 T G HET exonic 
RANBP9: nonsynonymous SNV       
NM_005493:exon1:c.A32C:p.Q11P, 
-2.495 -3.418 
Table 19. The rare variants that fell within areas identified by linkage analysis. The variant on Chromosome 20 has a positive LOD 












Chr 6 146,007,358 T C HET Exonic 




Chr6 150,464,476 G T HET Exonic 
PPP1R14C: nonsynonymous SNV       
NM_030949:exon1:c.G148T:p.V50 
1.505 1.582 
Chr 11 22,284,483 T C HET Splicing 




Chr 20 36,560,190 C T HET Exonic 




Table 20. The final list of candidate genes. A SIFT score of <0.05 predicts the mutation to be 













Function SIFT Score PolyPhen2 score 
PPP1R14C 0.004 0.01 1.6 Protein phosphatase inhibitor 0.45 0.012 




n/a but within canonical 
splice site 
VSTM2L 0.0045 0.01 1.6 
Potential modulator of 
NFKB signalling,  
involved in cell 
proliferation.  
0.07 0.355 
EPM2A 0.0005 0.0 1.6 
Involved in neuronal 




Table 21. The SNVs in PPP1R14C exon 1 in eighteen unrelated EC cases 
(P1-P18). One SNV is novel and rs2297672 has a MAF of 0.39. N = variant 
absent, Y = variant present. 
 DbSNP ID Novel rs2297672 
 Position 6:150464335_G/A 6:150464356; G/A 
P1_1 N Y 
P1_2 N Y 
P1_3 Y N 
P1_4 Y Y 
P1_5 Y Y 
P1_6 N Y 
P1_7 Y Y 
P1_8 N Y 
P1_9 N N 
P1_10 Y Y 
P1_11 N N 
P1_12 Y Y 
P1_13 Y N 
P1_14 N N 
P1_15 N Y 
P1_16 N N 
P1_17 N N 
P1_18 N Y 
4.3.5 Discussion 
There are three main exon capture kits on the market. They differ markedly in 
type of bait used to capture reads and also in density and target regions. Of 
these the Agilent Sure Select Human Exome Kit gives good coverage of 
Ensembl coding regions. Moreover the long RNA baits give it an edge over its 
competitors in detecting indels. 
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4.3.5.1 Quality control 
Reliable data requires a depth of at least 5 reads per variant with a minimum of 
20% of reads showing that variant for heterozygous SNVs and 80% for 
homozygous. The sensitivity to detect heterozygous variants with 10 reads is 
78.6%, but increases to 95.2% at 20x and approximately 100% at 30x and 
greater (Choi et al., 2009). As 93.96% of the exome was covered 20X and 
96.55% covered at least 10X, the data extracted was considered to be of good 
quality. 
4.3.5.2 Filtering 
Disease gene identification strategies for various models have been reviewed 
by Gilissen (Gilissen et al., 2012). The advent of next generation sequencing 
has shifted the problem from that of struggling to identify a candidate gene to 
that of elimination of sufficient numbers in order to arrive at a manageable 
quantity of candidates. Following quality control procedures, there remain 
approximately 25,000 variants in the exome and splice sites in each individual. 
The removal of synonymous variants reduces the number to 10,000. Further 
filtering involves the elimination of SNVs not common to both affected 
individuals. However as these are related individuals, large parts of the genome 
will be shared and several potential candidates may remain.  
Linkage data may be used to identify areas which are identical by descent to all 
affected members. These areas may be prioritised and SNVs that lie outside the 
linkage peaks may be discarded. This strategy has been successfully used to 
identify a number of genes, including variants responsible for a tooth eruption 
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disorder (Yamaguchi et al., 2011). SNPs captured by exome sequencing may 
be used for linkage analysis, greatly reducing the search area. However as the 
markers in genotypes inferred from WES are sparser and less heterozygous 
than those from microarrays, linkage data from the latter is considered superior 
(Smith et al., 2011). Even within these linkage areas, large numbers of genes 
may remain. As the disease segregates within the family under study, it may be 
assumed that the same variant is responsible for the phenotype and variants not 
common to both exomes may be discarded.  
Homozygosity or heterozygosity may be deduced from the mode of 
transmission and nonsynonymous variants are usually filtered out; bearing in 
mind that synonymous variants may cause alternate splicing, affecting protein 
properties. The assumption of a Mendelian gene with a major effect allows the 
field to be further narrowed to novel or rare SNVs. The frequency of identified 
variants is obtained from dbSNP or the 1000 genomes database. Caution must 
be exercised as many disease studies submit their findings to dbSNP. Similarly, 
samples submitted to the 1000 Genomes Project mostly have no associated 
medical or phenotype data. Thus both data bases may be ‘contaminated’ with 
causal variants where the quoted population frequency may not match that 
under study. Care must therefore be taken not to discard the true variant and 
search parameters may be relaxed to a frequency of <1% in the database.  
Three novel variants as well as 25 other variants with a frequency of less than 
1% were found to be common to the two exomes. These were not all in the 
linkage peaks, indeed, the LOD scores for the novel variants was less than -2.5 
in the conservative ‘affected only’ V8 analysis and lower in the full family V7 
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analysis. Only four variants were inherited IBD in common to both genomes in 
analysis V8 and indeed the variant on Chromosome 20 has a negative LOD 
score in analysis V7. However the presence of novel variants common to 5th
degree relatives may be significant and the segregation of these genes with the 
phenotype requires examination. The variant rs4904210 on PAX9 is a common 
variant present in 34% of the population. It has been implicated as a risk factor 
for tooth agnesis (Wang, 2011). The V8 'affected only' LOD score indicates 
that it may not be common to all affected members, however the V7 'full 
family' analysis assigns a score of -0.5. This score is low, but is not exclusive 
of linkage. 
4.3.5.3 Candidate genes 
After applying the various filtering strategies, the final list of candidate genes 
totals four: 
A low-frequency SNV in ANO5. This variation is present in the 3’ splice 
region of exon 17. It is present at a very low frequency in the 1000 Genomes 
database. but is not present in dbSNP or in the pool of Maltese individuals. 
ANO5 affects bone formation, particularly in the jaws. Mutations in exon 11 of 
ANO5 are responsible for gnathodiaphyseal dysplasia, an autosomal dominant 
disorder affecting long bones and the jaws, in particular the formation of 
fibrous lesions in tooth-bearing regions. ANO5 is expressed in bone and 
periodontal ligament, the latter being intimately involved in tooth eruption 
(Tsutsumi et al., 2004). It is also linked to the NELL1 gene, which plays a key 
role in both intramembranous and endochondral ossification during early 
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development (Desai et al., 2006), its function and range of expression making 
it a good candidate. ANO5 is in the region of the highest LOD score (2.58) in 
Pedigree V7 and the SNV did segregate with the affected phenotype, with only 
one unaffected family member, #43, carrying the SNV (Figure 11). No 
variations were found in the exon or intron-exon boundaries of exon 17. 
A low frequency SNV identified in exon 1 of PPP1R14C, which falls in the 
region on Chromosome 6 that gave a LOD score of 1.6 in Pedigree V7, 
indicating an area of interest. This SNV is present at a frequency of 1% in a 
pool of 50 Maltese individuals. It is a protein kinase C-potentiated inhibitory 
protein for type 1 Serine/Threonine phosphatases, which works via the MEK-
ERK pathway (Wenzel et al., 2007). It inhibits PP1, which acts on AXIN, 
which participates in both the MAPK and WNT pathways, with inhibition of 
PP1 enhancing Β-CATENIN degradation (Voronkov and Krauss, 2013). It also 
interacts with SAP25, which is involved in transcriptional repression mediated 
by mSIN3A, which in turn influences RUNX2 expression (Shiio et al., 2006, 
Westendorf, 2006, Wenzel et al., 2007). It has been found to be 
expressed in many tissues, including bone marrow and osteoblasts. Its known 
function and range of expression make it a viable candidate gene. It is not 
within the highest range of LOD score; however the variable penetrance of the 
condition makes silent carriers very likely and indeed the SNV did segregate 
with the affected phenotype, with two unaffected family members, #36 and 
#411, carrying the SNV. The scores given by both SIFT and PolyPhen2 do not 
indicate that protein function should be affected; however as previously stated, 
these predictions operate with a wide margin of error. Exclusion based on 
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prediction has proved to be erroneous (Ng et al., 2010b). Other SNVs were 
found in exon 1 of PPP1R14C in other affected, unrelated individuals, 
implying that other causative mutations may be present. 
A low-frequency SNV in VSTM2L, present at 1% in the pool of Maltese 
individuals. Little is known about the function of this gene; however it may 
play a role in cell proliferation, in the modulation of NFKB function and in 
neuronal differentiation. It may also act to modulate the action of 
neuroprotective peptides ( Mortazavi et al., 2006, Halsey et al., 2007, Rossini 
et al., 2011). The function of the gene is appropriate in that it may affect cell 
proliferation and that NFKB plays a part in osteoclastogenesis, which in turn 
affects tooth eruption. Both the SIFT and PolyPhen2 scores indicate low 
pathogenicity. However the SNV does not segregate with the phenotype, being 
present in five other unaffected family members and a founder (#39) (Figure 
11). Nor were any mutations found in exon 2 or the intron-exon boundaries in 
the unrelated affected individuals. This is not altogether a surprising finding, as 
the V7 linkage analysis takes into account information from unaffected 
relatives in computing the haplotypes. 
A low-frequency SNV in EPM2A, not present in the pool of Maltese 
individuals, which encodes LAFORIN, a dual-specificity protein phosphatase 
that hydrolyses phosphotyrosine and phosphoserine/threonine substrates. 
LAFORIN also binds complex carbohydrates and plays a role in glycogen 
metabolism. LAFORIN acts together with MALIN to accelerate the 
degradation of misfolded proteins and may be part of the neuronal defence 
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Figure 11. The distribution of the variants in the family. The SNVs in ANO5 and PPP1R14C together are necessary to produce the 
phenotype.
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mechanism against cytotoxic proteins (Garyali et al., 2009). However 
LAFORIN is not associated with bone or craniofacial development and has not 
been shown to be expressed in teeth, bone or the periodontal ligament. The 
known expression pattern and gene function is therefore not appropriate. The 
SNV on EPM2A did segregate with the phenotype however as its position is 
physically very close to PPP1R14C, this is not altogether surprising. No 
mutations were found in exon 2 or the intron-exon boundaries in the unrelated 
affected individuals. 
The variant in PPP1R14C is present as a rare allele in a sample of the Maltese 
population; however neither of the SNVs in PPP1R14C or ANO5 are present in 
a sample of 18 consecutive, unrelated sporadic EC cases, indicating that these 
variants will only account for a small percentage of the heredity of EC. In order 
to determine whether these two genes are expressed in tooth tissue or 
supporting structures, in situ hybridisation was carried out in human embryos. 
In order to confirm whether PPP1R14C or ANO5 were expressed in teeth or 
supporting tissues, is situ hybridisation was carried out on both genes.  
4.4 In situ hybridisation 
The technique was published in 1969 and the use of radiolabelled RNA probes 
described in 1984 (Gall and Pardue, 1969, Cox et al., 1984). ISH is designed to 
localise gene expression in tissues. Specific probes are manufactured, which 
may be DNA or RNA, complementary to the sequence targeted. Double 
stranded DNA probes are prepared by cleaving off the DNA plasmid with 
restriction enzymes, single stranded probes may be manufactured by PCR 
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using Taq polymerase and antisense primer extension. RNA probes are 
prepared by cloning the cDNA template into a transcription vector flanked by 
two RNA polymerase sites. This enables both sense and antisense probes to be 
manufactured. DNA probes are easier to synthesise and more stable, however 
RNA probes are more specific. 
These probes are labelled either radioisotopically and visualised by exposure to 
radiosensitve film, or with a nonradioactive substance such as digoxigenin, 
which may then be visualised by immunofluorescent staining. Isotope ISH is 
the more sensitive of the two techniques, and has the added advantage that the 
results may be quantified. Several isotopes may be used, however S35 gives the 
most rapid and sensitive results (Wilcox, 1993). The disadvantage of isotopic 
labelling is the use of biohazardous material and the limited shelf life of the 
probes. Nonisotopic probes are more stable, more sensitive and give much 
more rapid results, making them useful in clinical laboratories; however the 
results can not be quantified. Acetylation of the tissue will prevent backgound 
due to nonspecific binding and the addition of dithiothreitol to the 
hybridisation solution of S35 probes will prevent oxidization of the sulphur.  
4.4.1 Results 
Microphotographs of the in situ hybridisation may be seen in Figures 12 and 
13. The background binding of both probes was similar, therefore non-specific
binding was judged not to affect the result. 
Thickening Stage 
PPP1R14C expression is observed in both epithelium and mesenchyme. 
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Faint expression of ANO5 is observed in epithelium.  
Bud Stage 
Strong expression of PPP1R14C is found in mesenchyme, while PPP1R14C 
shows weak expression in bud epithelium. 
No expression of ANO5 could be detected in tooth germs. 
Cap Stage 
PPP1R14C is strongly expressed in mesenchyme, whereas it shows weak 
expression in cap epithelium. 
ANO5 is barely expressed in lingual cap epithelium. 
Bell Stage 
PPP1R14C is strongly expressed in ameloblasts and odontoblasts, whereas it 
shows weak expression in dental papilla cells and the dental follicle. 
ANO5 is weakly expressed in ameloblasts and rostral dental papillae including 
odontoblasts. It is also weakly expressed in the dental follicle.  
4.4.2 Discussion 
Both genes are expressed in tooth tissue. PPP1R14C is expressed to varying 
degrees at all stages in epithelium, mesenchyme and dental follicle. PPP1R14C 
inhibits the protein phosphorylator PPP1CA, which plays a part in the 
MEK/ERK and WNT pathways. These pathways play a vital role in most 
developmental processes including bone and teeth, the strong expression of the 
gene here supporting PPP1R14C as a candidate. ANO5 shows weaker 
expression, chiefly in epithelium and then in ameloblasts and odontoblasts at  
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Figure 12. ANO5 in situ. There is weak or no expression in dental tissue in 
the initial stages of tooth formation, however there is diffuse, weak 
expression in both tooth and dental follicle in the later stages of tooth 
formation. The yellow dots outline the developing tooth germ indicated by 
the arrows. Scale 200 µM. 
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Figure 13. PPP1R14C in situ. There is strong expression in dental tissues 
throughout tooth formation. There is particularly strong expression in 
ameloblasts and weak expression in the follicle and supporting tissues at 
the bell stage of formation. The yellow dots outline the developing tooth 
germ indicated by the arrows. Scale 200µM. 
129 
the bell stage. Its expression in calcifying tissues lends support to the theory 
that this gene might function as an intracellular calcium-release channel and 
that it might regulate a calcium-dependent signaling pathway by modifying the 
intracellular calcium concentration (Tsutsumi et al., 2004). Its expression in 
dental follicle tissue is consistent with previous publications of expression 
inperiodontal ligament cells. As it is the dental follicle that controls tooth 
eruption, disruption of PPP1R14C or ANO5 function could well be a cause of 
ectopic eruption. Either or both genes may be the cause of EC. 
Sequencing the variations in the family shows that only the affected members 
have SNVs in both PPP1R14C and ANO5 (Figure 11). Members with only one 
or the other variation are unaffected, as are those with combinations of the 
other candidate genes. It is apparent in Figure 11 that mutations in two genes, 
ANO5 and PPP1R14C are necessary to precipitate the EC phenotype in this 
family, either mutation alone not being sufficient. Individuals #36 and #411 are 
both unaffected but carry the mutant form of PPP1R14C. Similarly, #43 carries 
the mutant form of ANO5 but is also unaffected. Whether one gene has greater 
influence that the other is not clear, either could contribute in varying degrees 
to the phenotype. It is possible that one variation is insufficient, both being 
necessary for ectopic eruption to occur. This combination has been termed 
“pathogenic” digenic inheritance (Ming and Muenke, 2002). 
Disorders with significant familial aggregation and which exhibit a strong 
genetic component may be diagnosed as monogenic. However these may 
exhibit complex inheritance patterns which depart from classical Mendelian 
inheritance. Thus the phenotypes of single gene disorders may manifest as 
complex traits (Dipple and McCabe, 2000) The causes for atypical patterns of 
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inheritance are several (Van Heyningen and Yeyati, 2004) however in this case 
a digenic form of inheritance may be in operation, with mutations in both genes 
necessary to produce the EC phenotype.  
Tooth formation and eruption involve several complex pathways and these 
genes could act in the same or in related pathways to affect protein production. 
The involvement of more than one gene is consistent with the variable 
penetrance and expressivity of the trait, possibly complicated by the presence 
of modifier genes, which may affect the clinical manifestation of the disease 
altering the penetrance and/or expressivity of the phenotype (Gropman and 
Adams, 2007). #47 does not carry any of the SNVs identified, however may 
have related, but as yet unidentified causative variants. 
These mutations have not been found to be present in several unrelated EC 
cases. If the condition were due to genetic drift with a single founder effect, 
then the same mutations would have been detected. It is likely that, due to the 
complex pathways leading to bone and tooth development, genetic 
heterogeneity exists, possibly due to multiple founders. Similar instances have 
been described for rare diseases in isolated populations (Richard et al., 1995). 
4.5 Conclusion 
The aims of the study have been reached, in that the evidence for a genetic 
aetiology for EC has been established by the familial relative risk and the 
segregation analysis, which has also determined the genetic model for the trait. 
Linkage analysis based on the findings of the segregation analysis has 
identified areas of interest in an extended Maltese family. The second aim has 
also been reached in that whole exome sequencing has implicated variants in 
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the genes ANO5 and PPP1R14C in the aetiology of EC in this family. A 
digenic or oligogenic aetiology is in keeping with the clinical findings of 
variable penetrance and variable expression of EC However the discordance of 
identical twins points to a significant environmental or epigenetic component. 
The genes MSX1 and PAX9 have been excluded as a cause of EC, as have the 
SNPs identified by Geller (Geller et al, 2011) associated with normal eruption. 
4.5.1 Future investigations 
The presence of novel variants common to 5th degree relatives may be 
significant and the segregation of these genes with the phenotype requires 
examination The variant rs4904210 may be associated with hypodontia in this 
family and also bears investigation. 
The discordance of the monozygotic twins is not consistent with a genetic 
aetiology. This phenomenon may either be due to the twinning process itself or 
may be an indication of environmental or epigenetic factors. The number of 
multiple births in the sample raises the possibility of epigenetic effects related 
to the twinning process or CNVs and methylome analysis as well as CNV 
analysis should also be undertaken in discordant twins.  
The exons and intron-exon boundaries of both genes PPP1R14C and ANO5 
may be investigated in unrelated cases, as variants in other parts of the gene 
may be responsible. Other genes in the pathways of action of these genes may 
also be investigated. Custom targeted sequencing may offer a solution here. 
Other extended families affected with EC may be recruited and investigations 
carried out in the light of the results of this study.  
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The products of the genes ANO5 and PPP1R14C or any other genes identified 
in other affected individuals may be tested to see whether the RNA transcripts 
are altered. Quantitative Reverse Transcription Polymerase Chain Reaction 
(RT-qPCR) may be used to detect changes in RNA transcripts and their levels 
and determine whether both genes are at fault.  
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I am a Maltese citizen and am over/under* eighteen (18) years of age. 
I have been asked to participate in a research study entitled: The Aetiology of Ectopic 
Maxillary Canine Teeth 
The purpose and details of the study have been explained to me by Dr S Camilleri and 
any difficulties which I raised have been adequately clarified. 
I give my consent to the Principal Investigator and his delegate either make the 
appropriate observations/tests or both or take the necessary samples. I am aware of any 
inconveniences which this will cause. 
I understand that the results of this study may be used for medical or scientific 
purposes and that the results achieved from this study in which I am participating may 
be reported or published: however, I shall not be personally identified in any way, 
either individually or collectively, without my express written permission. 
I am under no obligation to participate in this study and am doing so voluntarily. 
I may withdraw from the study at any time, without giving any reason. This will not 
influence in any way the care and attention and treatment normally given to me 
(applicable only in case of patients receiving treatment). 
I understand that any complications and/or adverse effects which may arise during or 
as a consequence of the study will be recorded and any treatment which this may 
entail will be given within the Government Health Services. 
I am not receiving any remuneration for participating in this study. 
In case of queries during the study I may contact Dr S Camilleri. on 23401876 or 
Email: simon.camilleri@um.edu.mt 
Signature of participant. (In case of minors, parent or guardian to sign). 
Name of participant (in block letters) 
Id. No.: 
Signature of Chief Investigator/Investigator 
Name of Chief Investigator/Investigator 
Id. No.: ………………….. 
DATE 
.* delete where applicable 
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FORMOLA TA KUNSENS 
Jiena cittadin Malti u qbizt/ma qbiztx* it-tmintax (18) is-sena. 
Talbuni biex niehu sehem fi studju ricerka bl-isem ta': Investigazzjoni fi snien ma 
telghux 
Il-ghan u d-dettalji ta' l-istudju spjegahomli it-tabib Simon Camilleri, li wkoll iccarali 
xi mistoqsijiet li ghamilt. 
Naghti l-kunsens tieghi lill-persuna responsabbli ghal din ir-ricerka u l-assistenti 
taghha biex jaghmlu l-osservazjonijiet li hemm bzonn jew inkella jiehdu l-kampjuni u 
nifhem li dan jista' jkun ta' skomdu ghalija. 
Jiena nifhem li r-rizultati ta' dan l-istudju jistghu jintuzaw ghal skopijiet xjentifici u 
jista' jigi ppubblikat rapport bil-miktub: jekk isir hekk, b'ebda mod ma nista' nkun 
identifikat/a, individwalment jew bhala parti minn grupp, minghajr il-kunsens tieghi 
bil-miktub. 
Jiena ma ghandi l-ebda dmir li niehu sehem f'dan l-istudju u dan qed naghmlu minn 
rajja. 
Jiena nista', meta rrid, ma nkomplix niehu sehem fl-istudju, u minghajr ma' naghti 
raguni. Jekk naghmel hekk xorta nibqa' niehu l-kura li ssoltu tinghatali (tapplika biss 
ghal pazjenti Ii qed jiehdu kura). 
Jiena nifhem li jekk ikun hemm xi kumplikazzjoni jew effetti mhux mistennija waqt l-
istudju, dawn jigu mnizzla bil-miktub u jekk ikun hemm bzonn xi kura, kif jinghata 
fis-Servizz Nazjonali tas-Sahha. 
Jiena mhux qed nithallas biex niehu sehem f'dan l-istudju. 
Jekk ikolli xi diffikulta' waqt l-istudju, nista' nistaqsi ghal: Simon Camillei fuq numru 
23401876 Email: simon.camilleri@um.edu.mt 
Firma tal-participant. (Filkas ta’ minorenni, jiffirma il-genitur jew gwardjan.) 
Isem tal-participant (b 'ittri kbar) 
Numru ta' l-identita 
Firma tal-persuna responsabbli ghal din ir-ricerka 
Isem tal-persuna responsabbli ghal din ir-ricerka 
Numru ta' l-identita’ 
DATA 
*aqta fejn ma japplikax
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INFORMATION SHEET 
CONSENT TO PARTICIPATE IN A GENETIC STUDY INVESTIGATING 
UNERUPTED TEETH 
DESCRIPTION OF THE STUDY. The University of Malta is carrying out a study on 
impacted maxillary canine teeth in Maltese nationals and is inviting you to participate 
in this study. This work would involve compilation of a family tree and isolation, 
analysis and storage of your DNA (molecule of heredity).  
This study is scheduled to continue for a number of years and participation is 
voluntary. You will be required to supply relevant medical and dental history, together 
with a sample of cells obtained from the inside of your mouth by means of a 
mouthwash. This will be used to obtain DNA. The DNA will be used to produce 
molecular genetic data that will be assembled into a database. 
PROCEDURES.  You would be asked questions (either directly or by questionnaire) 
regarding your and your family’s general health and dental condition. 
You would be provided with one bottle of ordinary mouthwash. You would be 
required to rinse out your mouth and then spit the mouthwash back into the bottle, 
once first thing in the morning on rising. The mouthwash would then be collected for 
examination. 
Should it be necessary, we may ask you to have a dental examination, photographs, 
Xrays or casts of your teeth at our expense. 
YOUR RIGHTS.  Participation in this study is voluntary. You have the right to end 
your participation at any time, and to decide whether the material already collected can 
remain part of the study or must be destroyed. You also have the right to determine 
which of the above procedures you are willing to complete. Confidentiality will be 
preserved in any scientific publication of the data, and we will not provide genetic 
information back to you, except in the unusual circumstances listed in ‘OTHER 
ISSUES’, below. You may ask questions at any time during your participation. 
RISKS, INCONVENIENCE AND DISCOMFORT. There is no risk to your health, 
nor are any uncomfortable procedures involved during participation. 
BENEFITS. There is no material benefit to you for taking part. However others might 
benefit in the event of a test or cure being developed as a direct result of this study. 
OTHER ISSUES RELATED TO THIS PROPOSAL 
FUTURE RESEARCH. Our specific research plans have been summarized in the first 
paragraph of this document. In the course of the research, we will obtain samples of 
your cells. While we will do some testing immediately, we may store your DNA from 
your cells in the freezer for related studies. The storage will be for a maximum period 
of 6 years, unless the sample is used up before this time. In addition, certain 
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information obtained will be stored in our research records. Your DNA will not be 
used for other research purposes without your prior permission. If you agree to the use 
of your sample in future research, you will be able to discuss any concerns you have 
about this research with a genetic counselor or your medical doctor. 
UNANTICIPATED MEDICAL INFORMATION. During the course of this 
investigation, it is possible (although not likely) that we will obtain unanticipated 
information about your health or genetic makeup. If this information is deemed to be 
vital to your medical health, we will provide this to your physician after having 
obtained your permission. This information cannot compromise any other individual. 
Circumstances may require further information or another cell sample. In this case we 
will contact you through your physician. 
FAMILY RELATIONSHIPS. In the course of this study, it is possible (although not 
likely) that we may discover information about relationships within the family, such as 
adoption or paternity. We will not provide this type of information to anybody. The 
exception would be the extraordinary circumstance should this information be required 
for the medical care of the individuals involved. If we are convinced that this is 
necessary, we will provide the information to the physician who is providing medical 
care to the patient. 
CONFIDENTIALITY. All information collected or discovered about you or your 
family is considered confidential and private. All relevant records and files will be 
kept in a locked office in the University of Malta. Control of this information is in 
your hands. No-one, not even other members of your family can access this 
information without your permission. 
COLLECTION OF, RESEARCH ON, AND STORAGE OF GENETIC MATERIAL. 
It should be clear to you that your DNA sample will only be used for research. No 
other testing or research will be conducted on your sample unless you specifically give 
permission (as indicated below). The DNA isolated from your cell sample will be 
stored in locked freezers contained in secure buildings at the University of Malta. The 
samples will be labeled and stored by codes defined by us. The only individual who 
will have access to the codes will be the principal investigator of this study, Dr. Simon 
Camilleri. Dr Camilleri undertakes to exchange only coded anonymised research 
results with foreign investigators, and therefore your identity will not be revealed to 
anyone. 
CONTACTS. This study is supervised by the Principal Investigator, Dr. Simon 
Camilleri who can be contacted at 23401876 or email simon.camilleri@um.edu.mt 
with any related questions. 
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TAGHRIF 
KUNSENS BIEX TIE}U SEHEM FI STUDJU GENETIKU - 
INVESTIGAZZJONI TA’ SNIEN LI MA TELGHUX. 
TIFSIRA TAL-ISTUDJU.  L-Universita’ ta’ Malta qed taghmel studju fuq certi snien 
(imsejhin in-nejbiet ta’fuq) li ma jitilghux. Dan l-istudju qed isir fuq nies 
ta’nazzjonalita Maltija u inti qed tigi mistieden/na tiehu sehem. Dan jinvolvi 
kompilazzjoni tal- ‘family tree’ tieghek u isolazzjoni, analisi u hazna tad-DNA, li hija 
il-molekula tal-eredita’ tieghek. 
Dan l-istudju mahsub li jkompli ghal xi 6 snin. Is-sehem huwa volontarju. Inkunu 
nixtiequ min ghandek xi informazzjoni dwar sahhtek generali u ta’ snienek flimkien 
ma ftit celloli min halqek. Ic-celloli jigu migbura bit-tlahlih ta’ halqek. Min dawn ic-
celloli niehdu id-DNA. Minnu nohorgu data fuq l-istruttura genetika li jigi imdahhal 
fcdatabase  
PROCEDURA. Tigi mitlub/a informazzjoni dwar is-sahha generali w is-sahha ta’ 
snienek u tal-familja tieghek.  
Tigi mitlub kampjun bzieq billi tobzoq gol-flixkun ipprovdut. Dan jigi migbur u 
ezaminat. 
Jekk ikun hemm bzonn, nitolbu li jsir ezami ta snienek jew niehdu ritratti, x-rays jew 
forma ta’ halqek, spejjez taghna. 
DRITTIJIET TIEGHEK. Sehem f’dan l-istudju huwa min rajk. Ghandek id-dritt 
ittemm sehmek meta jidhirlek u tiddeciedi jekk il-materjal migbur jibqa’ parti mill-
istudju jew jigi distrutt. Ghandek ukoll id-dritt tiddeciedi liema proceduri tixtieq li 
isiru jew ma jsirux. Il-kunfidenzjalita’ tigi mharsa f’kull publikazzjoni ta’ data u ahna 
qatt ma naghtu informazzjoni genetika lil-hadd hlief fic-cirkostanzi specjali 
imsemmija izjed l-isfel, taht ‘AFFARIJIET OHRA RELATATI LIL-PROPOSTA’.  
Tista’ taghmel mistoqsjiet meta’ trid waqt li tkun qed tiehu sehem.  
RISKJU, INKONVENJENZA U SKUMDITA’. Ma hemm l-ebda riskju lis-sahha 
tieghek, lanqas ma hemm proceduri skomdi jekk tiehu sehem. 
BENEFICCJI. Ma hemm l-ebda beneficcju materjali ghalik billi tiehu sehem. Izda 
ohrajn jistghu jibbenefikaw jekk fil-kas li jigi zviluppat test jew kura bhala risultat 
ta’dan l-istudju. 
AFFARIJIET OHRA RELATATI LIL-PROPOSTA. 
RICERKA FIL-FUTUR. L-iskopijiet taghna gew imsemmija fl’ewwel paragrafu ta’ 
dan id-dokument. Ghas-skopijiet tar-ricerka ser niksbu xi celloli tieghek. Minkejja li 
jsiru testijiet mal-ewwel, ghandna mnejn nahznu ftit DNA go freezer ghal studji simili. 
Id-DNA jigi mizmum ghal mhux izjed min sitt snin, sakemm ma jintuzax kollu. 
Apparti hekk, inzommu certu informazzjoni fir-records taghna. 
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Id-DNA mhux ser jintuza ghar-ricerka ohra minghajr permess specifiku tieghek. 
Jekk taqbel li id-DNA tieghek jintuza il-quddiem, tkun tista tiddiskuti mac tabib jew 
kunsillier genetiku jekk hemm xi hsiebijiet jinkwetawk 
INFORMAZZJONI MEDIKU MHUX MISTENNI. Filwaqt l-investigazzjoni hemm 
possibilta’, avolja zghira, li niksbu informazzjoni mediku mhux mistenni dwar sahhtek 
jew l-ghamla genetika tieghek. Jekk dan l-informazzjoni jigi mahsub li jkollu x’jaqsam 
ma xi kura medika tieghek, ahna naghtuh lit-tabib tieghek biss u bil-permess tieghek 
dejjem.  
Dan l-informazzjoni ma jistax jikkomprometti bniedem iehor. Jista jkun il-kas li jkun 
hemm bzonn ta’ izjed informazzjoni jew li jinkisbu izjed celloli. F’dan il-kas naghmlu 
kuntatt mieghek permess tat-tabib tieghek. 
RELAZZJONIJIET FAMILJARI. Filwaqt l-investigazzjoni hemm possibilta’, avolja 
zghira, li niksbu informazzjoni dwar relazzjonijiet fil-familja e.z. kazijiet ta’ 
adottazjoni jew ta paternita’. Dan it-tip ta informazzjoni ma jigi moghti lil-hadd, hlief 
fic-cirkostanzi straordinarju li dan l-informazzjoni jehtieg ghal-kura medika tal-
individwi koncernati. F’dan il-kas l-informazzjoni jigi pprovdut lit-tabib li qed jaghti 
il-kura. 
KUNFIDENZJALITA’ Kull informazzjoni migbur jew miksub dwarek jew il-familja 
tieghek hu kkunsidrat kunfidenzjali u privat. Il-kotba u il-files relevanti jinzammu 
maqfulin go ufficcju fl-Universita ta’ Malta. Il-kontroll ta’ dan l-informazzjoni huwa 
f’idejk. Haddiehor, lanqas membri tal-familja tieghek, ma jista jkollhom access 
minghajr il-permess tieghek. 
KOLLEZZJONI, RICERKA U HAZNA TA’ MATERJAL GENETIKU. Ghandu ikun 
car li il-kampjun ta celloli tieghek jigi wzat ghar-ricerka biss. L-ebda ricerka jew 
testijiet ohra ma jsiru minghajr il-permess specifiku tieghek kif indikat taht. Id-DNA 
miksub mic-celloli tieghek jigi mahzun go freezers imsakkrin go bini imsakkar fl-
Universita’ ta’ Malta. Dawn il-kampjuni jigu identifikati minn codes taghna. L-uniku 
bniedem li jkollu access ghal dawn il-codes ikun l-Investigatur Principali, Dr. Simon 
Camilleri. Dan jintrabat li johrog ir-rizultati taht dawn il-codes anonimizzati biss, 
sabiex ismek ma jinkixef lill-hadd 
KUNTATTI.Dan l-istudju huwa taht il-harsien tal-Investigatur Prinicipali, Dr. Simon 
Camilleri. Tista tikkuntatjah fuq 23401876 jew email simon.camilleri@um.edu.mt  
b’xi mistoqsijiet relatati. 
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Appendix 2. Tables and Pedigrees 
Table 22. Genetic conditions where failure of eruption is a feature. 
Condition OMIM Phenotype Gene Mode of Inheritance Gene function/Pathogenesis 









delay/failure of eruption, 
supernumerary teeth 
RUNX2 Autosomal dominant 
Osteoblast-specific 
transcription factor, 
regulator of osteoblast 
differentiation 
Primary Failure of 
eruption #125350 
Localised failure of 





through stimulation of 
inhibitory G proteins 
Frontometaphyseal 
Dysplasia 
#305620 Partial anodontia  Delayed tooth eruption  
Retained deciduous teeth 




Ectopic teeth,  
delay/failure of eruption, 
oligodontia 
ED1 X linked recessive 
Regulatory role in both 




EDARADD Autosomal recessive 
#129490 EDA3 Autosomal dominant 
Osteogenesis #166200 Delayed eruption, COL1α1, Autosomal dominant Reduced amounts of 
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Imperfecta dentinal dysplasia COL1α2 normal collagen I. 
Osteopetrosis 
#166600 Failure of eruption, root 
deformation. 
CLCN7 Autosomal dominant 
Inactive Osteoclasts 
#259700 TCIRG1 Autosomal recessive 
Osteopathia Striata 
%300373 
Failure of eruption OSCS Autosomal/X linked dominant Not known %166500 
Pyknodysostosis  #265800 
Delayed eruption of 
deciduous teeth  
Delayed eruption of 
permanent teeth  
Hypodontia 
CATHEPSIN 
K Autosomal recessive 
Major lysosomal 




Delayed tooth eruption 
Hypodontia  
Unknown Autosomal dominant Unknown 
Albright Hereditary 
Osteodystrophy #103580 
Delayed tooth eruption 
Enamel hypoplasia  GNAS1 Autosomal dominant 
Regulator of Calcium 
Metabolism 
Osteoglophonic 
Dysplasia #166250 Failure of eruption FGFR1 Autosomal dominant 
Regulator of cellular 
responses 
Oculo-Facio-Cardio-
Dental Syndrome #300166 Delayed eruption BCOR X linked dominant 
Key transcriptional 




Retained deciduous teeth 
Ectopic teeth 











Delayed tooth eruption 




Chondroectodermal #225500 Neonatal teeth EVC/EVC2 Autosomal recessive Essential role in 
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Dysplasia Hypodontia  
Delayed eruption 
skeletal development 
Cornelia De Lange 
Syndrome #122470 
Widely spaced teeth 






Hunter Syndrome +309900 Delayed tooth eruption Widely spaced teeth IDS X-linked dominant 
Hydrolysis of 2-sulfate 
groups 
Incontinentia Pigmenti #308300 
Hypodontia  
Delayed eruption 
Conical forms  
Accessory cusps 






Delayed eruption  
Malocclusion  
Notched incisors  
DHOF X-linked dominant Not known 
Pallister-Killian 






%216400 Delayed eruption of deciduous teeth  






Type VI +253200 Delayed eruption ARSB Autosomal recessive 
Aryl sulphatase B 
deficiency 
Hutchinson-Gilford 
Progeria Syndrome #176670 
Delayed and abnormal 
tooth eruption and 
morphology 
LMNA Autosomal dominant 




Table 23. The variants with a frequency of 1% or less in the 1000 genomes database which were common to both exomes. 
Chr  Position 
Allele 
details SIFT score dbSNP 
1000g 
freq Ref Alt 
2 61345243 G A exonic 
KIAA1841:NM_032506:exon20: 
c.G2020A:p.A674T, 0.69 RS148264616 0.0005 
3 37370566 A T exonic 
GOLGA4:NM_001172713:exon17: 
c.A6240T:p.R2080S, . RS11924014 0.0055 
3 38753732 A T exonic 
SCN10A:NM_006514:exon22: 
c.T4009A:p.S1337T, 0.58 RS11711062 0.0014 
4 110681527 C T exonic 
CFI:NM_000204:exon6: 
c.G782A:p.G261D, 0.08 . 0.0009 
6 26410148 T C splicing 
BTN3A1:NM_194441:exon6: 
c.937+6T>C, . RS77721150 0.0064 
6 31626080 C T splicing C6orf47: . RS75629491 0.0077 
6 32946119 G C exonic 
BRD2:NM_001199456:exon9: 
c.G1654C:p.A552P, 0.22 RS55952113 0.0033 
6 146007358 T C exonic 
EPM2A:NM_005670:exon2: 
c.A376G:p.I126V, 1 RS150452237 0.0005 
6 150464476 G T exonic 
PPP1R14C:NM_030949:exon1: 
c.G148T:p.V50L, 0.45 RS200448500 0.004 
6 160575837 G A exonic 
SLC22A1:NM_003057:exon9: 
c.G1393A:p.G465R, . . 0.0082 
8 68028252 C G exonic 
CSPP1:NM_024790:exon11: 
c.C1376G:p.S459C, . RS146431326 0.0022 
8 71646361 T A exonic 
XKR9:NM_001011720:exon5: 
c.T824A:p.F275Y, . RS74941166 0.0041 
8 86121636 T C exonic 
E2F5:NM_001083588:exon6: 
c.T875C:p.I292T, 0.23 RS187526876 0.0023 
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8 87081697 C G exonic 
PSKH2:NM_033126:exon1: 
c.G155C:p.R52P, . RS140592507 0.0047 
8 87437445 A C splicing 
WWP1:NM_007013:exon10: 
c.1062-7A>C . RS142212058 0.0031 
8 106431420 A G exonic 
ZFPM2:NM_012082:exon2: 
c.A89G:p.E30G, 0.05 RS121908601 0.0026 
8 106814597 G A exonic 
ZFPM2:NM_012082:exon8: 
c.G2287A:p.V763I, 0.11 RS117908591 0.0026 
11 22284483 T C splicing 
ANO5:NM_001142649:exon17: 
c.1798-9T>C, . . 0.0005 
14 60027862 C G exonic 
C14orf38:NM_001164399:exon7: 
c.G928C:p.D310H, 0.13 RS180781165 0.0007 
14 64689913 G A exonic 
SYNE2:NM_182913:exon8: 
c.G1141A:p.E381K, 0.48 RS150172232 0.0018 
14 72054708 G A exonic 
SIPA1L1:NM_015556:exon2: 
c.G119A:p.R40Q, 0.14 RS78621209 0.0069 
18 31324766 G A exonic 
ASXL3:NM_030632:exon12: 
c.G4954A:p.V1652M, . RS17746949 0.0085 
19 39207742 G A exonic 
ACTN4:NM_004924:exon10: 
c.G929A:p.R310Q, . RS112545413 0.0067 
20 36560190 C T exonic 
VSTM2L:NM_080607:exon2: 
c.C275T:p.A92V, 0.07 RS146022041 0.0045 
22 24225971 G A exonic 
SLC2A11:NM_001024939:exon9: 
c.G1006A:p.E336K, . RS79905160 0.0014 
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Pedigree V1, the full family tree. 
Pedigrees used in Linkage Analysis Study
177 
Pedigree V2, with uninformative family members removed. 
178 
Pedigree V3, the full family, split into two. 
179 
Pedigree V4, a further reduced version of V2, used for quality control. 
180 
Pedigree V6, identical to V2 but with #41 marked as ‘status unknown’. 
181 
Pedigree V7, identical to V2 but with #41 marked as unaffected. 
182 
Pedigree V8, identical to V2 but with all clinically unaffected members and #41 classified as ‘status unknown’. 
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Appendix 3. Publications 
Abstract submitted to the British Society for Dental Research, March 2006. 
Title of talk: The Aetiology Of Ectopic Maxillary Canine Teeth 
Presenter: Simon Camilleri, Department of Orthodontics 
Supervisors: Fraser McDonald, Christian Scerri 
Objectives: To elucidate the mode of inheritance of ectopic canines. 
Introduction: The aetiology of ectopic maxillary canines has been proposed to be genetic 
and is associated with incisor-premolar hypodontia as well as with various other anomalies. 
The Maltese population has a high prevalence of ectopic teeth, especially ectopic canines, as 
compared to other populations. This has been ascribed to the ‘Founder Effect’ phenomenon, 
the population having grown from under 20,000 to over 400,000 in the past 500 years. 
Methods: Probands with ectopic maxillary canines were identified during routine clinical 
examination. The inclusion criteria were a positive family history of ectopic canines, peg 
incisors or missing teeth in more than one generation or with an affected first cousin. 
Families with a member affected by a genetic syndrome were excluded. 
Ectopic or missing teeth were identified by clinical examination or from existing records. 
Radiographic investigation was undertaken where necessary. 
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Twenty-two families were examined, comprising a total of 98 individuals. Pedigrees were 
constructed and the percentages of affected first-degree relatives determined. 
Results: Analysis suggests autosomal dominant transmission. 12% of first degree relatives 
had ectopic canines, 4% had transposed canines and a further 12% exhibited hypodontia, in 
particular upper lateral and lower central incisors. 
Penetrance is highly variable between families and there seems to be no clear pattern of 
augmentation or attenuation of symptoms.  
One concordant pair of fraternal twins and one discordant pair of identical twins were 
included in the sample. 
Conclusion: The genetic aetiology of ectopic canines is supported by this study, as is its 
close association with incisor-premolar hypodontia. Expressivity is also highly variable with 
other eruption anomalies such as maxillary and mandibular canine transposition forming part 
of the phenotype. The discordant identical twins suggest the possibility of epigenetic factors 
influencing eruption of teeth. 
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Abstract submitted to the American Society of Human Genetics Conference October 2006. 
Title of talk: The Aetiology Of Ectopic Maxillary Canine Teeth 
Presenter: Simon Camilleri, Department of Orthodontics 
Supervisors: Fraser McDonald, Christian Scerri 
Objectives: To elucidate the mode of inheritance of ectopic canines. 
Introduction: The aetiology of ectopic maxillary canines has been proposed to be genetic 
and is associated with incisor-premolar hypodontia as well as with various other dental 
anomalies. The Maltese population has a high prevalence of ectopic teeth, especially ectopic 
canines, as compared to other populations. This has been ascribed to the ‘Founder Effect’, the 
population having grown from under 20,000 to over 400,000 in the past 500 years. 
Methods: Thirty consecutive probands with a family history of ectopic canines were 
identified. 152 first, 51 second and 113 third degree relatives were contacted and their dental 
status ascertained by direct examination, anamnestic records, or written or telephone 
questionnaire. Pedigrees were constructed; the risk to the relatives was determined and 
plotted against the degree of relation. 
Results: Analysis of the pedigrees suggests autosomal dominant transmission. 12% of first 
degree relatives had ectopic canines, 3.9% had transposed canines and a further 9% exhibited 
hypodontia, in particular upper lateral and lower central incisors. There is an appreciable 
relative risk in second and third degree relatives. The female to male ratio of the sample is 
2.06, with no difference in the incidence of relatives of male or female probands. Penetrance 
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is highly variable as is expressivity, with wide variation in the number and severity of 
ectopicity of teeth. 
Conclusion: The genetic aetiology of ectopic canines is supported by this study. The data 
points to the action of a single major gene with incomplete penetrance and variable 
expressivity. 
Review
Runx2 and dental development Simon Camilleri, Fraser McDonald
Department of Orthodontics, Dental Institute of
Kings College London, London, UK
Mutations of Runx2 [also known as Core-binding factor
a1 (Cbfa1), PEBP2A1, and AML3) have been identiﬁed
as being responsible for cleidocranial dysplasia (CCD)
(Fig. 1) (1). This is an autosomal-dominant inherited
disorder characterized by patent fontanelles, wide cranial
sutures, frontal bossing, hypoplasia of the clavicles, short
stature, ectopic and delayed eruption of teeth, supernu-
merary teeth, and other skeletal anomalies. Gene
knockout experiments have produced similar skeletal
phenotypes in mice (2).
RUNX2 is an osteoblast-speciﬁc transcription factor
necessary for the diﬀerentiation of pluripotent mesen-
chymal cells to osteoblasts (3). The presence of RUNX2
in fully diﬀerentiated cells supports the concept that
RUNX2 is also required in maintaining fully functional
cells, at least in bone (3–5).
RUNX2 has also been identiﬁed as essential for tooth
formation (4, 6). Dental abnormalities seen in CCD
patients (7, 8) may be a direct result of RUNX2 dys-
function in tooth-forming cells. The dental abnormalities
in CCD suggest an important role for RUNX2 during
formation of the dentition.
The Runx2 gene is 220 kb long (9) and contains eight
exons (5, 10, 11). It belongs to the runt domain (RUNX)
family of genes. These genes, named Runx1, -2 and -3,
exhibit a high amino acid homology. Their protein
products form a heterodimer with core-binding factor b
(CBFb) (12).
CBFb is required for the eﬃcient function of RUNX2
in skeletal development (13), allosterically enhancing
DNA binding by RUNX proteins at the runt homology
domain (RHD) (14). Furthermore, it plays an important
role in stabilizing RUNX proteins against proteolytic
degradation by the ubiquitin–proteasome system (15).
Runx2 and bone
Bone tissue consists of hydroxyapatite crystals and var-
ious kinds of extracellular matrix (ECM) proteins,
including type I collagen, osteocalcin, osteonectin, oste-
opontin, bone sialoprotein (BSP), and proteoglycans
(16, 17). These bone matrix proteins are secreted and
deposited by polarized mature osteoblasts, which are
aligned on the bone surface (18). The precise roles of
matrix proteins in the formation of bone are not fully
elucidated (19, 20). The formation of hydroxyapatite
crystals is also regulated by osteoblasts.
The establishment of Runx2 null mice clearly demon-
strated that this transcription factor is essential for
osteoblast diﬀerentiation, as these mice had no bone
tissue, osteoblasts or osteoclasts, despite normal cartila-
ginous skeletal patterning. Chondrocyte maturation,
however, is perturbed as a consequence (2, 21).
Runx2 is also active in mature osteoblasts. Mature
mice, in whom active RUNX2 levels have been reduced,
exhibit decreased expression of the genes encoding the
main bone matrix proteins, BSP, osteocalcin, osteopon-
tin and collagen type I (4). These genes are regulated via
the RUNX2-binding sites in the proximal promoter
segments of the respective genes (14).
RUNX2 has thus been shown to be essential for nor-
mal bone formation, with perturbation of bone forma-
tion if the levels are insuﬃcient. Overproduction will also
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aﬀect bone formation. Osteoblasts taken from non-syn-
dromic synostosed sutures in children exhibited an
increase in Runx2 expression, possibly explaining the
enhanced proliferation and bone-forming ability of these
cells (22). However, adult transgenic mice overexpressing
Runx2 showed osteopenia with a decrease in bone min-
eral density. This was attributed to reduced osteoblast
maturation, but also to enhanced receptor activator of
nuclear factor kappa b ligand (RANKL) and matrix
metalloproteinase-13 (MMP-13) production with
enhanced osteoclastogenesis (23). Neonatal transgenic
mice showed maturational blockage of osteoblasts, but
did not show enhanced osteoclastogenesis, possibly
because of the diﬀerent ages of the experimental mice
(24). The results of these experiments are consistent with
evidence that Runx2 is regulated, in part, through a
negative feedback loop by activity of the RUNX2 pro-
tein on its own promoter, to control variations in gene
expression and function during osteogenesis (25).
Runx2 expression decreases with age. This may be one
possible explanation for impaired osteoblast function
and reduced bone formation with aging (26).
RUNX2 is aﬀected by a diversity of signaling path-
ways. Binding of ECM proteins to cell-surface integrins,
mechanical loading, ﬁbroblast growth factor 2 (FGF2),
parathyroid hormone (PTH), and bone morphogenetic
proteins (BMP), all inﬂuence RUNX2-dependent tran-
scription. These post-translational changes act via the
mitogen-activated protein kinase (MAPK) and protein
kinase A and C (PKA, PKC) pathways, activating
RUNX2 by phosphorylation (27–29) (Fig. 2). Further
control of the RUNX2 molecule occurs through the
counterplay of acetylation and ubiquitinization (29–31)
(Fig. 3) The Runx2 gene, in fact, plays a central role in
co-ordinating multiple signaling pathways aﬀecting
osteoblast diﬀerentiation.
A species-speciﬁc diﬀerence in action may, however,
exist. Osteoblast diﬀerentiation in rodents is associated
with an increase in RUNX2 production. However, in
human bone marrow stem cells, enhanced transactiva-
tion activity occurs with no change in Runx2 mRNA or
protein levels. This activity has been ascribed to post-
translational phosphorylation of key residues in the
RUNX2 protein (32).
RUNX2 domains
RUNX2 binds to the core binding factor site, also
known as the osteoblast-speciﬁc cis-acting element 2
(OSE2) (33), which is found in the promoter regions of
all the major osteoblast-characteristic genes, such as
osteocalcin, type I collagen, BSP, osteopontin, MMP-13,
and alkaline phosphatase. Together with other factors,
such as activator protein 1 (AP-1) and mothers against
decapentaplegic homolog (SMADs), it controls their
expression (34, 35). The RHD is responsible for the
DNA-binding properties of RUNX2 (Fig. 4).
Three transactivation domains and one major repres-
sion domain have been identiﬁed in the RUNX2 protein
(36). The ﬁrst transactivation domain is located in the
N-terminal 19 amino acids of the protein, while the
second is located in the glutamine/alanine (Q/A) domain.
In the latter, transactivation depends on a stretch of
29 glutamine residues. Deletion of the alanine stretch
does not aﬀect transactivation; however, expansion has a
repressive function (1), and expansion may also play a
role in nuclear localization (37).
The third activation domain is present in the N-ter-
minal portion of the proline/serine/threonine (PST)-rich
domain. A mutation in this region has been shown to
cause a failure to interact with SMADs, reducing the
response of osteoblasts to the Transforming growth
factor-b/Bone morphogenetic protein (TGF-b/BMP)
signaling pathway (38). This region has also been shown
to interact with the co-activator molecule, p300, aﬀecting
expression of the osteocalcin gene (39). This action is
independent of the acetyltransferase activity of p300,
which protects RUNX2 from degradation by SMAD
ubiquitin regulatory factor (SMURF)-mediated ubiqui-
tination and also increases the transactivation potential
of RUNX2 (31).
Fig. 1. A 12-yr-old female patient with cleidocranial dysplasia. (A) Lateral skull radiograph showing a wormian bone in the temporal
suture region and a hypoplastic maxilla. (B) Panoramic radiograph showing supernumerary and unerupted teeth, some of which are
ectopic. Typically, the lower permanent central incisors and all four ﬁrst permanent molars have erupted.
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The C-terminal part of the PST domain is a repression
domain (36, 40). The terminal ﬁve amino acids (the
VWRPY motif) are highly conserved and may bind the
corepressor proteins of the transducin-like enhancer of
split (TLE) or Groucho-related genes (Grg) family (41).
The down-regulation of TLE/Grg expression during
osteoblast diﬀerentiation is a potential mechanism for
relief of Runx2 repression during cell diﬀerentiation (42).
Other parts of the molecule have been shown to react
with other corepressors, such as histone deacetylases
(HDAC) (40), SIN3 (43), and yes-associated proteins
(YAP) (44) (Table 1 and Fig. 4). A review of RUNX2
corepression was made by Westendorf (45).
RUNX2 is imported to the nucleus after transcription
and must bind to speciﬁc regions of the nuclear matrix to
eﬀect transcriptional control (53), colocalizing with
co-activators such as SMADs (35) and RNA poly-
merases, at nuclear sites that support RNA synthesis (54).
This function is eﬀected by the nuclear matrix target-
ing signal (NMTS) region, a 38 amino acid segment
situated between the RHD and PST domains (55). Point
mutations in the NMTS region have been shown to aﬀect
the intranuclear localization of RUNX2, possibly
aﬀecting its interaction with target genes that are
involved in osteolytic activity (38, 56).
The interaction of transcription factors with cellular
signal transducers at particular points in the nuclear
matrix may partly explain the tissue-speciﬁc action of the
RUNX proteins and of transcription factors in general.
RUNX2 isoforms
RUNX2 has two major N-terminal isoforms, whose
transcription from the Runx2 gene is separately regulated
by either a proximal promoter or a distal promoter
(Fig. 5) (10). The product of the proximal promoter
starts with the amino acid sequence, MRIPVD, and is
known as Type I, PEBP2A or P56. That of the distal
promoter product starts with the amino acid sequence,
MASNSL, and is known as Type II, Til-1 or P57. OSF2
(Type III) is a splice variant of Type II, present only in
the mouse. It starts with the sequence MLHSPH, and its
function is similar to the Type II isoform. It is not
essential for optimal transcriptional activation (57), and
it may play a species-speciﬁc role in the regulation of
transcription (10).
Fig. 3. Bone morphogenetic proteins (BMP) and transforming
growth factor-b (TGF-b) act on P300 to acetylate (Ac)
RUNX2, protecting it from degradation via the ubiquitin
pathway. Histone deacetylases (HDACs) deacetylate RUNX2,























Fig. 2. Multiple signaling pathways converge on RUNX2 to
initiate osteoblast diﬀerentiation. BMP2, Bone Morphogenic
Protein 2; ECM, Extracellular Matrix; FGF2, Fibroblast
Growth Factor 2; AP-1, Activator Protein 1; ERK, Extra-
cellular signal related kinase; FAK, Focal adhesion kinase; Fos,
Oncogene Fos; Fra, Fos related antigen; G, G alpha protein;
Jun, Oncogene Jun; MEK1/2, Mitogen activated protein ki-
nase/Extracellular signal related kinase1/2; OSE2, Osteoblast
Speciﬁc Element 2; Osx, Osterix; PTH, Parathyroid hormone;
PTHR, Parathyroid hormone related protein; Raf, Oncogene
Raf; Ras, Retrovirus associated DNA sequences; RTK,
Receptor Tyrosine Kinase; SBE, SMAD binding element;
Smad, Mothers against decapentaplegic protein. Modiﬁed after
Franceschi RT, Xiao G. J. Cell Biochem. Vol.88, 3 Pages: 446-
454. Copyright  2003 Wiley-Liss, Inc., A Wiley Company.
Reprinted with permission of Wiley-Liss, Inc., a subsidiary of
John Wiley & Sons, Inc.
Fig. 4. Distribution of the diﬀerent domains of the RUNX2
protein. The sites of interaction with various corepressor mol-
ecules are also shown. AD, transactivation domain; HDAC,
histone deacetylase; SIN3A, SIN3A protein; NMTS, nuclear
matrix targeting signal; PST, proline/serine/threonine rich do-
main; Q/A, glutamine/alanine-rich domain; RD, repression
domain; RUNT, Runt homology domain; TLE, transducin-like
enhancer of split; VRWPY, conserved repression signal; YAP,
yes-associated protein.
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The presence of multiple isoforms of the Runx2 gene
product is consistent with other members of the Runx
transcription family, including Runx1 and Runx3, that
exist as multiple isoforms with diﬀerent transactivation
potentials (58).
Type I and Type II isoforms diﬀer functionally, but
both are crucial in bone development. Type I is expressed
ubiquitously in both non-osseous mesenchymal tissues
and on osteoblast progenitor cells. It plays an important
role in a wide range of cellular diﬀerentiation events and
its expression is not aﬀected by the diﬀerentiation status
of the cell. In terms of intramembraneous bone forma-
tion, it probably is involved in the initial commitment
steps and continues to exert its eﬀects to the ﬁnal dif-
ferentiation of osteoblasts.
Type II expression is increased during osteoblast dif-
ferentiation and is induced as a response to BMP2,
suggesting that it is necessary for the maintenance of the
osteoblast phenotype and that Type I may have a regu-
latory role (Fig. 6) (59).
In contrast to the ﬁndings of Ducy et al. (3) and Xiao
et al. (10), Harada et al. (60) found all three isoforms to
be present in the bones of adult mice and concluded that
all three are involved in stimulating osteoblast diﬀeren-
tiation, exerting diﬀerent functions in the process of
diﬀerentiation depending on the cell type and the
Table 1
Known co-activators and corepressors of RUNX2. CBFB, core binding factor subunit B; GR65, Groucho related gene 5; HDAC3, histone
decetylase3; HDAC5, histone decetylase 5; HDAC6, histone decetylase 6; MORF, monocytic leukemia zinc ﬁnger protein-related
factor; pRb, retinoblastoma 1; Sin3A, Sin3 protein; TAZ, tafazzin; TLE/GROUCHO, transducin-like enhancer of split/Groucho related
genes; TWIST, Twist protein; YAP1, yes associated protein 1
Protein Reference Class Function
CBFB Yoshida et al. (13) Co-activator Enhances DNA binding of RUNX2
GRG5 Wang et al. (46) Co-activator Dominant-negative inhibitor of larger TLE proteins
HDAC3 Schroeder et al. (47) Corepressor Blocks RUNX2 dependent transcription
HDAC4 Vega et al. (48) Corepressor Prevents DNA binding
HDAC6 Westendorf et al. (40) Corepressor Deacetylation of histones
MORF Pelletier et al. (49) Co-activator Potentiates RUNX2 dependent transcription
MOZ Pelletier et al. (49) Co-activator Potentiates RUNX2 dependent transcription
SIN3A Fenrick et al. (43) Corepressor Alters subnuclear localization
p-300 Jeon et al. (31),
Sierra et al. (39)
Co-activator Acetylation of RUNX2/potentiates Vitamin D actions
pRb Thomas et al. (50) Co-activator Potentiates RUNX2 dependent transactivation
TAZ Cui et al. (51) Co-activator Potentiates RUNX2 dependent transactivation
TLE/GROUCHO McLarren et al. (41)
Javed et al. (42)
Corepressor Colocalizes at subnuclear level
TWIST Bialek et al. (52) Corepressor Prevents DNA binding of RUNX2
YAP1 Zaidi et al. (44) Corepressor Colocalizes at subnuclear level
Fig. 5. Diagram of the Runx2 promoter region. The P2 pro-
moter drives expression of the Type I isoform and is associated
with cell proliferation. The P1 promoter drives expression of the
Type II variant, associated with commitment to a calciﬁed tis-
sue line. A mini-intron separates Exon 0 from exon )1. Tran-
scription from this site produces the Type III variant, which has
similar properties to Type II but is found only in mice.
A, arginine; D, aspartic acid; H, histidine; I, isoleucine; L,
leucine; M, methionine; N, asparagine; P, proline; R, arginine;
S, serine; V, valine.
Fig. 6. Fibroblast growth factor 2 (FGF2) stimulates produc-
tion of the Type 1 isoform from the P2 promoter to initiate cell
commitment and proliferation. Bone morphogenetic protein 2
(BMP2), produced by these cells, acts via distal-less homeobox
5 (DLX5) on the distal P1 promoter to produce the Type 2
isoform, which encourages maturation of the osteoblast and
exit from the cell cycle. The action of DLX5 is antagonized by
muscle segment homeobox 2 (MSX2). Information derived
from Bannerjee et al. (59), Choi et al. (64) and Lee et al. (65).
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downstream gene promoter. Because production of the
Type II isoform is restricted to later events of cell dif-
ferentiation, being found only in pre-osteoblasts and
osteoblasts, its contribution is probably more speciﬁc in
the ﬁnal step into osteoblast diﬀerentiation and is
necessary for osteoblast maturation and skeletogenesis
(61, 62). However, the expression pattern and function of
both isoforms is not very diﬀerent in the later stages of
osteoblast diﬀerentiation (63).
The expression of Type I Runx2 is stimulated by
FGF2. This commits precursor cells to the osteoblast
lineage and permits cellular proliferation. Runx2 Type I
stimulates production of BMP2 and this, in turn, aﬀects
Runx2, its eﬀect being mediated by distal-less homeobox
5 (DLX5) (64). Lee et al. (65) found that DLX5 specif-
ically transactivates the Runx2 distal (P1) promoter in
committed osteoblasts and that its action is antagonized
by MSX2 (Fig. 6).
The pattern of isoform expression may be diﬀerent in
tooth tissue, with a high expression of Type I and weak
expression of Types II and III in the ameloblast and
odontoblast layers of neonatal mouse incisors (66).
However, Types II/III have been shown to be indis-
pensable for tooth germ development past the bud stage
and they play a role in the diﬀerentiation of ameloblasts
and odontoblasts, which is necessary for transcription of
dentine matrix protein 1 (DMP1), dentine sialoprotein
(DSPP), amelogenin (AMGN), and ameloblastin
(AMBN) in cultured mouse mandibles (67).
Dual translational control of Runx2, via both the
internal ribosomal entry site (IRES) and cap-dependent
mechanisms, exists for the P1 and P2 promoters. This
provides another level of control of RUNX2 isoforms
and may be a means to ﬁne-tune Runx2 expression
across a wide range of cellular conditions where the
amount of Runx2 gene products may be an important
determinant of their biological eﬀects (68).
Further isoforms of RUNX2 exist as a result of
alternative splicing. This also is consistent with ﬁndings
for other RUNX factors and may explain the diﬀerent
spatiotemporal patterns of expression of the gene (10, 58,
69, 70). The timing of expression of diﬀerent RUNX2
isoforms, in conjunction with other transcription factors
and depending on the level of diﬀerentiation of the cell,
may well serve as a method of control of bone and tooth
formation.
Runx2 and osteoclastogenesis
Overexpression of Runx2 increases osteoblast number
but inhibits their terminal maturation, resulting in
accumulation of less mature osteoblasts and consequent
osteopenia (24). Osteoclastogenesis is increased, possibly
by the increased production of RANKL and MMP-13
(two factors involved in bone formation–resorption
coupling) by the immature osteoblasts (23).
Osteoprogenitor cells have greater potential to support
osteoclast development than more diﬀerentiated cells
(71). Osteoclastogenesis is strongly induced by undiﬀer-
entiated stromal marrow cells, which produce high
RANKL levels. As maturation proceeds, RANKL levels
drop and those of its antagonist, osteprotegerin (OPG),
rise (72). The stimulus to osteoclastogenesis is reduced
accordingly and the diﬀerentiated osteoblasts proceed to
the formative phase of bone formation.
The precise role of RUNX2 in osteoclast regulation is
controversial. Opg is strongly expressed in Runx2–/–
calvarial cell lines, whereas Rankl is not (73, 74). How-
ever, RUNX2-binding elements are present in the pro-
moter region of the Opg gene. RUNX2 increases the
activity of the Opg promoter, suggesting that RUNX2
regulates osteoclastogenesis by inducing the expression
of Opg (75). TGF-b inhibits bone resorption by induc-
tion of Opg and its eﬀects are mediated by RUNX2 and
SMADs (76).
A RUNX2-binding site is present on the mouse and
human Rankl promoter (77), but RUNX2 failed to sti-
mulate the transcriptional activity of the promoter
region of the Rankl gene, showing that that RUNX2
possibly does not regulate Rankl in the same manner as
other known targets (78). However, RUNX2 induced
Rankl expression and suppressed Opg expression in the
presence of 1,25(OH)2D3 (74). On the other hand, forced
production of soluble RANKL was found to be insuﬃ-
cient for the complete rescue of osteoclast diﬀerentiation
in Runx2–/– mice, suggesting the presence of another
requirement for osteoclast diﬀerentiation. Also,
treatment of RUNX2-deﬁcient calvarial cells with
1,25(OH)2D3, aﬀected both Rankl and Opg expression
and induced osteoclastogenesis, showing that expression
of Rankl and Opg, and initiation of osteoclastogenesis,
may be induced via alternative pathways (79).
Colony-stimulating factor 1 (CSF-1) and RANKL are
widespread; however, osteoclasts are conﬁned to calciﬁed
tissue. The addition of CSF-1 and RANKL to serum-
free cell cultures produced no osteoclasts (80). This
suggests the existence of other factors or ECM proteins,
possibly induced by RUNX2 in osteoblasts, which are
required for osteoclast diﬀerentiation.
RUNX2 in odontogenesis
In the developing mammalian tooth, the cranial neural
crest-derived dental mesenchyme consists of the dental
papilla and dental sac. The dental papilla gives rise to
dental pulp and odontoblasts; the dental sac gives rise
to the periodontium, including the osteoblasts that
contribute to the alveolar process. The alveolar process
is a specialized intramembranously formed bone that
provides the primary support structure for the denti-
tion.
The expression of Runx2 in both the dental papilla
and dental sac suggests a potential involvement of
this gene in the diﬀerentiation of odontoblasts and
osteoblasts lining bone in the periodontal space (6,
81). Mice deﬁcient in RUNX2 exhibit an arrest of
molar tooth development at the early cap stage, sug-
gesting a requirement for RUNX2 in the progression of
tooth development from the cap stage to the bell stage
(6).
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In mouse embryonic mandibular ﬁrst molar tooth
germs, Runx2 expression is initiated by FGF produced
by the odontogenic epithelium, shortly after com-
mencement of epithelial thickening, and is followed by
expression of RANKL in the early alveolar bone ossiﬁ-
cation centers and that of its receptor, receptor activator
of nuclear factor kappa B (RANK) and OPG in tooth
bud epithelium and mesenchyme. Thus, Runx2 is not
involved in the initiation of tooth formation, but is
intimately involved in regulating the expression of
mesenchymal molecules that act reciprocally on the
epithelium to control the histo- and morpho-diﬀerenti-
ation of the enamel organ (6, 82, 83).
Runx2–/– mouse molars show arrested development at
the bud stage, whereas incisors, which develop earlier,
progress to the bell stage and show dentine formation,
although odontoblasts are abnormal and no enamel is
formed (6, 84).
Enamel knot marker genes, including cyclin-dependent
kinase inhibitor 1A (p21), Fgf4, ectodysplasin A receptor
(Edar) and Bmp4, are down-regulated in Runx2–/– lower
molars, but are expressed normally in the upper molars.
Sonic Hedgehog (Shh) is completely absent in Runx2–/–
lower molars, while weak signals remain at the tip of the
tooth bud in the upper molars (83).
Lower molars are more severely aﬀected than upper
molars in Runx2–/– mice, and incisors are less aﬀected
than molars. Hence, RUNX2 may have diﬀerent down-
stream target genes in diﬀerent regions of the jaws.
Similar regional diﬀerences in molecular regulation is
evident in relation to other genes, notably Dlx (85) and
ActivinbA (86). The diﬀerent origins of the neural crest
cells populating the maxillary and mandibular primordia
may explain their diﬀerent behavior (87). However, the
developmental proﬁles of Runx2 expression in odonto-
blasts and osteoblasts, both derived from mesenchyme, is
also diﬀerent (6), suggesting that the gene may also be
diﬀerentially regulated in these cells.
Runx2 is thus essential for tooth development up to
the bell stage, being necessary for the formation of the
enamel knot, which controls growth and folding of the
enamel organ epithelium. Whether Runx2 is essential for
the later stages of tooth development is still unknown, as
Runx2–/– mice do not survive beyond birth.
Prior to crown development, Type II Runx2 is
strongly expressed in dental papilla mesenchyme, which
gives rise to the pulpal cells and odontoblasts. Type II
Runx2 is markedly down-regulated at the bell stage in
the dental papilla, after morphogenesis is complete.
Expression continues, albeit at a lower level, in the cells
of the dental papilla, particularly near the apical por-
tion, as well as in the odontoblasts lining the pulp
chamber. Expression is evident throughout the further
development of the tooth and at all stages of root
formation, including formation of the periodontium.
Cementoblasts, cementocytes, periosteal tissue, osteo-
blasts, and osteocytes all showed expression of Type II
Runx2. No expression was found in osteoclasts. The
forming periodontium contains a decreasing gradient of
transcripts and immunostaining from crown to the root
tip (88) (Figs 7, 8).
Ameloblasts
Runx2 expression controls downstream factors acting on
the development of the enamel organ epithelium. The
importance of Runx2 in amelogenesis is evidenced by the
lack of enamel in the incisor tooth germs of Runx2–/–
mice. RUNX2 is also present in late secretory- and
maturation-stage ameloblasts (6).
AMBN is an extracellular matrix protein that may
play a role in enamel crystal formation in the developing
dentition. It is used as an ameloblast-speciﬁc gene mar-
ker. The murine Ambn promoter contains two RUNX2-
binding sites. RUNX2 interacts with functionally
important regions of the Ambn promoter, and mutations
of the Ambn promoter’s RUNX2-binding sites diminish
promoter activity. This indicates that RUNX2 possesses
an important function in transcription of the Ambn gene
(89). Runx2 Type II mRNA remains strongly expressed
in both immature and mature ameloblasts (81). Thus,
Fig. 7. Patterns of Runx2 expression. (A) Initiation stage.
Expression is induced in the mesenchyme by the odontogenic
epithelium. (B) Bud stage. Expression is maintained around the
ingrowing dental epithelium. (C) Cap stage. Expression is sus-
tained in the mesenchyme and the dental follicle. RUNX2 is
necessary for Sonic Hedgehog (Shh) expression and for for-
mation of the enamel knot. (D) Bell stage. In this stage,
expression is down-regulated in the dental papilla but is
maintained in the dental follicle and surrounding mesenchyme.
Fig. 8. Runx2 mRNA expression in the secretory stage.
Pre-ameloblasts show no expression; however, this is strongly
up-regulated in maturational phase cells. There is diﬀuse
expression throughout the dental papilla, with up-regulation in
pre-odontoblasts. Diﬀerentiated odontoblasts, however, show
no expression. The periodontal ligament shows strong expression
as do cementoblasts and cementocytes. d, dentine; e, enamel;
od, odontoblasts; ma, maturational amleoblasts; p, dental
papilla; pa, pre-amleoblasts; pdl, periodontal ligament.
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Runx2 is involved in the early stages of enamel organ
formation, and tooth morphogenesis and may also play a
direct role in formation of tooth enamel. Histological
investigation of extracted permanent teeth in CCD show
evidence of hypoplasia (90, 91). This does not appear to
be the case for deciduous teeth (92).
Odontoblasts
Osteoblasts and odontoblasts share several similarities,
including the expression of similar genes. Indeed, the
main non-collagenous components of the odontoblastic
extracellular matrix (DSPP or DMP1) are also present in
other tissues, such as osteoblasts (93) and periodontium
(94), albeit at much lower levels.
Multiple RUNX2-binding sites have been identiﬁed in
the regulatory elements of the mouse Dspp gene (66).
RUNX2 increased Dspp expression in immature odon-
toblasts, but down-regulated expression in more mature
cells, showing that the eﬀect of RUNX2 is dependent on
the state of diﬀerentiation of the target cell (95).
RUNX2 is also involved in the regulation of DMP1 in
osteoblasts, although it is not essential for DMP1
expression in odontoblasts, indicating the involvement of
other unidentiﬁed odontoblast-speciﬁc transcription
factors or co-activators (96, 97). Jiang et al. (81) found
Type III Runx2 expression in immature odontoblasts at
all stages, including cells in the dental papilla, conﬁrming
their potential to diﬀerentiate to odontoblasts.
Growth and diﬀerentiation in Runx2+/– human pri-
mary pulp cells are diﬀerent to Runx2+/+ cells as a result
of variations in gene expression patterns and signaling
(98). Therefore, the eﬀects of haploinsuﬃcency may well
inﬂuence the diﬀerentiation of odontoblasts from these
cells. Runx2 is up-regulated in early odontoblasts (99),
showing that levels of RUNX2 are necessary at this
stage. However, unlike in osteoblasts, Runx2 expression
is remarkably low or undetectable in diﬀerentiated
odontoblasts (88, 100).
This down-regulation of expression in newly diﬀeren-
tiated and functional odontoblasts suggests that Runx2
plays an essential and stage-speciﬁc role in the lineage
determination and terminal diﬀerentiation of odonto-
blasts from dental papilla mesenchyme (101). It also
highlights the diﬀerent eﬀects of this gene in diﬀerent
tissues.
Cementum
The origins of cementum-producing cells, and whether
they share common precursors with osteoblasts, are
unclear (102). Most cells embedded in the cellular
cementum express Runx2 mRNA and RUNX2 protein
to various degrees (88). As cementoblasts are mineraliz-
ing cells, this is not a surprising ﬁnding.
The result of Runx2 haploinsuﬃciency on cemental
tissue seems to vary between species. Both acellular
and cellular cementum formation is defective in per-
manent teeth in CCD subjects. This does not seem to
be the case in the deciduous teeth of CCD subjects (7,
103).
Reports on cementum formation in Runx2+/– mice are
inconsistent (104, 105). Chung et al. (105) explained the
similarity between mutant and wild-type mice in the
study of Zou et al. (104) by the mice being too young to
have developed their full root length. However, cemen-
tum formation in primary teeth in subjects with CCD
seems to be normal (92). If the mouse dentition does
represent the human primary dentition, gross abnor-
malities are not expected to be found in heterozygous
mice.
Reports of root morphology in CCD literature varies
from excessive root length (106), deformation (8,107),
and spiky (108).
Periodontal ligament
Type II Runx2 is also expressed in periodontal ligament
(PDL) ﬁbroblasts, although BSP, a marker of osteoblast
diﬀerentiation and biomineralization, is not (81). The
action of RUNX2 seems to be suppressed by a mech-
anism designed to maintain PDL width (109). The factor
S100A4 has been implicated (110).
However, these cells maintain the potential to diﬀer-
entiate to osteoblasts under certain conditions, such as
mechanical stress (111). Deformation of PDL osteoblasts
increases Runx2 expression, protein levels, and also its
DNA-binding activity, the latter possibly being caused by
activation of the ERK (extracellular signal related ki-
nase) MAPK pathway (34), although the bone response
to stress is similar in both heterozygous and wild-type
mice. Orthodontic tooth movement is not aﬀected in
Runx2 +/– mice (105); one functioning gene seems to be
suﬃcient to produce an adequate bone response.
Tooth maturation and eruption
Runx2 controls the maturation of both osteoblasts and
odontoblasts. Therefore, a delay in tooth maturation is
expected in RUNX2-deﬁcient tissues. This is reﬂected in
the clinical situation, where the dental maturation of
CCD subjects is retarded by as much as 4 years when
compared with unaﬀected subjects (8, 106, 112).
Zou et al. (104) found no diﬀerence in dental devel-
opment or eruption timing between heterozygous
knockout and wild-type mice. One functioning allele
seems to be suﬃcient for normal dental development in
the mouse. Yoda et al. (113) reached a similar conclu-
sion as regards tooth development, but found a signiﬁ-
cant diﬀerence in tooth eruption times. This was
explained as being caused by a time-speciﬁc lack of
osteoclastic response, suggesting that heterozygous mice
cannot recruit suﬃcient osteoclasts for active alveolar
bone resorption. This is essential for the prompt timing
of tooth eruption. The results also suggest the possibility
that insuﬃcient alveolar bone resorption is one of the
cellular mechanisms of the delayed tooth eruption in
CCD patients.
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The methods used in these studies are diﬀerent and
may explain the disparity in the conclusions. Further-
more, it must be pointed out that in CCD the primary
dentition is rarely aﬀected. It may be assumed that the
dentition in mice represents the human primary denti-
tion, where the eﬀects of haploinsuﬃciency on the
eruption and formation of the human dentition may be
too subtle to detect in the clinical situation. One major
shortcoming of the murine model in this respect is that
no secondary dentition develops.
Primary teeth erupt on time in CCD patients. Simi-
larly, the permanent lower incisors and ﬁrst molars
generally erupt on time. However, the subsequent per-
manent teeth exhibit a delay in eruption, presumably as a
result of defective eruption pathway formation (Fig. 1).
There does not seem to be a close correlation between the
number and positioning of supernumerary teeth and the
delay in eruption (114, 115).
Similarly, birth length in CCD children is normal, but
height drops below or around the second centile between
4 and 8 yr of age (116, 117). This pattern of development
is reﬂected in the facial morphology, the characteristic
frontal bossing and maxillary retrusion often not
becoming evident until the later stages of childhood
(118). Thus, the eﬀect of haploinsuﬃciency on the cra-
niofacial complex manifests late in a large number of
cases. Whether this is caused by variation in RUNX2
isoform levels, or simply by a greater requirement for the
gene product at that age, is unclear.
As the skeletal symptoms of CCD are not usually a
social or physical handicap, and develop late, one of the
factors leading to a diagnosis of CCD cases may be the
observed anomalies in tooth eruption leading the patient
to present for treatment (8).
Tooth eruption is controlled by precise osteoclast–
osteoblast interaction. Osteoclastogenesis in the alveolar
bone, which is essential for the accommodation of nor-
mal tooth development and eruption, is mediated by
RANK–RANKL signaling (119). The spatiotemporal
pattern and relative abundance of CSF-1, RANKL, and
OPG during tooth eruption are key determinants of site-
speciﬁc osteoclast activity in bone surrounding the tooth
(120).
Runx2 is expressed in the alveolar bone at all stages of
development and during tooth eruption (4,81). Evidence
points to RUNX2 acting, either directly or indirectly, on
the OPG/RANK/RANKL system to inﬂuence bone
remodeling. Communication takes place between tooth
germs and bone-forming/resorbing cells, synchronizing
the two processes, perhaps to ensure correct spatial
positioning of teeth in the jaws (82,121). The delayed and
ectopic eruption of teeth seen in subjects with CCD may
be caused by loss of function of RUNX2, both in respect
of reduced CSF-1 production and disruption of the
OPG/RANK/RANKL pathway.
Bone healing in CCD patients is not inﬂuenced.
Normal healing has been reported after maxillofacial
surgery (122), and osseointegration seems to be unaf-
fected (123). Deciduous teeth are extracted, and bone
is removed over unerupted teeth in order to encourage
their eruption (124). It is possible that the inﬂamma-
tory response to surgery may induce tooth eruption by
re-activation of monocyte recruitment and osteoclast
formation.
Supernumerary teeth
Supernumerary teeth are considered to be a diagnostic
feature of CCD. However, the number of supernumerary
teeth is variable, and several reports exist where no
supernumeraries exist or hypodontia is reported (125–
127).
Minor mutations in the highly conserved RHD are, in
general, more likely to produce the classic CCD pheno-
type than the more robust ﬂanking Q/A and PST
domains. The phenotype in mutations involving the
RHD is dependent on the residual transactivation
potential of the protein (126, 128).
A dose-related eﬀect seems to be present, as the milder
cases of CCD, and those exhibiting primary dental
anomalies, are associated with mutations that reduce,
but do not abolish, protein stability, DNA binding, and
transactivation. However, attempts to correlate the
number of supernumerary teeth with the severity of
skeletal symptoms are inconclusive. Furthermore, iden-
tical mutations produce diﬀerent numbers of supernu-
merary teeth (126–130). All CCD mutations, including
those which primarily feature dental anomalies, have
highly variable phenotypic expression. This may indicate
the overlying inﬂuence of other factors.
Runx2–/– and Runx2+/– mice were both found to
exhibit lingual buds in front of the upper molars, and
these were much more prominent than in wild-type mice
(84,87). Furthermore, Shh signaling was not inhibited in
the lingual buds of the knockout mice (87). Shh is
necessary for tooth formation, both in the bud and cap
stages (131), and its expression is spatially controlled to
limit it to regions of tooth development (132).
These buds presumably represent the mouse secondary
dentition, and it is likely that RUNX2 acts to inhibit
formation of these buds. It may appear contradictory
that the inhibition of RUNX2 function may arrest pri-
mary tooth development but stimulates the formation of
secondary teeth. However, it is not unusual, during
embryogenesis, for the same gene to have diﬀerent eﬀects
at diﬀerent developmental stages (87).
RUNX2 may normally function as a cell growth
inhibitor in immature osteoblasts. It acts by supporting
exit from the cell cycle, thus promoting increased
expression of the osteoblast phenotype (133). Human
Runx2 +/– pulp cells proliferate at a far greater rate than
their normal counterparts (98). This lends support to the
theory that Runx2 controls the proliferation of cells and
may exert speciﬁc control on the dental lamina and the
formation of successive dentitions.
It is easy to see how loss of function of this gene would
encourage proliferation of the dental lamina. It is also
easy to see how tooth eruption may be aﬀected. How-
ever, the lack of correlation between the loss of RUNX2
function and the number of supernumerary teeth con-
fuses matters. It is interesting to note that a mutation
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aﬀecting just the terminal VWRPY repressor motif
produced a phenotype with only mildly hypoplastic
clavicles and supernumerary teeth (5).
Concluding remarks
Runx2 is temporally and spatially regulated. The several
signaling pathways that converge on this gene, and the
existence of numerous splice variants with diﬀerent N
and C termini, substantiate its diverse actions on bone
and tooth tissues.
One eﬀect of a mutation may be to alter the propor-
tions of the splice variants of the gene which will, in turn,
aﬀect its downstream pathways by altering the levels of
interacting products. This would have diﬀerent eﬀects on
diﬀerent tissues. The inconclusive results of attempts to
correlate the number of supernumerary teeth with
eruption timing or skeletal eﬀects would support this, as
the action of RUNX2 on the dental lamina would be
diﬀerent to that on osteoblast function.
The dosage sensitivity exhibited helps to explain the
large intrafamilial variability. Genetic or epigenetic
modiﬁers may inﬂuence the phenotype, as may the
transcriptional status of the unmutated allele (126).
There exist several cases of clinically diagnosed CCD
where no mutation is detectable. Locus heterogeneity is a
possible explanation for this; however, all CCD families
tested map to the 6p21 locus (134–137).
Another explanation may be mutations within as-yet
poorly characterized intronic or regulatory sequences.
Variations in the promoter sequence point to a possible
alternative mechanism for disruption of normal RUNX2
function (138, 139). Hypermethylation of the P2 pro-
moter of the Runx3 gene severely aﬀects its function
(140, 141). Given the high homology between these
genes, the possibility of epigenetic eﬀects on the Runx2
regulatory regions should not be discounted.
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INTRODUCTION
The ectopic canine is the second most frequently impacted tooth after thethird molar, appearing in 3% of the Western population (Ericson and
Kurol, 1986).
The etiology is controversial. A genetic basis has been suggested (Bjerklin
et al., 1992; Peck et al., 1994). Several studies have shown the etiology of
ectopic canines to be genetic and associated with other genetically interrelated
dental anomalies (Svinhufvud et al., 1988; Bjerklin et al., 1992; Pirinen et al.,
1996; Baccetti, 1998). The sex ratio shows a bias toward females (Becker et
al., 1981; Ericson and Kurol, 1988), similar to other dental anomalies of
genetic origin (Rose, 1966; Davis, 1987). The racial variation, female
preponderance, familial occurrence, and association with other dental
anomalies imply a polygenic etiology (Kotsomitis and Freer, 1997).
Environmental factors have also been identified. Palatal displacement of
the canine may be due to local environmental factors, such as anatomically
anomalous or late-developing lateral incisor roots (Becker et al., 1981;
Chaushu et al., 2002, 2003). Excess space in the dental arch has been
implicated (Paschos et al., 2005). There is evidence that both genetic and
environmental factors may be involved. (Ely et al., 2006). Alteration of the
local environment by extraction of the deciduous canines will ameliorate the
condition (Ericson and Kurol, 1988; Power and Short, 1993).
The prevalence of ectopic canines in Maltese schoolchildren is 4-5.5%
(Camilleri, 1995; Camilleri et al., unpublished observations). This is higher
than previously published figures (Ericson and Kurol, 1986), possibly due to
the 'founder effect', since the Maltese population has grown dramatically,
from 17,000 in 1535 to over 300,000 today (Blouet, 2004). This relative
abundance and familial clustering of cases prompted a study to test the
hypothesis that ectopic canines have a genetic etiology.
METHODS
Ethical approval was obtained from the University of Malta Medical School
Ethics Committee. Informed consent was obtained from all participants prior to
inclusion in the study. Thirty-seven consecutive probands with ectopic maxillary
canines were identified during routine clinical examination at the private
practice of SC and at the School Dental Clinic, Floriana. The inclusion criteria
were Maltese Citizenship and a positive history of ectopic (buccally or palatally
displaced) canines or failure of eruption of the canine tooth by the age of 16.
Individuals affected by a genetic syndrome likely to have an adverse influence
on tooth eruption were excluded. A further set of 26 consecutive families was
selected on the strength of two probands, to identify families with a stronger
predisposition. Families with an affected twin were investigated even if the other
twin was unaffected. Ectopic or missing teeth were identified by clinical
examination, from existing records, or family history, and radiographic
investigation was undertaken only where clinically necessary.
We analyzed the pedigree data to assess the familial risk of ectopic canines and
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other related phenotypes, using the computed familial relative risk.
We used the segregation analysis program Pedigree Analysis
Program (PAP) (Hasstedt, 2005) to model the inheritance of
ectopic canines throughout the 63 pedigrees. Pedigree members
were defined as affected or unaffected with ectopic canines (with
no further clinical information used). Genetic models assumed a
single locus model with penetrances and mutation frequency
maximized for each model. Nested models were compared by the
likelihood ratio test, where the difference in -2 ln (likelihood) has a
chi-square distribution, with the degrees of freedom equal to the
difference in the number of additional parameters fitted in the most
general model. Sporadic (no genetic effect), recessive, and
dominant models were compared with a co-dominant model. A
polygenic model was also tested and compared with the dominant
model. An ascertainment correction for the probands in each
family was applied.
Five sets of monozygotic and six sets of dizygotic twins were
included in the sample. A further two sets of monozygotic twins
and one set of triplets were subsequently referred by a colleague.
These were not included in the pedigree or segregation analyses;
however, they were used in assessments of pairwise concordance.
RESULTS
The number of individuals of known dental status was 524.
One hundred and thirty-nine individuals had ectopic canines.
The percentage of dental anomalies in the sample for first-
degree relatives was noted, and differences against published
population prevalences were investigated. The prevalence of
ectopic canines was significantly higher in first-degree relatives
(15%, p < 0.001) compared with 4.4-5.5% for the Maltese
population (Camilleri, 1995; Camilleri et al., unpublished
observations). Lateral incisor agenesis was also higher (7.88%,
p = 0.01, as opposed to 3.21% for the general population)
(Camilleri and Mulligan, 2007).
There were eight cases of maxillary canine transposition in the
whole sample. Three were probands, five were first-degree
relatives; one was a second-degree relative. Seven were in the
upper jaw, giving a prevalence of 1.4%. This is significantly
higher (p < 0.001) than the prevalence of 0.27% estimated in a
Caucasian population (Yilmaz et al., 2005). Two cases of
mandibular canine-lateral incisor transposition were also recorded.
The percentages of first-, second-, and third-degree
relatives with ectopic maxillary canines were used to calculate
the relative risk (
R
) to the first-, second-, and third-degree




/) where  is the
population prevalence and 
R
is the percentage of relatives
affected according to the type of relative, i.e., of the first,
second, or third degree (Table 1).
Ascertainment was corrected for by exclusion
of the probands from the calculation. We then
used the relative risk to plot the drop-off for
each decreasing degree of unilineal
relationship (Fig. 1), which was close to the
theoretical decrease for a genetic disease.
There was no difference in ectopic canine
risk between families ascertained from one or
two probands for first-, second-, or third-
degree relatives (p = 0.49, p = 0.52, p = 0.65).
Nor was there a difference in the numbers of
sib-sib and parent-offspring affected pairs for
each type of family ascertainment (p = 0.89).
There was an appreciable sex bias, with the affected
Female-to-Male Ratio for first-, second-, and third-degree
relatives being 1.78. The sex ratio for the probands was 1.64,
and elimination of the probands from the calculation gave a
ratio of 1.89. However, there was no appreciable risk difference
between relatives of male or female probands (p = 0.77). The
proportion of male first-degree relatives affected vs. the
proportion of female first-degree relatives was not significant
(p = 0.12).
Although there was no evidence of sex-linked transmission,
85% of the three-generation families showed instances where
an obligate carrier showed a normal phenotype, although the
condition was transmitted to their children (Fig. 2). There was
no apparent pattern of augmentation or attenuation of
phenotype through the generations.
We used the segregation analysis program PAP to fit
different genetic models to the pedigrees, estimating parameters
such as penetrance and mutation frequency. We applied a
likelihood ratio test to determine any significant difference in the
fit of the various models (Table 2). All the genetic models fitted
provided a significantly better fit than the sporadic model,
confirming that ectopic canines have a genetic basis. The -2log
likelihood of the co-dominant model was very similar to the
dominant model, but had more parameters. Therefore, the
dominant model provided the more parsimonious model, with
Figure 1. Relative risk drop-off. The reduction in Relative Risk against
Degree of Relation is very similar to the theoretical curve for inheritance
of a genetic disease. (R = Relative Risk).
Table 1. Relative Risks: Proportions of Ectopic Canine-affected Individuals Used for
Calculation of the Relative Risks
Relatives Affected
with Ectopic Canines Total Number Percentage of Relative
2 probands 1 proband of Individuals Relatives Affected Risk
1st-degree relatives 16 15 203 15.27 2.78
2nd-degree relatives 6 8 117 11.97 2.18
3rd-degree relatives 5 3 85 9.41 1.71
Average sampled family size 10 7
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the -2log (likelihood) for the recessive model being substantially
higher. A mixed-dominant model did not provide a sufficiently
improved fit, implying that there is no evidence for a polygenic
component in addition to the Mendelian locus. These results
show that a single dominant gene best accounts for the
inheritance of ectopic canines in these pedigrees, with a mutation
frequency of 11% and penetrances of 36% in mutation carriers.
From the dominant model fitted in the segregation analysis,
the risk to the sibling of an ectopic canine case was calculated
to be 0.18. This is similar to the estimate of 0.15 obtained from
the pedigree analysis (RR 2.78 x population prevalence 5.5%).
The population prevalence predicted by the dominant model
was determined according to the formula: q2 * p
1










are the penetrances for the three genotypes. The calculated
prevalence was 7%, which also compared well with the
estimated population prevalence of 5.5%. This supports the
dominant model as being the most likely.
Seven pairs of monozygotic twins were found. Of these,
five were completely discordant, in that one twin was
unaffected (Fig. 2). Of the other two pairs, one pair was mirror-
image, and the other set had one twin affected unilaterally, the
other bilaterally. The pairwise concordance in this sample was
28.6%. Seven pairs of dizygotic twins are also on record, with
two showing concordance for ectopic canines, a pairwise
concordance rate of 28.6%.
DISCUSSION
Dental Anomalies
There was a significantly higher prevalence of ectopic canines
in first-degree relatives of ectopic canine probands (15%, p <
0.001) as compared with figures for the Maltese population
(Camilleri, 1995; Camilleri et al., unpublished observations).
Familial clustering is a common feature of the trait; however,
this could be due to environmental as well as genetic factors.
The prevalence of canine transposition in the sample was
far higher than the 0.27% prevalence estimated in a Caucasian
population (Yilmaz et al., 2005). The highly significant
difference is indicative of transposition, being an extreme
variant of ectopic canine, and is consistent with the highly
variable expression exhibited.
The prevalence of lateral incisor agenesis in the Maltese
population is 3.21% (Camilleri and Mulligan, 2007). The high
figure found in association with ectopic canines suggests that
both traits are related, in keeping with previous evidence
(Becker et al., 1981; Svinhufvud et al., 1988; Peck et al., 1994;
Pirinen et al., 1996; Baccetti, 1998).
Pedigree Analysis
The pattern of transmission was that of an autosomal-dominant
trait with low penetrance. Expression was highly variable both
within and between families. Incomplete penetrance was
evident, with obligate carriers unaffected by ectopic canines.
This may be explained by the highly variable expressivity seen,
with failure of penetrance in some cases.
Considering the high population prevalence, the figure for

R
suggests a significant genetic component. When the drop-
off in 
R
(decreasing degrees of relation) is plotted as a
function of the Relative Risk, the gradual decrease for every
decreasing degree of relationship is suggestive of a genetic
contribution and does not rule out genetic heterogeneity
between families. This analysis cannot distinguish between
single-locus or multi-locus inheritance for ectopic canines
(Risch, 1990). However, there is no difference in prevalence
between families ascertained from one or two probands for
first-, second-, or third-degree relatives. Nor is there a
difference in the sib-sib/parent¬offspring relationships in the
two types of families. This is indicative of a single gene, since
multiple genes would be expected to give a higher prevalence
in families ascertained from two probands.
There was a considerable sex bias toward females, and,
surprisingly, elimination of the probands from the calculation
produced an increase in the Female-to-Male ratio of the
sample. There is no plausible explanation to date for this bias.
However, there was no significant difference between the risks
to relatives of male or female probands, as expected for an
autosomal major gene. Were the
trait to be multifactorial, the risk
would be higher for the relatives of
the less susceptible sex (Farrer and
Cupples, 1998).
Segregation Analysis
The inheritance of ectopic canines in
the families was modeled assuming a
single major gene and with
polygenic inheritance. The results of
the segregation analysis implied that
the sporadic model was rejected
compared with all the genetic
models. The dominant model fitted
equally as well as the co-dominant
Figure 2. Ectopic canine pedigree. Pedigree showing autosomal-
dominant transmission, incomplete penetrance, and discordant identical
twins, with the trait transmitted to the offspring of the affected twin. The
arrow indicates the proband.
Table 2. Segregation Analysis Results: the -2 Log Likelihoods* of the Various Models Tested
Allele Penetrance Heritability -2 Log No. of 
Model Freq. AA AB BB h2 Likelihood Parameters p-value
Mixed dominant 0.89 0 0.32 0.47 379.76 4 - 0.09
Polygenic - 0.12 0.4 384.49 2 0.07
Sporadic - 0.18 - 387.86 1 0.01
Dominant 0.89 0 0.36 - 380.34 3 1.00
Co-dominant 0.89 0 0.36 0.36 - 380.34 4 0.09
Recessive 0.38 0 0.32 - 383.22 3 -
* These were compared by the Likelihood Ratio test. P-value columns show pairwise tests of models in
adjacent rows, with a significant p-value implying that the more complex model provides a better fit
to the family data. The dominant model provides the best overall fit.
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model, suggesting that a dominant model adequately describes
inheritance in these pedigrees. The polygenic model was
rejected, and there was no evidence for a polygenic component
in addition to a dominantly inherited major gene. The low
penetrance (36%) for the dominantly inherited gene allows for
the existence of an additional environmental influence, which
would determine which genetically susceptible individuals show
the phenotype.
Twins
The inclusion of the first five sets of monozygotic and the first
six sets of dizygotic twins was serendipitous, since selection
was on the basis of affected probands only. The low
concordance shown by the monozygotic twins is consistent
with epigenetic or environmental factors influencing the
eruption of teeth, and is at variance with the epidemiological
evidence of a significant genetic component. Furthermore, the
incidence of monozygotic twinning for the Maltese Islands is
4.5 per 1000 (Savona-Ventura and Grech, 1988). The
prevalence of monozygotic twins selected consecutively in this
sample was nearly double that number, and the difference was
statistically significant (p = 0.01).
Monozygotic twins share identical DNA sequences;
however, they are often discordant for certain phenotypes.
Hypodontia, a genetic disorder associated with ectopic canines,
is more prevalent in twins. These exhibit(AQ) a high degree of
discordance (Keene, 1971; Lapter et al., 1998; Townsend et al.,
2005). It is possible that epigenetic events may be responsible
for discordant expression in genetically identical individuals.
Indeed, certain imprinting-associated diseases, such as
Beckwith-Wiedemann Syndrome, are associated with multiple
births and discordance in monozygotic twins (Elliott and
Maher, 1994). In contrast, ectopic movement of the maxillary
canine has been detected in children as young as 5 years of age
(McSherry and Richardson, 1999), and the rapidly growing
child is susceptible to a multitude of factors that potentially
affect intrabony movement of the canine. Evidence for
environmental influence on epigenetic mechanisms further
clouds the issue (Bird, 2007).
In conclusion, the evidence gathered from analysis of the
pedigrees supports the hypothesis of a genetic etiology for
ectopic canines, with a single locus being involved, although
genetic heterogeneity across pedigrees cannot be ruled out in a
modeling study. The most likely mode of transmission is
autosomal-dominant. The incomplete penetrance of the
dominant locus allows for an environmental component.
Further investigation into the molecular etiology of ectopic
canines is therefore justified, although the number of
monozygotic twins in the sample, plus the discordance of these
twins, raises the possibility of gene silencing.
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